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ABSTRACT
In these studies, the microRNA miR-31 was identified as a potent inhibitor of breast
cancer metastasis. miR-31 expression levels were inversely associated with the propensity to
develop metastatic disease in human breast cancer patients. Additionally, various functional
analyses revealed that miR-31 expression was both necessary and sufficient to impede breast
cancer metastasis. These effects did not involve confounding influences on primary tumor
development; instead, miR-31 exerted its anti-metastatic activities by impinging upon at least
three distinct steps of the invasion-metastasis cascade: local invasion, one or more early post-
intravasation events, and metastatic colonization. At a mechanistic level, miR-31 impaired
metastasis via the pleiotropic suppression of a cohort of target genes that otherwise operate to
promote metastasis, including integrin α5, radixin, and RhoA. Significantly, the concomitant re-
expression of integrin α5, radixin, and RhoA sufficed to override the full spectrum of miR-31’s
anti-metastatic activities. Moreover, the concurrent short hairpin RNA-conferred knockdown of
endogenous integrin α5, radixin, and RhoA levels closely phenocopied the known consequences
of ectopic miR-31 expression on metastasis. Integrin α5, radixin, and RhoA were found to act
during at least partially unique steps of the invasion-metastasis cascade downstream of miR-31.
Notably, the temporally controlled re-activation of miR-31 in already-established metastases
elicited metastatic regression. These anti-metastatic therapeutic responses were attributable to the
capacity of acutely re-expressed miR-31 to induce both cell cycle arrest and apoptosis; such
effects arose specifically within the context of the foreign microenvironment present at a
metastatic locus. When taken together, these findings provide mechanistic insights concerning
the regulation of breast cancer metastasis and suggest that miR-31 may represent a clinically
useful prognostic biomarker and/or therapeutic target in certain aggressive human carcinomas.
In addition, a novel experimental system for the unbiased identification of metastasis-
relevant genes was described. The utility of this system was demonstrated in an initial proof-of-
concept screen, which implicated RhoJ as a previously unappreciated modulator of cell motility.
Collectively, these observations imply that the single-cell clone-based screening methodology
outlined herein may represent a generally useful means by which to enumerate novel regulators
of various metastasis-relevant processes.
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Cancer: Clinical Realities
Cancer is currently the second leading cause of mortality in the United States, and this
disease is estimated to have claimed the lives of nearly 600,000 individuals during 2009 alone.
Moreover, more than 1.5 million new cases of cancer are diagnosed within this country annually
(The American Cancer Society, 2009). Unfortunately, despite a more sophisticated
understanding of the etiology of cancer and a greater emphasis placed on early detection of the
disease, overall mortality rates in the United States from cancer have not diminished greatly over
the past 15 years (The American Cancer Society, 2009). As such, cancer continues to pose a
major threat to human health and further research regarding the molecular basis of this disease is
imperative in order to devise prognostic and/or therapeutic strategies that more effectively
diagnose, control, and combat cancer.
Cancer is a Genetic Disease
The vast majority of human cancers arise via the accumulation of a series of genetic
mutations and epigenetic changes that alter the ability of a cell to appropriately control its
proliferation, survival, and differentiation (Kinzler and Vogelstein, 1996; Hanahan and
Weinberg, 2000). Broadly speaking, there exist two basic classes of cancer-relevant genes:
oncogenes and tumor suppressor genes. Oncogenes can promote cellular proliferation and/or
survival; therefore, the aberrant activation of an oncogene can foster tumorigenic progression. In
contrast, tumor suppressor genes normally function to inhibit inappropriate cellular proliferation
and/or survival; accordingly, the inactivation of a tumor suppressor gene can drive tumor
development. In many cases, oncogenes and tumor suppressor genes play biochemically
antagonistic roles within signal transduction pathways that control numerous fundamental cell-
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biologic functions (Kinzler and Vogelstein, 1996; Hanahan and Weinberg, 2000). Thus, genetic
perturbations occurring within a cancer cell can lead to biochemical changes that ultimately
manifest themselves as the altered cell-biologic properties characteristic of neoplastic cells.
Recent genome-wide sequencing of patient tumor specimens has revealed that a typical
human tumor contains mutations in approximately 90 distinct genes (Sjöblom et al., 2006; Wood
et al., 2007). While many of these mutations are likely to have arisen as passive byproducts of
the intrinsic genetic instability of tumor cells (so called “passenger mutations”), it is generally
believed that the deregulation of between four and eleven of these 90 mutated genes causally
contribute to the pathogenesis of the disease (referred to as “driver mutations”) (Hanahan and
Weinberg, 2000; Sjöblom et al., 2006; Wood et al., 2007).
Traditionally, it has been posited that these mutation-bearing cancer genomes evolve via
a process akin to Darwinian selection: variation is continuously introduced into the population
via stochastic mutational events, and then those cell clones possessing variations that confer a
proliferation and/or survival advantage become overrepresented within the population.
Subsequently, this new, genetically altered population becomes the fodder for additional rounds
of mutation and clonal selection (Nowell, 1976). Thus, cancer arises via a multi-step process that
progressively converts normal cells of the body into highly malignant derivates via the
accumulation of defined genetic alterations.
Breast Cancer
Breast cancer – the most commonly diagnosed cancer type in women in the United
States, as well as the second leading cause of cancer-associated mortality in women in this
country (The American Cancer Society, 2009) – is one such cancer that arises through the
16
progressive accumulation of genetic mutations. At a cell-biologic level, breast cancers are
carcinomas, meaning that they originate from the neoplastic transformation of epithelial cells
(Visvader, 2009). Epithelia are sheet-like layers of cells present throughout the body; breast
epithelial cells are characterized by precisely defined apical-basal polarity, the presence of
homotypic E-cadherin-mediated cell-cell junctions, and their topological location in close
juxtaposition to a relatively thin layer of specialized extracellular matrix (ECM) known as the
basement membrane. Within the context of intact breast tissue, the basement membrane
separates the epithelium from a complex assemblage of underlying mesenchymal support cells,
which are collectively referred to as the stroma (Nelson and Bissell, 2006).
Importantly, due to their acquired complement of genetic perturbations, breast
carcinomas typically display a loss of cell polarity, altered expression of epithelial cell-cell
adhesion molecules, disruption of the basement membrane and/or aberrations in its constituent
components, and an altered cast of surrounding stromal cells (Nelson and Bissell, 2006). Indeed,
emerging evidence indicates that the tissue architecture of normal breast epithelium can serve as
an intrinsic barrier to tumor formation that must be overcome by incipient carcinoma cells before
they can develop into overt neoplasias (Nelson and Bissell, 2006). Hence, molecular alterations
that drive mammary carcinoma progression often alter the typical cell-biologic homeostasis of
normal breast tissue.
At a genetic level, breast cancer is a heterogeneous disease comprised of at least five
distinct molecularly defined subtypes (Sørlie et al., 2001). Importantly, these different subtypes
of breast cancer differ markedly in terms of both prognosis for the development of terminal
disease and responsiveness to rationally designed targeted therapeutic agents (Sørlie et al., 2001;
Desmedt et al., 2008). However, despite these differences, one clinical reality shared by all of the
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subtypes of breast cancer stems from the fact that the single most reliable predictor of ultimate
patient outcome is the presence of localized versus systemic disease at the time of initial
diagnosis (i.e., whether tumor cells remain confined solely within breast tissue or, instead, are
already also present at various anatomically distant organ sites) (Steeg, 2006). In fact, this poor-
prognosis criterion involving diagnosis with systemic disease is common to the overwhelming
majority of carcinomas originating from a wide spectrum of other epithelial tissues as well
(Steeg, 2006). Systemic disease occurs as a byproduct of metastasis – the spread of tumor cells
from their initial site of growth to secondary loci throughout the body.
Metastasis: the Major Obstacle to Effectively Treating Human Tumors
The association of metastasis-positivity with poor patient outcome across a diverse array
of carcinoma types is not an epiphenomenon of cancer progression; instead, distant metastases –
rather than the primary tumors from which these malignant lesions were initially spawned – are
responsible for greater than 90% of human mortality from carcinomas (Fidler, 2003; Gupta and
Massagué, 2006). Whereas essentially curative measures can be undertaken via surgical
resection and standard adjuvant therapy when patients present with well-confined primary
tumors, metastatic disease is largely inoperable given its systemic nature (Steeg, 2006).
Moreover, already-disseminated metastatic tumor cells appear to be more refractory to
conventional therapeutic agents than are the cells present in a corresponding primary tumor
(Dean et al., 2005). Accordingly, when taken together, these observations indicate that our ability
to effectively manage the impact of cancer on human health is quite dependent on our capacity to
interdict – and perhaps even reverse – the process of tumor metastasis.
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The Invasion-Metastasis Cascade
At a cell-biologic level, metastases are the final end-products of a highly complex, step-
wise process termed “the invasion-metastasis cascade”, whereby the epithelial cells in a primary
tumor (1) become motile, (2) invade locally through their surrounding ECM, (3) intravasate into
the lumen of a blood vessel, (4) survive the rigors of vasculature mediated-transport, (5) arrest at
a secondary organ site, (6) extravasate into the parenchyma of a distant tissue, (7) adapt to
initially survive in a foreign microenvironment in order to form micrometastases, and finally (8)
re-initiate their proliferative program at the site of metastasis to generate macroscopic and
clinically detectable neoplastic growths (a step often referred to as “metastatic colonization”)
(Fidler, 2003; Gupta and Massagué, 2006). Importantly, as will be discussed below, each of
these complex cell-biologic events is driven by the acquisition of defined molecular alterations
that endow the incipient metastatic carcinoma cells with an ability to progress onward to the next
step of the invasion-metastasis cascade.
1. Cell Motility
Attaining a motile phenotype is a crucial pre-requisite for achieving competence to
complete subsequent steps of the invasion-metastasis cascade. In many forms of cell motility,
individual tumor cells move along their substratum in response to contextual cues (Friedl and
Wolf, 2003; Sahai, 2005). Therefore, one inherent barrier to single-cell motility imposed by the
epithelial origin of carcinoma cells is the presence of intercellular, E-cadherin-mediated cell-cell
junctions, which serve to prevent carcinoma cells from disaggregating from their neighbors.
As one solution toward overcoming this obstacle, tumor cells can opportunistically co-opt
an evolutionarily conserved developmental program known as the epithelial-mesenchymal
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transition (EMT) (Thiery, 2002; Polyak and Weinberg, 2009). The EMT converts otherwise-
immotile epithelial cell clusters into single mesenchymal cells that possess a high migratory
capacity. Genetically, the EMT is governed by a number of pleiotropically acting transcription
factors – including Slug, Snail, Twist, Zeb1, and Zeb2 – all of which stimulate entrance into a
mesenchymal state by, for example, transcriptionally repressing the expression of E-cadherin
(Polyak and Weinberg, 2009). Thus, the actions of these EMT-promoting transcription factors
allow cohorts of cohesive epithelial cells to disaggregate and subsequently move as individual
units, thereby surmounting intrinsic physical barriers imposed by normal epithelial tissue
architecture that oppose the process of cell motility.
Classically, the single-cell motility of carcinoma cells has been viewed as a four-step
cyclical process involving (1) the polarized extension of actin-rich protrusions in the direction of
intended migration, (2) formation of integrin-mediated adhesive focal contacts between these
forward-reaching actin protrusions and the substratum, (3) stress fiber-dependent actomyosin-
evoked contraction of the cell body, and (4) the release of focal contacts specifically at the rear,
lagging edge of the cell and resulting propulsion of the cell body forward (Lauffenburger and
Horwitz, 1996). More recently, this stress fiber- and integrin-dependent form of single-cell
motility has been coined “mesenchymal migration”, a name ascribed so as to distinguish it from
an alternative single-cell migration-conferring pathway that operates independently of integrin-
mediated focal adhesions and is termed “amoeboid migration” (Friedl and Wolf, 2003; Sahai,
2005). In the amoeboid single-cell motility program, cell movement arises due not to stress fiber-
and integrin-dependent contractile forces, but instead as a consequence of the actions of the
small GTPase Rho and its downstream effector kinase ROCK on the organization of more
diffusely localized patches of cortical actin. These actions, in turn, allow highly deformable
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individual cells to essentially glide along their substratum (Friedl and Wolf, 2003; Sahai, 2005).
Consequently, there exist at least two molecularly distinct single-cell motility programs that can
be hijacked by carcinoma cells to facilitate their locomotion.
As a third alternative, tumor cells can move as largely cohesive multi-cellular units
through the process of “collective migration”. In this form of motility, entire sheets of tumor
cells linked by intact cell-cell adhesion molecules are able to execute in concert the repeating
four-step cycle characteristic of mesenchymal single-cell motility (cells at the leading edge of the
cluster extend protrusions and form focal contacts, contractile forces are generated, and cells at
the rear of the cluster release their interfaces with the substratum to facilitate forward
translocation) (Friedl and Wolf, 2003; Sahai, 2005). As in mesenchymal single-cell motility,
collective migration is orchestrated by the actions of various integrins and actomyosin-regulating
proteins (Friedl and Wolf, 2003; Sahai, 2005). Thus, tumor cells are capable of moving as either
individual units or, instead, as cohesive multi-cellular cohorts via defined genetic and
biochemical pathways involving cell-matrix interactions and the focalized control of actin
dynamics.
The importance of these distinct cell motility programs within the context of metastasis
derives from the capacity of tumor cells to interconvert between these various motility-
promoting strategies in response to changing environmental conditions (Friedl and Wolf, 2003;
Sahai, 2005). For example, if a tumor cell population that typically migrates via single-cell
mesenchymal-type motility is treated with an antibody that blocks integrin function, the cells in
the population can undergo a mesenchymal-to-amoeboid transition, thus allowing the tumor cells
to continue their translocation by shifting to an integrin-independent migration program (Friedl
and Wolf, 2003; Sahai, 2005). For this reason, it has been proposed that anti-migratory
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therapeutic strategies must be capable of simultaneously inhibiting mesenchymal motility,
amoeboid motility, and collective motility in order to demonstrate true efficacy (Friedl and Wolf,
2003; Sahai, 2005). Hence, tumor cells have evolved a variety of molecular mechanisms by
which to achieve motility, thus enabling them to successfully translocate even in the wake of
insults that abrogate entire individual migration pathways.
2. Local Invasion
Once tumor cells have become motile, they are then able to begin to invade locally. Local
invasion refers to the ability of carcinoma cells that formerly resided within an intact epithelial
tissue to physically enter into the surrounding tumor-associated stroma (Fidler, 2003; Gupta and
Massagué, 2006). In order to reach the stroma, the tumor cells must first penetrate the basement
membrane – a thin layer of specialized ECM that separates the epithelial and stromal tissue
compartments (Nelson and Bissell, 2006).
The basement membrane surrounding most carcinoma cells is comprised of a complex
array of glycoproteins and proteoglycans, including various collagens, laminins, and fibronectin
(Nelson and Bissell, 2006). In addition to the structural roles played by the basement membrane
– essentially serving as a physical barrier between carcinoma cells arising within an epithelium
and the adjacent stromal compartment – components of this ECM also play vital roles in signal
transduction events within the carcinoma cells via pathways initiated by integrin-mediated cell-
matrix interfaces. Moreover, the ECM contains a rich repository of tethered growth factor
molecules, which can subsequently be liberated by the actions of extracellular proteases secreted
by carcinoma cells (Nelson and Bissell, 2006). Therefore, disruption of the basement membrane
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by carcinoma cells profoundly alters both the physical and biochemical microenvironment within
which tumor cells reside.
During carcinoma progression, degradation of the basement membrane is principally
executed by members of the matrix metalloproteinase (MMP) family. These substrate-specific
proteolytic enzymes efficiently degrade well-defined ECM components; consequently, in normal
epithelial tissue, the activity of MMPs is carefully controlled via a combination of transcriptional
and post-translational regulatory events (Coussens et al., 2002). Carcinoma cells have devised a
number of means by which to derail this tight modulation of MMP activity, almost invariably
leading to enhanced MMP function and thus degradation of ECM components that lie in the path
of invading tumor cells (Coussens et al., 2002).
Hence, once carcinoma cells have attained both cell motility and the ability to dissolve
constituents of the ECM, they are able to successfully traverse the basement membrane and enter
into the neighboring tumor-associated stroma. The cancer cells are then able to engage in
heterotypic signaling events with a complex milieu of stromal cells – including fibroblasts,
myofibroblasts, macrophages and other immune cells, adipocytes, mesenchymal stem cells, and
endothelial cells – that are capable of further enhancing the aggressive behaviors of carcinoma
cells (Joyce and Pollard, 2009). For example, stromal myofibroblasts can promote primary tumor
growth and angiogenesis in breast cancer xenograft models by secreting stromal cell-derived
factor-1 (SDF-1) (Orimo et al., 2005); similarly, mesenchymal stem cells recruited to the tumor
stroma can secrete chemokine ligand-5 (CCL5) to enhance the migration and invasion of breast
carcinoma cells (Karnoub et al., 2007). More generally, microarray gene expression profiling of
the tumor-associated stroma reveals characteristic expression signatures that are associated with
patient metastatic outcome in human breast tumors (Finak et al., 2008) Thus, genetic influences
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on the cell-biologic processes of metastasis are not solely tumor cell-intrinsic; rather, the
molecular composition of tumor-adjacent stromal cells can also play a critical role in dictating
metastatic progression.
Importantly, in addition to the malignancy-promoting attributes that certain stromal cell
types can impart to invading carcinoma cells, entry of the epithelial tumor cells into the stroma –
driven by the genetic events outlined above – also provides abundant opportunities for the cancer
cells to physically gain access to either the lymphatic or hematogenous circulation and thereby
disseminate systemically.
3. Intravasation
Intravasation refers to the process of locally invasive carcinoma cells exiting their
surrounding stroma and entering into the lumen of a lymphatic vessel or a blood vessel (Fidler,
2003; Gupta and Massagué, 2006). Although lymphatic spread of carcinoma cells is routinely
observed in human tumors – and, in fact, represents an important prognostic biomarker for the
propensity for disease progression – cancer cell dissemination via the bloodstream appears to
represent the major mechanism by which incipient metastatic carcinoma cells broadly disperse
throughout the body (Fidler, 2003; Gupta and Massagué, 2006).
The detailed molecular mechanisms by which tumor cells complete the cell-biologic task
of intravasating into the lumina of blood vessels remains an area of active investigation.
However, it is likely that this process can be facilitated by defined genetic changes occurring
within carcinoma cells that promote their ability to cross the endothelial cell barrier that lines
blood vessels. For example, the EMT-promoting transcription factor Twist was shown to
enhance the intravasation of murine mammary carcinoma cells (Yang et al., 2004), ostensibly by
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either increasing the ability of tumor cells to invade through endothelial cell sheets or more
generally augmenting the invasive and/or migratory capacity of carcinoma cells.
Of perhaps even more widespread relevance to the process of intravasation is the physical
nature of tumor-associated blood vessels. Through a variety of cellular mechanisms – many of
which converge on members of the vascular endothelial growth factor (VEGF) family – tumor
cells are capable of stimulating the formation of new blood vessels within their local
microenvironment through a process known as neo-angiogenesis (Hanahan and Folkman, 1996).
In contrast to the blood vessels present in non-tumor-containing tissues, the neo-vasculature
created by cancer cells is quite tortuous and is prone to vascular leakiness (Jain, 2005;
Stockmann et al., 2008). Accordingly, because the intercellular interactions between endothelial
cells lining the lumina of tumor-associated blood vessels are inherently weak, it is probable that
locally invasive carcinoma cells can often cross into the lumen of a tumor-proximal blood vessel
without substantial difficulty – and perhaps even in the absence of additional acquired molecular
alterations.
4. Survival in the Circulation
Once they have successfully intravasated into the lumen of a blood vessel, tumor cells
can be broadly disseminated throughout the body via transit through the hematogenous
circulation. Recent technological advances have facilitated the direct detection of tumor cells
within the bloodstream of human cancer patients (Nagrath et al., 2007; Pantel et al., 2008). Of
interest, it has been demonstrated that quantitation of the overall numbers of circulating tumor
cells present in patients afflicted with any of a variety of carcinoma types provides a prognostic
indicator of likely disease outcome (Pantel et al., 2008), as well as a means by which to rapidly
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gauge the responsiveness of a given tumor to neo-adjuvant or adjuvant therapies (Maheswaran et
al., 2008). Thus, tumor cells can indeed be detected in the bloodstream of carcinoma patients;
ostensibly, these isolates contain the precursor cells of eventual overt metastases that are actively
in the process of disseminating.
Carcinoma cells present in the hematogenous circulation must survive a variety of
cellular stresses in order to reach a secondary organ site intact. First, tumor cells in the
circulation are deprived of integrin-conferred adhesion to the ECM (Reddig and Juliano, 2005).
Because this integrin-mediated signaling provides a source of essential survival-promoting
signals, epithelial cells that lack proper cell-matrix adhesion normally undergo anoikis – a form
of apoptotic cell death triggered by the loss of anchorage to a substratum (Reddig and Juliano,
2005). At a molecular level, anoikis is regulated by a number of cell surface receptors, including
various integrins (Gupta and Massagué, 2006). Thus, in order for tumor cells to survive
vasculature-mediated transport, it appears that they may first have to become refractory to
anoikis-mediated cell death by constitutively activating pro-survival signaling pathways that are
otherwise dampened upon matrix detachment.
Additionally, tumor cells in the systemic circulation must overcome two additional
threats in order to survive until they reach a secondary organ site: (1) the damages imposed by
hemodynamic shear forces and (2) detection by predatory cells of the immune system (Gupta and
Massagué, 2006). Conveniently, carcinoma cells seem to be capable of simultaneously evading
both of these cytotoxic influences through the utilization of a single mechanism involving the co-
option of platelets. More specifically, by forming relatively large emboli via interactions with
blood platelets, tumor cells are able to both shield themselves from shear forces and also evade
immune detection (Nash et al., 2002). Thus, platelet-coated tumor cells that have also become
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resistant to anoikis are able to persist in a viable state within the circulation until they arrest at a
secondary tissue locus.
5. Arrest at a Distant Organ Site
Eventually, tumor cells that retain viability within the systemic circulation will become
lodged in the microvasculature present at an anatomically distant organ site. Despite the
theoretical ability of metastasizing carcinoma cells traveling through the hematogenous
circulation to disseminate to a wide variety of secondary loci, clinicians have long-noted that
individual carcinoma types stereotypically form metastases at only a limited subset of these sites
(Fidler, 2003; Gupta and Massagué, 2006). Of relevance to this observation, one point of
contention within the metastasis research community concerns whether tumor cells actively
“home” to specific distant organs at an appreciable frequency via genetically driven ligand-
receptor interactions or, instead, predominantly simply arrest within capillary beds stochastically
due to size restrictions imposed by the diameters of those blood vessels (Gupta and Massagué,
2006). To be certain, the anatomical layout of the vasculature precludes the arrest of carcinoma
cells within the capillary beds of certain distant organ sites when those capillary beds lie
downstream of other microvessels whose diameter is insufficient to permit the passage of
circulating tumor cells (Fidler, 2003; Gupta and Massagué, 2006).
However, compelling evidence has also been obtained indicating that at least certain
populations of carcinoma cells are capable of forming specific adhesive interactions – mediated
by cell-matrix adhesion molecules, cell-cell adhesion molecules, or chemokine receptors – at
particular secondary organ sites, which preferentially favor entrapment of the disseminating
tumor cells there (Gupta and Massagué, 2006). For example, expression of _3_1 integrin
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heterodimers on the membranes of disseminating breast carcinoma cells and fibrosarcoma cells
has been proposed to mediate their lung-selective arrest via interactions with the cognate ligand
of _3_1 integrin – laminin-5 – which lies exposed on the surface of the pulmonary vascular
basement membrane (Wang et al., 2004). The relative prevalence of these and analogous
molecularly driven strategies that facilitate the organ-specific arrest of disseminated carcinoma
cells awaits future study.
6. Extravasation
Regardless of the particular mechanism by which cancer cells initially become trapped
within the microvasculature at a distant organ site, tumor cells lodged in blood vessels are likely
to attempt to extravasate from the lumen of those vessels into the parenchyma of that tissue. In
order to do so, carcinoma cells must cross the endothelial cell layer that separates vessel lumina
from the stromal microenvironment of that organ (Fidler, 2003; Gupta and Massagué, 2006).
Superficially, extravasation seems to represent the exact reverse of the process of
intravasation; however, there are reasons to believe that these processes may, in fact, be
mechanistically quite distinct from one another. As discussed previously, the neo-vasculature
formed by a tumor at its primary site of growth is tortuous and leaky (Jain, 2005; Stockmann et
al., 2008); conversely, endothelial cell permeability at a secondary organ site can be very low
(Nguyen et al., 2009). For example, incipient metastatic carcinoma cells attempting to reach the
brain parenchyma must traverse the blood-brain barrier; similarly, the endothelial cells lining the
lumina of pulmonary microvessels are largely impermeable. In contrast, however, carcinoma
cells arriving in the bone encounter fenestrated sinusoids that likely pose only a minor obstacle
to extravasating tumor cells (Nguyen et al., 2009). Thus, the nature of the specific tissue
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microenvironment present at the site of metastasis holds great consequences for the progression
and fate of disseminated tumor cells – a critically important point that will be revisited in greater
detail below.
Molecular mediators of extravasation have historically proven difficult to identify.
However, a recent study discovered that angiopoietin-like 4 (Angptl4) promotes lung metastasis
in human breast cancer xenograft models via disruption of pulmonary vascular endothelial cell
cell-cell junctions, thereby increasing retention of the carcinoma cells at this metastatic locus
(Padua et al., 2008). Of note, Anglptl4 did not augment the metastatic abilities of these same
breast cancer cells to the bone, nor did Anglptl4 enhance their intravasation efficiency (Padua et
al., 2008); hence, Anglptl4 specifically promoted the process of extravasation, and did so only
within the particular microenvironmental context of the lung. These findings provide empirical
evidence for a model in which extravasation at certain secondary organ sites necessitates defined
genetic programs that are not required for either intravasation away from a primary tumor or
extravasation at alternative secondary organ sites.
7. Initial Survival in a Foreign Microenvironment and Micrometastasis Formation
Although examples of intraluminal metastatic growth have been reported (Al-Mehdi et
al., 2000), metastases predominantly arise following the extravasation of tumor cells into the
parenchyma of a secondary organ site. A critical pre-requisite for metastasis formation therefore
becomes an acquired ability of disseminated carcinoma cells that have successfully extravasated
to survive within the foreign microenvironment afforded by the tissue parenchyma present at the
site of metastasis (Fidler, 2003; Gupta and Massagué, 2006). At first glance, this may seem to
represent a rather trivial hurdle for a metastasizing carcinoma cell that has already endured
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numerous perils in order to translocate systemically; however, the cells that populate a primary
tumor were evolutionarily selected on the basis of accumulated genetic alterations that promoted
their ability to survive and proliferate specifically within their orthotopic site of growth
(Hanahan and Weinberg, 2000). Thus, if the microenvironment at the site of metastasis differs
substantially from that previously encountered by the carcinoma cells at the primary tumor locus
– in terms of either the representation of heterotypically signaling stromal cells, the constituency
of the surrounding ECM, or the spatial architecture of the tissue itself – then the disseminated
tumor cells are unlikely to be able to sufficiently activate certain requisite pro-survival molecular
signaling pathways within this novel microenvironment.
Some have proposed that carcinoma cells can solve this problem of an incompatible
microenvironment at the metastatic site via the establishment of a “pre-metastatic niche” (Kaplan
et al., 2005). According to this model, cancer cells residing in a primary tumor induce the
mobilization of hematopoietic progenitor cells from the bone marrow to the future site of
metastasis formation, and these hematopoietic cells then modify the local microenvironment of
that site by secreting matrix metallopeptidase 9 (MMP-9) – all of this occurring prior to the
carcinoma cells ever arriving at the secondary locus (Kaplan et al., 2005). Activation of MMP-9
at the future site of metastasis is believed to result in the stimulation of various integrins, as well
as the liberation of sequestered SDF-1 (Kaplan et al., 2005). Thus, tumor cells reaching this
modified anatomically distant microenvironment are able to more readily adapt to form
retention- and survival-promoting interactions with their new stromal milieu.
Notably, the creation of a supportive pre-metastatic niche could potentially represent a
broadly important determinant of metastatic propensity, as the organ site spectrum of metastases
formed by lung carcinoma cells can be altered simply by re-routing the niche-forming
30
hematopoietic cells to different organs (Kaplan et al., 2005). It is worth noting that aspects of the
molecular details underlying the pre-metastatic nice concept have recently been questioned
(Dawson et al., 2009), and thus this model remains controversial. More generally, however, it is
clear that tumor cells must deploy genetically driven cell-autonomous or cell-non-autonomous
means to modify the novel microenvironment encountered at the site of metastasis in order for
them to initially survive at an ectopic location and form small micrometastases.
8. Metastatic Colonization
Once disseminated tumor cells adapt to initially survive within an ectopic, secondary
microenvironment, the carcinoma cells usually do not rapidly progress from small
micrometastases into large, robustly growing macroscopic metastases. Instead, most of the
disseminated tumor cells persist in a state of apparent dormancy – retaining viability in the
absence of any net gain or net loss in overall cell number (Chambers et al., 2002). Two models –
which are not mutually exclusive – have been proposed to rationalize the behavior of these
occult micrometastases. In the first model, the tumor cells continue to proliferate within the
parenchyma of the new tissue, yet an increase in total cell number does not occur due to the
counterbalancing effects of a high rate of apoptosis in these actively dividing cells; a failure of
the disseminated cells to trigger neo-angiogenesis at the secondary locus has been proposed as a
possible mechanistic explanation for this phenomenon (Holmgren et al., 1995). The second
model holds that the disseminated tumor cells are largely quiescent, with their proliferation at the
metastatic site greatly impaired due to incompatibilities with the foreign microenvironment
encountered at the site of metastasis (Chambers et al., 2002).
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This appreciation that disseminated tumor cells often encounter significant difficulties as
they attempt to form macroscopic metastases is not a new concept. In fact, more than 120 years
ago, Stephen Paget articulated his “seed and soil” hypothesis of metastatic outgrowth based upon
clinical observations detailing preferential metastasis of a given type of cancer to one or more
particular distant organ sites (Paget, 1889). This viewpoint posits that, while tumor cells are
broadly disseminated during the course of malignant progression, detectable metastases only
develop at those sites (“soils”) where the tumor cells (“seeds”) are suitably adapted for survival
and proliferation (Paget, 1889). Importantly, the “seed and soil” hypothesis does not distinguish
between the proliferation/apoptosis counterbalance model and the quiescence model of
micrometastatic dormancy.
Consistent with the “seed and soil” hypothesis, evidence emanating from a number of
laboratories – most notably the work of Fidler and colleagues – has directly documented that
specific organ microenvironments are indeed inherently more or less hospitable to certain types
of disseminated tumor cells, independent of influences stemming from the anatomical layout of
the vasculature (Hart and Fidler, 1980; Fidler, 2003). For example, melanoma cells readily
metastasized to sub-cutaneous grafts of lung tissue but failed to metastasize to identically placed
– and identically vascularized – sub-cutaneous grafts of renal tissue, thereby reflecting the
known proclivity of melanomas to form pulmonary metastases (Hart and Fidler, 1980; Fidler,
2003). More recently, the Massagué laboratory has identified a number of genes whose
expression facilitates the metastatic colonization of breast cancer cells specifically to either bone
(Kang et al., 2003), lung (Minn et al., 2005), or brain (Bos et al., 2009). Ostensibly, these genetic
factors favor outgrowth in an organ-selective manner due to their ability to allow disseminated
tumor cells to overcome specific obstacles to macroscopic metastasis formation imposed by the
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tissue microenvironment of a particular organ. Indeed, many of these genes play crucial roles of
apparent relevance to the colonization of only a single specific microenvironment. One example
of this is provided by the osteoclastic cytokine interleukin-11 (IL-11), which facilitates the
formation of osteolytic bone metastases by breast cancer cells (Kang et al., 2003). The
observation that these genetic factors act in a highly tissue site-specific manner further
underscores the reality that successful metastatic colonization requires a delicate interplay
between disseminated tumor cells and the particular microenvironment within which these cells
come to reside.
An additional consideration pertinent to the topic of metastatic colonization derives from
an appreciation that the precursor cells of macroscopic metastases must possess a relatively high
self-renewal capacity in order to form large malignant growths. On the basis of research carried
out over the last decade, some have proposed that only a sub-population of the neoplastic cells
present in a tumor – the so-called “tumor-initiating cells” (TICs) – possess the extensive self-
renewal capacity required to seed new tumors (Rosen and Jordan, 2009). Indeed, xenograft serial
transplantation studies involving several human tumor types lend support to this model, although
the applicability of these findings to all types of human malignancies remains a subject of
intensive ongoing debate (Rosen and Jordan, 2009). Of particular relevance to metastatic
colonization, the TIC hypothesis asserts that one or more TICs must disseminate from a primary
tumor during the course of disease progression in order for a macroscopic metastasis to develop;
accordingly, if a non-TIC disseminates to a secondary locus, its limited self-renewal capacity
precludes it from spawning a macroscopic metastasis (Brabletz et al., 2005). At a molecular
level, one class of molecules that has been implicated in regulating the TIC-state are EMT-
promoting transcription factors, such as Snail, Twist, and Zeb1 (Polyak and Weinberg, 2009);
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this unexpected convergence between a single molecular pathway that appears to promote both
motility and self-renewal is noteworthy, as the pleiotropic actions of these transcription factors
may concomitantly facilitate multiple distinct aspects of the metastatic process.
By concurrently solving microenvironmental incompatibilities and activating self-
renewal pathways via the actions of the genetic factors outlined above, some carcinoma cells
succeed in completing the endeavor of metastatic colonization and thereby generate
macroscopic, clinically detectable metastases (Fidler, 2003; Gupta and Massagué, 2006). The
formation of robustly growing macroscopic metastases represents the endpoint of the invasion-
metastasis cascade. In many respects, only those foci that have completed the process of
metastatic colonization truly ought to be referred to as “metastases”, as these are the only
malignant growths that have overcome the complex series of obstacles – from physical barriers
associated with preventing the initial escape of cancer cells from a primary tumor all of the way
through to the ability of disseminated carcinoma cells to adapt to survive and thrive within a
novel microenvironment – that normally operate to oppose metastasis formation. Hence, via the
accumulation of acquired genetic alterations, cancer cells are capable of completing an intricate,
multi-step cell-biologic process that culminates in the formation of macroscopic – and oftentimes
life-threatening – malignant growths at a secondary organ site.
Metastasis is a Highly Inefficient Process
The invasion-metastasis cascade – which, as detailed above, is the cell-biologic program
that governs the creation of metastases – is extraordinarily inefficient (Chambers et al., 2002).
For example, large numbers of circulating tumor cells can be detected within the bloodstream of
human cancer patients that possess few – if any – overt metastases (Nagrath et al., 2007). Thus,
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the ability of tumor cells to exit from their initial site of growth and intravasate into the systemic
circulation does not guarantee the subsequent formation of clinically detectable metastases.
This point was vividly demonstrated by observing ovarian cancer patients who were
provided palliative remediation via the insertion of peritoneovenous shunts (Tarin et al., 1984).
In addition to relieving pain, this treatment – which evacuates ascites fluid into the venous
circulation – liberated millions of cancer cells into the systemic circulation; nevertheless, these
patients largely failed to develop detectable metastases even several years after installation of the
shunts (Tarin et al., 1984). Taken together, these observations begin to suggest that later steps of
the invasion-metastasis cascade – namely, survival in the circulation, arrest at a distant organ
site, extravasation, initial survival in a foreign microenvironment to permit micrometastasis
formation, and/or metastatic colonization – are successfully completed at only a very low
frequency.
Detailed work in experimental model systems has further defined the particular steps of
the metastatic process that appear to be rate-limiting. More specifically, the Chambers laboratory
discovered that survival in the circulation, arrest at a distant organ site, and extravasation
occurred quite efficiently in multiple carcinoma cell types (Luzzi et al., 1998; Chambers et al.,
2002). In contrast, however, once tumor cells exited the lumen of a microvessel into the
parenchyma of a distant tissue, high rates of attrition were observed. Importantly, although a
significant number of successfully extravasated tumor cells failed to initially survive within a
foreign microenvironment and form micrometastases, the subsequent process of metastatic
colonization was substantially more inefficient – perhaps even by several orders of magnitude
(Luzzi et al., 1998; Chambers et al., 2002). Hence, it appears likely that metastatic colonization
typically represents the rate-limiting step of the invasion-metastasis cascade.
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Further support for this supposition is provided by clinical observations in carcinoma
patients concerning the kinetics of distant relapse and disease recurrence. In many human tumor
types – for example, breast cancers – detectable metastases often arise only many years or even
decades after the apparent complete resection of a patient’s primary tumor (Nguyen et al., 2009).
Because the metastatic cells must have been shed by the primary tumor prior to its surgical
removal, this implies that these cells persisted in an occult – yet viable – state for many years.
The most parsimonious interpretation of these clinical observations is that, although the incipient
metastatic precursor cells were capable of disseminating to a distant organ site and retaining
viability at that locus, the appearance of clinically detectable metastases was substantially
delayed due to the gross inefficiency of the process of metastatic colonization (Nguyen et al.,
2009). Ostensibly, during this long period of latency, the disseminated tumor cells underwent
gradual genetic evolution in order to overcome obstacles that initially precluded successful
metastatic colonization.
When taken together, these observations reveal that only an extremely small minority of
the cells that initially enter into the invasion-metastasis cascade ultimately complete the process
and yield macroscopic metastases. However, despite the high rates of cellular attrition that
accompany various steps of the metastatic process, metastasis-competent cells nevertheless
ultimately arise in many human cancer patients – where they often represent the source of
terminal disease (Fidler, 2003; Gupta and Massagué, 2006). Together, these points naturally
draw attention to questions regarding the cellular origin of the precursor cells of overt
metastases, as well as the timing and spatial localization of the genetic events that drive the
molecular evolution of these cells toward metastatic competence.
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How, When, and Where Do the Precursor Cells of Overt Metastases Arise During the
Course of Tumor Progression?
The above discussions indicate that (1) metastatic colonization is often the rate-limiting
step of the invasion-metastasis cascade and (2) the genetic and cell-biologic requirements for a
tumor cell to thrive at an orthotopic site versus an ectopic site can be quite different. It is
therefore reasonable to ponder how – under the Darwinian clonal selection model of cancer
pathogenesis – metastasis-competent cells can initially arise at the requisite frequency within a
primary tumor (Bernards and Weinberg, 2002). In some instances, the answer may be somewhat
trivial: certain genetic changes can confer acquired abilities that promote cellular proliferation
and/or survival at both the primary site of growth and at a metastatic locus. Genes whose altered
activities participate in tumor progression in this manner have been termed “metastasis initiation
genes” and “metastasis progression genes” (Nguyen et al., 2009). In the case of pleiotropically
acting factors, even if the specific biochemical function responsible for endowing these growth-
promoting attributes differs between the context of a primary tumor and an ectopic
microenvironment, selection for heightened overall activity of the factor may still occur during
primary tumor development. This might lead, in turn, to enrichment of cells possessing this
genetic alteration within the primary tumor and thus an increased probability for those cells to
initiate the invasion-metastasis cascade.
More puzzling is the problem of how cells expressing “metastasis virulence genes” – i.e.,
genetic factors that confer a proliferation and/or survival advantage only within the context of
specific ectopic, secondary microenvironments (Nguyen et al., 2009) – can arise at an
appreciable frequency during the course of malignant progression. Because altered activity of
these gene products – by definition – does not impact primary tumor development, cells
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expressing these factors cannot possibly be selected for during the evolution of a primary tumor
under the Darwinian model (Bernards and Weinberg, 2002). Nevertheless, in light of the fact that
metastatic disease often involves the aberrant activity of such metastasis virulence genes
(Nguyen et al., 2009), it is clear that cells bearing these genetic alterations do arise at a
reasonably high frequency. One possible explanation for this observation involves the stochastic
accumulation of genetic changes affecting metastasis virulence genes as “passenger mutations”
within tumor cell populations that possess unrelated “driver mutations” (Sjöblom et al., 2006;
Wood et al., 2007) that serve as the basis for the initial clonal expansion of these cells within a
primary tumor. Accordingly, purely by chance, sub-populations of cells that inadvertently
possess a high proclivity for metastasis formation might come to exist within a primary tumor.
An alternative model to explain how cells expressing metastasis virulence genes can arise
at a frequency sufficient to induce metastasis formation considers the possibility that cells might
disseminate from a primary cancerous lesion relatively early during the course of tumor
progression. These early disseminating cells are then proposed to undergo multiple rounds of
clonal selection already within the specific microenvironment where overt metastases will
ultimately develop – notably, a microenvironment where genetic alterations in metastasis
virulence genes can now be evolutionarily selected for (Klein, 2009). This so-called “parallel
progression model” was recently put forth by Klein and coworkers in light of several
independent observations from human carcinoma patients and experimental animal models: (1)
not-yet fully neoplastic cells are routinely disseminated in a systemic manner from even the
earliest pre-malignant lesions (Nagrath et al., 2007; Hüsemann et al., 2008), (2) untransformed
epithelial cells present in the systemic circulation can survive within the vasculature, arrest at a
distant organ site, extravasate, and initially survive in a foreign tissue microenvironment
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(Podsypanina et al., 2008), (3) early-disseminating pre-neoplastic cells retain at least some
capacity for cell proliferation at a secondary organ site (Hüsemann et al., 2008; Podsypanina et
al., 2008), and (4) patient-matched primary tumors and distant metastases can harbor
significantly different spectra of genetic alterations (Schmidt-Kittler et al., 2003). Thus, it is
possible that only partially aberrant cells disseminated relatively early during the course of
disease progression represent the precursor cells of overt metastases, owing to the gradual clonal
evolution of these cells at the site of eventual metastasis formation – all of this occurring
independently from the clonal expansion transpiring within the population of cells that comprise
the primary tumor from which these disseminated cells were initially spawned. If ultimately
proven correct, the parallel progression model would represent a major paradigm shift, and
would hold major implications for the design of effective therapeutic agents aimed at the
remediation of metastatic disease.
Importantly, the parallel progression model is not disproved by the observation that gene
expression signatures predictive of the propensity for metastatic progression can be identified by
microarray analysis of carcinoma patient primary tumors (v’ant Veer et al., 2002; Ramaswamy et
al., 2003). This is because the “metastasis signatures” could, in actuality, represent
“dissemination signatures” that facilitate the escape of not-yet fully neoplastic cells to an ectopic
secondary organ site, where these cells would then serve as the fodder for Darwinian selection.
Instead, the major conceptual incongruence that must be reconciled by proponents of the parallel
progression model concerns how the quasi-normal cells shed to distant organ sites can possibly
undergo enough successive cell divisions within a foreign microenvironment that does not
inherently support their proliferation to generate the genetic diversity required for subsequent
clonal selection. Further resolution of this point represents an important topic of ongoing
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research; until a mechanistic rationale for this issue can be provided, the parallel progression
model is likely to remain controversial.
Progress Toward a Detailed Molecular Understanding of Tumor Metastasis
As outlined in the preceding discussions, although a number of fundamental questions
concerning the basic nature of metastasis remain unresolved, research conducted over the past
decade has begun to implicate the actions of specific genetic factors in the regulation of discrete
cell-biologic aspects of the invasion-metastasis cascade. A diverse array of approaches have been
undertaken to this end, including a number of genomics- and functional-genomics-based
strategies, which have yielded a bevy of novel regulators of the metastatic phenotype (Clark et
al., 2000; van’t Veer et al., 2002; Ramaswamy et al., 2003; Kang et al., 2003; Minn et al., 2005;
Bos et al., 2009). Together, these studies have generated promising candidates for the
development of clinically informative prognostic biomarkers for metastatic progression, as well
as putative therapeutic targets for the remediation of metastatic disease. Also of interest, the first
two whole-genome sequences of patient-matched primary breast tumors and distant metastases
have recently been reported (Shah et al., 2009; Ding et al., 2010); while sample sizes are, at
present, too limited for meaningful interpretation of these findings, it is highly likely that
additional sequencing-based cataloging of the full roster of genetic alterations present in
clinically arising primary tumors and paired metastases will succeed in enumerating previously
unappreciated regulators of the metastatic process.
Importantly, however, despite intensive investigation, the currently assembled list of
metastasis-relevant genes is quite rudimentary, and alternative approaches for the identification
of molecular regulators of metastasis are required in order to more fully comprehend the highly
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complex etiology of metastatic disease. Moreover, the bulk of the prior work conducted on
molecular mediators of tumor metastasis has focused on the roles of traditional protein-encoding
genes. More recently, however, additional classes of regulatory molecules of putative importance
to the regulation of metastatic progression have been uncovered. One prominent class of
understudied potential modulators of metastasis are microRNAs (miRNAs).
MicroRNAs
miRNAs are an evolutionarily conserved family of short regulatory RNAs that modulate
gene expression post-transcriptionally via sequence-specific interactions with the 3’ untranslated
regions (UTRs) of cognate mRNA targets (Ambros, 2004; Bartel, 2004). miRNAs were
originally identified by Ambros and Ruvkun through forward genetic screens in the nematode
worm C. elegans (Lee et al., 1993; Wightman et al., 1993). Initially considered a peculiarity of
worm development, it was only years later – after the discovery of RNA-interference
technologies (Fire et al., 1998) and elucidation of the first miRNA that was evolutionarily
conserved from nematodes to humans (Reinhart et al., 2000) – that miRNAs began to attract
widespread attention. Although this field is still in its infancy, remarkable progress has been
made over the past decade; consequently, we are now beginning to comprehend in significant
detail the mechanisms underlying miRNA biogenesis, miRNA targeting specificity, and the
biochemical means by which miRNAs silence gene expression post-transcriptionally (Filipowicz
et al., 2008; Bartel, 2009).
At present, more than 650 human miRNAs have been identified (Bartel, 2009). Because
each individual miRNA is capable of simultaneously modulating the expression levels of dozens
of distinct mRNA targets, current estimates posit that greater than half of the total mRNA species
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encoded in the human genome are subject to miRNA-mediated regulation (Friedman et al.,
2009). Therefore, it is perhaps not surprising that the pleiotropic actions of individual miRNAs
enable them to function as crucial regulators of cell and organismal homeostasis; indeed, specific
miRNAs critically modulate a variety of normal physiologic processes (Ambros, 2004; Bartel,
2004). Additionally, aberrant miRNA activity contributes to a number of pathological states,
including tumorigenic development (Esquela-Kerscher and Slack, 2006; Ventura and Jacks,
2009; Sotiropoulou et al., 2009).
MicroRNAs and Cancer
A role for miRNAs in cancer was first revealed by the work of Croce and associates, who
discovered that miR-15 and miR-16 were frequently deleted in human chronic lymphocytic
leukemias (Calin et al., 2002). Subsequent analyses revealed that these two miRNAs function as
bona fide tumor suppressor genes by inducing cell cycle arrest and apoptosis (Calin and Croce,
2006). Provocatively, more than 50% of miRNA-encoding genomic loci reside in chromosomal
regions that are known to be altered during the course of tumor pathogenesis (Calin et al., 2004),
and global downregulation of miRNA levels in human tumors has been reported (Lu et al.,
2005). Furthermore, characteristic aberrant miRNA expression profiles that are strongly
associated with both disease status and ultimate clinical outcome have been identified in many
types of neoplasias (Calin and Croce, 2006). Alterations in miRNA levels occurring during
tumor development are not epiphenomena of cancer pathogenesis, since genetic inhibition of the
miRNA biogenesis machinery accelerates tumor progression (Kumar et al., 2007; Kumar et al.,
2009). Consequently, modulation of the expression levels of certain miRNAs is likely to play a
causal role in tumorigenesis.
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In fact, research conducted over the past five years has revealed that the genes encoding a
number of miRNAs behave as classically defined oncogenes or tumor suppressor genes.
Mechanistically, many of these cancer-relevant miRNAs appear to exert their influences on
tumor progression via the downregulation of previously appreciated components of the
integrated circuit of a cancer cell (Esquela-Kerscher and Slack, 2006; Ventura and Jacks, 2009;
Sotiropoulou et al., 2009). Thus, miRNAs are likely to represent critical control nodes within
neoplastic signaling circuitry whose overall design is already well-established. Together, these
cancer-relevant miRNAs function in myriad distinct aspects of tumorigenesis (Esquela-Kerscher
and Slack, 2006; Ventura and Jacks, 2009; Sotiropoulou et al., 2009). As such, miRNAs
participate in critical ways in the regulation of essentially all aspects of tumor biology, including
metastatic progression.
MicroRNAs and Metastasis
miR-10b was the first miRNA recognized to alter the metastatic potential of human
cancer cells (Ma et al., 2007). Via gain-of-function approaches, it was demonstrated that ectopic
miR-10b expression endowed otherwise-non-aggressive human breast cancer cells with the
capacity to become motile and invasive, as well as seed distant micrometastases when implanted
as tumor xenografts (Ma et al., 2007). Subsequently, an unbiased functional genetic screen
involving the overexpression of approximately 450 miRNAs identified the miR-373/520c seed
family as pro-metastatic miRNAs in human breast cancer cells; once again, these effects were
ostensibly due to the ability of these miRNAs to promote cell motility and invasiveness (Huang
et al., 2008). Soon thereafter, miR-21 was highlighted as yet another motility- and metastasis-
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promoting miRNA in human breast and colorectal carcinoma cells (Asangani et al., 2008; Zhu et
al., 2008).
By combining in vivo selection for highly metastatic variants with gene expression
profiling, Massagué and co-workers implicated miR-126, miR-206, and miR-335 as the first
metastasis-suppressing miRNAs (Tavazoie et al., 2008). When ectopically expressed in breast
cancer xenograft models, these three miRNAs exerted unique effects on distinct aspects of the
metastatic process: whereas miR-126 acted as a general inhibitor of tumor cell proliferation (at
both the primary site and in distant organs), miR-206 and miR-335 instead specifically inhibited
cell motility and invasiveness (Tavazoie et al., 2008). Additionally, in a study comparing
metastasis-specific methylation of the promoters of human miRNA genes, miR-34b/c and miR-
148a were implicated as miRNAs whose overexpression was sufficient to impair metastasis
formation in human head-and-neck carcinoma xenografts by virtue of their ability to impede cell
motility and invasiveness (Lujambio et al., 2008).
While gain-of-function approaches in xenograft assays have demonstrated that each of
the aforementioned miRNAs was capable of altering metastatic capacity, it has remained unclear
whether these effects could be attributed specifically to influences on one or more steps of the
invasion-metastasis cascade. Resolution of this question has been obscured by the potentially
confounding reported influences of each of these miRNAs on primary tumor development, cell
proliferation, and/or apoptosis (Voorhoeve et al., 2006; Ma et al., 2007; Sathyan et al., 2007; Si
et al., 2007; Kondo et al., 2008; Tavazoie et al., 2008; Lujambio et al., 2008). Hence, the extent
to which miRNAs are capable of specifically regulating metastasis has remained incompletely
understood.
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Importantly, because an individual miRNA is capable of simultaneously regulating the
expression levels of dozens of target genes – and thus controlling numerous different signaling
networks together in parallel – deregulation of a single miRNA can potentially affect the
completion of multiple distinct steps of the invasion-metastasis cascade. This, in turn, would
carry significant implications for our understanding of the pathogenesis of high-grade
malignancies, as the functional pleiotropy of individual miRNAs might provide one explanation
for how tumor cells can accumulate the requisite genetic and epigenetic aberrations needed to
override the multiple safeguards that normally operate to prevent metastasis over the course of a
typical human lifespan.
Main Questions Addressed
As indicated above, our knowledge regarding the identity of molecular regulators of the
complex process of tumor metastasis remains only fragmentary. Hence, the studies that I
conducted – and which will be described herein – strived to identify novel regulators of
metastatic progression via the implementation of two distinct experimental approaches.
Moreover, the cell-biologic consequences of perturbing the expression levels of several of these
newly identified modulators of metastasis were investigated, as were the molecular mechanisms
underlying these observed responses.
First, I attempted to discern whether particular miRNAs played a vital role in controlling
breast cancer metastasis. At the time that these studies were initially undertaken, a role for
miRNAs in the regulation of tumor metastasis remained unexplored. In light of the pleiotropic
nature of gene regulation exhibited by miRNAs, I hypothesized that certain miRNAs might be
endowed with a capacity to crucially modulate metastatic progression. An expression-based
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screen for miRNAs whose levels were associated with metastatic potential in human breast
cancer cells uncovered the miRNA miR-31 as a putative regulator of metastasis. I then
investigated the possibility that miR-31 might function as a bona fide overseer of breast cancer
metastasis due to a capacity to intervene during multiple distinct steps of the invasion-metastasis
cascade via the pleiotropic suppression of a cohort of downstream effector molecules.
Second, I hypothesized that prior approaches for the identification of genetic factors
involved in metastatic progression had failed to enumerate a number of crucially important
metastasis-regulatory molecules due to the inability of these previous strategies to properly
preserve and assay the extensive – and functionally critical – heterogeneity intrinsic to tumor cell
populations. Therefore, I devised a novel experimental system for the unbiased discovery of
genes whose encoded products contribute to tumor metastasis and associated cell-biologic pre-
requisites for metastasis formation. Importantly, this new experimental approach was capable of
maintaining and investigating the profound phenotypic heterogeneity and genetic diversity that
pre-exists within tumor cell populations.
Collectively, these studies provide mechanistic insights regarding the genetic events that
drive the complex cell-biologic processes underlying the invasion-metastasis cascade. These
findings have implications for our comprehension of the etiology of metastatic disease.
Additionally, this work identifies novel genes that may one day serve as clinically useful
prognostic biomarkers and/or potential therapeutic targets for certain metastatic human
carcinomas.
46
REFERENCES
Al-Mehdi AB, Tozawa K, Fisher AB, et al. (2000). Intravascular origin of metastasis from the
proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 6, 100-
102.
Ambros V. (2004). The functions of animal microRNAs. Nature 431, 350-355.
Asangani IA, Rasheed SA, Nikolova DA, et al. (2008). MicroRNA-21 post-transcriptionally
downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in
colorectal cancer. Oncogene 27, 2128-2136.
Bartel DP. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116, 281-
297.
Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
Bernards R and Weinberg RA. (2002). A progression puzzle. Nature 418, 823.
Bos PD, Zhang XH, Nadal C, et al. (2009). Genes that mediate breast cancer metastasis to the
brain. Nature 459,1005-1009.
Brabletz T, Jung A, Spaderna S, Hlubek F, and Kirchner T. (2005). Migrating cancer stem cells –
an integrated concept of malignant tumour progression. Nat Rev Cancer 5, 744-749.
Calin GA and Croce CM. (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6,
857-866.
Calin GA, Dumitru CD, Shimizu M, et al. (2002). Frequent deletions and down-regulation of
micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA 99, 15524-15529.
Calin GA, Sevignani C, Dumitru CD, et al. (2004). Human microRNA genes are frequently
located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101,
2999-3004.
Chambers AF, Groom AC, and MacDonald IC. (2002). Dissemination and growth of cancer cells
in metastatic sites. Nat Rev Cancer 2, 563-572.
Clark EA, Golub TR, Lander ES, and Hynes RO. (2000). Genomic analysis of metastasis reveals
an essential role for RhoC. Nature 406, 532-535.
Coussens LM, Fingleton B, and Matrisian LM. (2002). Matrix metalloproteinase inhibitors and
cancer: trials and tribulations. Science 295, 2387-2392.
47
Dawson MR, Duda DG, Fukumura D, and Jain RK. (2009). VEGFR1-activity-independent
metastasis formation. Nature 461, E4-E5.
Dean M, Fojo T, and Bates S. (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5,
275-284.
Desmedt C, Haibe-Kains B, Wirapati P, et al. (2008). Biological processes associated with breast
cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 14, 5158-5165.
Ding L, Ellis MJ, Li S, et al. (2010). Genome remodelling in a basal-like breast cancer metastasis
and xenograft. Nature 464, 999-1005.
Esquela-Kerscher A, Slack FJ. (2006). Oncomirs - microRNAs with a role in cancer. Nat Rev
Cancer 6, 259-269.
Fidler IJ. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.
Nat Rev Cancer 3, 453-458.
Filipowicz W, Bhattacharyya SN, and Sonenberg N. (2008). Mechanisms of post-transcriptional
regulation by microRNAs: are the answers in sight? Nat Rev Genet 9,102-114.
Finak G, Bertos N, Pepin F, et al. (2008). Stromal gene expression predicts clinical outcome in
breast cancer. Nat Med 14, 518-527.
Fire A, Xu S, Montgomery MK, et al. (1998). Potent and specific genetic interference by double-
stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
Friedl P and Wolf K. (2003). Tumour-cell invasion and migration: diversity and escape
mechanisms. Nat Rev Cancer 3, 362-374.
Friedman RC, Farh KK, Burge CB, and Bartel DP. (2009). Most mammalian mRNAs are
conserved targets of microRNAs. Genome Res 19, 92-105.
Gupta GP and Massagué J. (2006). Cancer metastasis: building a framework. Cell 127, 679-695.
Hanahan D and Folkman J. (1996). Parameters and emerging mechanisms of the angiogenic
switch during tumorigenesis. Cell 86, 353-364.
Hanahan D and Weinberg RA. (2000). The hallmarks of cancer. Cell 100, 57-70.
Hart IR and Fidler IJ. (1980). Role of organ selectivity in the determination of metastatic patterns
of B16 melanoma. Cancer Res 40, 2281-2287.
Holmgen L, O’Reilly MS, and Folkman J. (1995). Dormancy of micrometastases: balanced
proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1, 149-153.
48
Huang Q, Gumireddy K, Schrier M, et al. (2008). The microRNAs miR-373 and miR-520c
promote tumour invasion and metastasis. Nat Cell Biol 10, 202-210.
Hüsemann Y, Geigl JB, Schubert F, et al. (2008). Systemic spread is an early step in breast
cancer. Cancer Cell 13, 58-68.
Jain RK. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic
therapy. Science 307, 58-62.
Joyce JA and Pollard JW. (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer
9, 239-252.
Kang Y, Siegel PM, Shu W, et al. (2003). A multigenic program mediating breast cancer
metastasis to bone. Cancer Cell 3,537-549.
Kaplan RN, Riba RD, Zacharoulis S, et al. (2005). VEGFR1-positive haematopoietic bone
marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827.
Karnoub AE, Dash AB, Vo AP, et al. (2007). Mesenchymal stem cells within tumour stroma
promote breast cancer metastasis. Nature 449, 557-563.
Kinzler KW and Vogelstein B. (1996). Lessons for hereditary colorectal cancer. Cell 87, 159-
170.
Klein CA. (2009). Parallel progression of primary tumours and metastases. Nat Rev Cancer 9,
302-312.
Kondo N, Toyama T, Sugiura H, Fujii Y, and Yamashita H. (2008). miR-206 Expression is
down-regulated in estrogen receptor _-positive human breast cancer. Cancer Res. 68, 5004-5008.
Kumar MS, Lu J, Mercer KL, Golub TR, and Jacks T. (2007). Impaired microRNA processing
enhances cellular transformation and tumorigenesis. Nat Genet 39, 673-677.
Kumar MS, Pester RE, Chen CY, et al. (2009). Dicer1 functions as a haploinsufficient tumor
suppressor. Genes Dev 23, 2700-2704.
Lauffenburger DA and Horwitz AF. (1996). Cell migration: a physically integrated molecular
process. Cell 84, 359-369.
Lee RC, Feinbaum RL, and Ambros V. (1993). The C. elegans heterochronic gene lin-4 encodes
small RNAs with antisense complementarity to lin-14. Cell 75, 843–854.
Lu J, Getz G, Miska EA, et al. (2005). MicroRNA expression profiles classify human cancers.
Nature 435, 834-838.
49
Lujambio A, Calin GA, Villanueva A, et al. (2008). A microRNA DNA methylation signature
for human cancer metastasis. Proc Natl Acad Sci USA 105, 13556-13561.
Luzzi KJ, MacDonald IC, Schmidt EE, et al. (1998). Multistep nature of metastatic inefficiency:
dormancy of solitary cells after successful extravasation and limited survival of early
micrometastases. Am J Pathol 153, 865-873.
Ma L, Teruya-Feldstein J, and Weinberg RA. (2007). Tumour invasion and metastasis initiated
by microRNA-10b in breast cancer. Nature 449, 682-688.
Maheswaran S, Sequist LV, Nagrath S, et al. (2008). Detection of mutations in EGFR in
circulating lung-cancer cells. N Engl J Med 359, 366-377.
Minn AJ, Gupta GP, Siegel PM, et al. (2005). Genes that mediate breast cancer metastasis to
lung. Nature 436, 518-524.
Nagrath S, Sequist LV, Maheswaran S, et al. (2007). Isolation of rare circulating tumour cells in
cancer patients by microchip technology. Nature 450, 1235-1239.
Nash GF, Turner LF, Scully MF, and Kakkar AK. (2002). Platelets and cancer. Lancet Oncol 3,
425-430.
Nelson CM and Bissell MJ. (2006). Of extracellular matrix, scaffolds, and signaling: tissue
architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22, 287-
309.
Nguyen DX, Bos PD, and Massagué J. (2009). Metastasis: from dissemination to organ-specific
colonization. Nat Rev Cancer 9, 274-284.
Nowell PC. (1976). The clonal evolution of tumour cell populations. Science 194, 23-28.
Orimo A, Gupta PB, Sgroi DC, et al. (2005) Stromal fibroblasts present in invasive human breast
carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.
Cell 121, 335-348.
Padua D, Zhang XH, Wang Q, et al. (2008). TGFbeta primes breast tumors for lung metastasis
seeding through angiopoietin-like 4. Cell 133, 66-77.
Paget S. (1889). The distribution of secondary growths in cancer of the breast. Lancet 1, 99-101.
Pantel K, Brakenhoff RH, and Brandt B. (2008). Detection, clinical relevance and specific
biological properties of disseminating tumour cells. Nat Rev Cancer 8, 329-340.
Podsypanina K, Du YC, Jechlinger M, et al. (2008). Seeding and propagation of untransformed
mouse mammary cells in the lung. Science 321, 1841-1844.
50
Polyak K and Weinberg RA. (2009). Transitions between epithelial and mesenchymal states:
acquisition of malignant and stem cell traits. Nat Rev Cancer 9, 265-273.
Ramaswamy S, Ross KN, Lander ES, and Golub TR. (2003). A molecular signature of
metastasis in primary solid tumors. Nat Genet 33, 49-54.
Reddig PJ and Juliano RL. (2005). Clinging to life: cell to matrix adhesion and cell survival.
Cancer Metastasis Rev 24, 425-439.
Reinhart BJ, Slack FJ, Basson M, et al. (2000). The 21 nucleotide let-7 RNA regulates
developmental timing in Caenorhabditis elegans. Nature 403, 901–906.
Rosen JM and Jordan CT. (2009). The increasing complexity of the cancer stem cell paradigm.
Science 324, 1670-1673.
Sahai E. (2005). Mechanisms of cancer cell invasion. Curr Opin Genet Dev 15, 87-96.
Sathyan P, Golden HB, and Miranda RC. (2007). Competing interactions between micro-RNAs
determine neural progenitor survival and proliferation after ethanol exposure. J Neurosci. 27,
8546-8557.
Schmidt-Kittler O, Ragg T, Daskalakis A, et al. (2003). From latent disseminated cells to overt
metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100,
7737-7742.
Shah SP, Morin RD, Khattra J, et al. (2009). Mutational evolution in a lobular breast tumour
profiled at single nucleotide resolution. Nature 461, 809-813.
Si ML, Zhu S, Wu H, Lu Z, Wu F, and Mo, YY. (2007). miR-21-mediated tumor growth.
Oncogene 26, 2799-2803.
Sjöblom T, Jones S, Wood LD, et al. (2006). The consensus coding sequences of human breast
and colorectal cancers. Science 314, 268-274.
Sørlie T, Perou CM, Tibshirani R, et al. (2001). Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-
10874.
Sotiropoulou G, Pampalakis G, Lianidou E, and Mourelatos Z. (2009). Emerging roles of
microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15, 1443-
1461.
Steeg PS. (2006). Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12,
895-904.
51
Stockmann C, Doedens A, Weidemann A, et al. (2008). Deletion of vascular endothelial growth
factor in myeloid cells accelerates tumorigenesis. Nature 456, 814-818.
Tarin D, Price JE, Kettlewell MG, et al. (1984). Mechanisms of human tumor metastasis studied
in patients with peritoneovenous shunts. Cancer Res 44, 3584-3592.
Tavazoie SF, Alarcón C, Oskarsson T, et al. (2008). Endogenous human microRNAs that
suppress breast cancer metastasis. Nature 451, 147-152.
The American Cancer Society. “Cancer Facts and Figures 2009”. 2009. www.cancer.org.
Thiery JP. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2,
442-454.
van’t Veer, Dai H, van de Vijver MJ, et al. (2002). Gene expression profiling predicts clinical
outcome of breast cancer. Nature 415, 530-536.
Ventura A and Jacks T. (2009). MicroRNAs and cancer: short RNAs go a long way. Cell 136,
586-591.
Visvader JE. (2009). Keeping abreast of the mammary epithelial hierarchy and breast
tumorigenesis. Genes Dev 23, 2563-2577.
Voorhoeve PM, le Sage C, Schrier M, et al. (2006). A genetic screen implicates miRNA-372 and
miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169-1181.
Wang H, Fu W, Im JH, et al. (2004). Tumor cell alpha3beta1 integrin and vascular laminin-5
mediate pulmonary arrest and metastasis. J Cell Biol 164, 935-941.
Wood LD, Parsons DW, Jones S, et al. (2007). The genomic landscapes of human breast and
colorectal cancers. Science 318, 1108-1113.
Wightman B, Ha I, and Ruvkun G. (1993). Posttranscriptional regulation of the heterochronic
gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855–862.
Yang J, Mani SA, Donaher JL, et al. (2004). Twist, a master regulator of morphogenesis, plays
an essential role in tumor metastasis. Cell 117, 927-939.
Zhu S, Wu H, Wu F, et al. (2008). MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res 18, 350-359.
52
Chapter 2
A Pleiotropically Acting
MicroRNA, miR-31, Inhibits
Breast Cancer Metastasis
Scott Valastyan1,2, Ferenc Reinhardt1, Nathan Benaich1,3, Diana Calogrias4,
Attila M. Szász4, Zhigang C. Wang5,6, Jane E. Brock4, Andrea L. Richardson4,
and Robert A. Weinberg1,2,7
1Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
2Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
3Department of Biology, Williams College, Williamstown, MA 01267, USA
4Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
5Department of Surgery, Brigham and Women’s Hospital, Boston, MA 02115, USA
6Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
7MIT Ludwig Center for Molecular Oncology, Cambridge, MA 02139, USA
53
This chapter is excerpted from the following publication (copyright permissions obtained):
Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson
AL, and Weinberg RA. (2009). A pleiotropically acting microRNA, miR-31, inhibits breast
cancer metastasis. Cell 137, 1032-1046.
F. Reinhardt provided technical assistance for the mouse studies. N. Benaich is a Williams
College summer student who assisted with several experiments. D. Calogrias, A.M. Szász, Z.C.
Wang, J.E. Brock, and A.L. Richardson provided clinical breast tumor specimens. A.M. Szász
also performed blinded histopathological assessment of the clinical specimens. A.L. Richardson
also assisted with data analysis pertaining to the clinical breast tumors. R.A. Weinberg
supervised the research and assisted with the writing of the manuscript. All other experiments,
data analysis, and writing were carried out by the thesis author, S. Valastyan.
54
INTRODUCTION
As described in Chapter One, metastases account for 90% of human cancer deaths (Gupta
and Massagué, 2006), yet our understanding of the molecular circuitry that governs metastatic
dissemination remains fragmentary. The invasion-metastasis cascade, which leads to these
growths, is a complex, multi-step process involving the escape of neoplastic cells from a primary
tumor (local invasion), intravasation into the systemic circulation, survival during transit through
the vasculature, extravasation into the parenchyma of distant tissues, the establishment of
micrometastases, and ultimately the outgrowth of macroscopic secondary tumors (colonization)
(Fidler, 2003).
MicroRNAs (miRNAs) constitute an evolutionarily conserved class of pleiotropically
acting small RNAs that suppress gene expression post-transcriptionally via sequence-specific
interactions with the 3’ untranslated regions (UTRs) of cognate mRNA targets (Bartel, 2009), as
was discussed previously in Chapter One. In mammalian cells, miRNAs effect gene silencing via
both translational inhibition and mRNA degradation; an individual miRNA is capable of
regulating dozens of distinct mRNAs, and together the >650 human miRNAs are believed to
modulate greater than one-third of the mRNA species encoded in the genome (Bartel, 2009).
As outlined in Chapter One, a central role for miRNAs in the establishment and
progression of human tumors has begun to emerge. More than 50% of miRNA-encoding loci
reside in chromosomal regions altered during tumorigenesis (Calin et al., 2004), and expression
profiling reveals characteristic miRNA signatures for many tumor types – including breast
neoplasias – that predict disease status and clinical outcome (Calin and Croce, 2006). In addition,
miRNAs have been identified that function as classical oncogenes or tumor suppressor genes
(Ventura and Jacks, 2009), as well as a limited number that act at late stages of tumor
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progression (Ma et al., 2007; Tavazoie et al., 2008; Huang et al., 2008; Asangani et al., 2008;
Zhu et al., 2008; Lujambio et al., 2008).
The extent to which miRNAs specifically affect metastasis remains unclear, as all the
miRNAs reported to affect metastasis also exert potentially confounding influences on primary
tumor development, apoptosis, and/or cell proliferation (Voorhoeve et al., 2006; Sathyan et al.,
2007; Ma et al., 2007; Si et al., 2007; Tavazoie et al., 2008; Kondo et al., 2008; Lujambio et al.,
2008) – a point that was highlighted previously in Chapter One. Moreover, a role for miRNAs in
steps of the invasion-metastasis cascade subsequent to local invasion has not been described.
The pleiotropic nature of gene regulation exhibited by miRNAs led me to hypothesize
that certain miRNAs might be endowed with a capacity to function as crucial modulators of
tumor metastasis. Here, I identify an anti-metastatic human miRNA, miR-31, that acts at
multiple steps of the invasion-metastasis cascade via repression of a cohort of pro-metastatic
targets.
RESULTS
miR-31 Expression is Specifically Attenuated in Metastatic Breast Cancer Cell Lines
To identify miRNAs that might regulate breast cancer metastasis, I selected 10 cancer-
associated miRNAs for further characterization due to their concordant identification among
expression profiling studies of clinical breast tumors (Iorio et al., 2005; Volinia et al., 2006),
global analysis of miRNA copy-number variation in human breast carcinomas (Zhang et al.,
2006), and localization of miRNA loci to cancer-relevant sites of chromosomal aberration (Calin
et al., 2004) (Supplementary Table 1). These studies did not stratify patients based on metastasis
status.
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Expression of the 10 candidate miRNAs was assayed in 15 human and mouse mammary
cell lines, which included normal epithelial cells, tumorigenic but non-metastatic cells, and
metastatic tumor cells (Supplementary Table 2). The levels of a single miRNA, miR-31, were
specifically attenuated in aggressive human breast cancer cells when compared to primary
normal human mammary epithelial cells (HMECs). While non-metastatic tumor cells (HMLER,
MCF7-Ras, and SUM-149) exhibited four-fold reduced miR-31, expression of this miRNA in
metastatic SUM-159 and MDA-MB-231 cells was diminished by >100-fold (Figure 1A).
Relative to its expression in normal murine mammary gland (NMuMG) cells, miR-31
levels in sub-lines derived from a single murine mammary tumor reflected their capacities to
metastasize: miR-31 was reduced by two-fold in metastatic D2.1 and D2A1 cells, but not in non-
aggressive D2.OR cells (Figure 1B). miR-31 levels were also inversely proportional to metastatic
ability in four mouse mammary carcinoma sub-lines derived from a single spontaneously arising
tumor: while miR-31 levels in non-aggressive 67NR cells were similar to those in NMuMG,
miR-31 expression was progressively diminished upon acquisition of the capacity to invade
locally (168FARN), to form micrometastases (4TO7), and to yield macroscopic metastases (4T1)
(Figure 1B). Thus, miR-31 levels are specifically attenuated in aggressive breast cancer cells.
miR-31 expression was heterogeneous in 4T1 cell primary mammary tumors; of note, the
proportion of cells expressing miR-31 was 10-fold reduced in lung metastases relative to the
fraction of miR-31-positive cells in the primary tumors from which they were derived (Figure
1C).  Also, five-fold fewer cells located near the invasive front of 4T1 cell mammary tumors
expressed miR-31, compared to cells in the interior of these tumors (Figure 1D). These data raise
the possibility that selective pressures diminish the prevalence of miR-31-expressing cells within
the pool of successfully metastasizing cells during the course of metastatic progression.
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miR-31 Expression Suppresses Metastasis-Relevant Traits in vitro
Given these inverse correlations between miR-31 levels and malignant phenotypes, I
assessed the potential for anti-metastatic roles for miR-31. Thus, I stably expressed miR-31 in
metastatic MDA-MB-231 human breast cancer cells (“231 cells”). This overexpression resulted
in miR-31 levels comparable to those in HMECs (Supplementary Figure 1A).
Ectopic miR-31 did not affect proliferation in vitro, but did reduce invasion by 20-fold
and motility by 10-fold (Figure 2A and Supplementary Figures 1B and 1C). These effects were
specifically attributable to the biological activities of miR-31, as equivalent overexpression of a
control miRNA, miR-145, failed to influence invasion or motility (Figure 2A and data not
shown). Also, miR-31-expressing cells exhibited 60% diminished resistance to anoikis-mediated
cell death (Figure 2B).
These defects could not be ascribed to toxicity resulting from ectopic miR-31
(Supplementary Figure 1D). The consequences of miR-31 expression were not unique to 231
cells: miR-31 reduced invasion, motility, and anoikis resistance, yet did not affect proliferation,
in aggressive SUM-159 human breast cancer cells (Supplementary Figure 2). Hence, miR-31
impairs in vitro surrogates of metastatic ability.
miR-31 Expression Suppresses Metastasis in vivo
Due to its effects on in vitro traits associated with high-grade malignancy, I asked if
ectopic miR-31 could inhibit metastasis in otherwise-aggressive cells. Thus, 231 cells expressing
miR-31 were injected into the orthotopic site – the mammary fat pad – of mice. Unexpectedly,
miR-31 enhanced primary tumor growth by 1.5-fold and correspondingly increased cell
proliferation (Figure 2C and Supplementary Figure 3A). Control 231 cell primary tumors
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displayed evidence of local invasion; however, miR-31-expressing tumors were well-
encapsulated and non-invasive (Figures 2D and 2E). These changes were not accompanied by
altered neo-vascularization (Supplementary Figure 3B).
Despite their ability to generate larger primary tumors, 231 cells expressing miR-31 were
strikingly impaired in their capacity to seed lung metastases. miR-31-expressing cells formed
95% fewer lesions than did controls 62 days post-implantation (Figure 2F). Thus, miR-31
suppresses metastasis from an orthotopic site, ostensibly due, at least in part, to its ability to
impede local invasion.
I addressed the possibility that miR-31’s impact on these parameters was attributable to
clonal variation in 231 cells by expressing miR-31 in a single-cell-derived population isolated
from the parental 231 cells (Supplementary Figure 4A) (Minn et al., 2005). As before, when
injected orthotopically, miR-31-expressing cells formed large, well-encapsulated primary tumors
and also reduced lung metastasis by five-fold (Supplementary Figures 4B-4D). Orthotopic
injection of SUM-159 cells expressing miR-31 further corroborated my earlier findings: miR-31
enhanced primary tumor growth, yet miR-31-expressing tumors were more well-confined than
control tumors (Supplementary Figure 5). These observations indicated that the ability of miR-
31-expressing cells to form larger, less invasive primary tumors, as well as to seed fewer
metastases, is a specific consequence of the biological activities of miR-31.
I determined if miR-31’s impact on metastasis was also attributable to effects on later
steps of the invasion-metastasis cascade, independent of its influence on local invasion. Thus, I
injected miR-31-expressing 231 cells directly into the circulation of mice, thereby circumventing
the initial steps of local invasion and intravasation. After one day, miR-31-expressing cells were
four-fold impaired in their ability to persist in the lungs (Figure 2G). This difference was not a
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consequence of an inability of miR-31-expressing cells to become lodged initially in the lung
microvasculature, as equal numbers of miR-31-expressing and control cells were detected in the
lungs 10 minutes and two hours post-injection (Figure 2G and Supplementary Figure 6A). These
observations suggested that miR-31 regulates early post-intravasation events, such as
intraluminal viability, extravasation, and/or initial survival in the lung parenchyma.
Three months after tail vein injection, miR-31-expressing 231 cells generated 40-fold
fewer lung metastases than did controls (Figure 2G). I also observed a dramatic effect on the size
of eventually formed lesions: after three months, miR-31-expressing cells generated only small
micrometastases while control cells formed macroscopic metastases; this occurred despite the
fact that miR-31-expressing and control cells established comparably sized micrometastases one
month post-injection (Figure 2G and Supplementary Figure 6B). Such effects on lesion size
implied that miR-31 affects metastatic colonization in addition to its influences on local invasion
and early post-intravasation events.
Inhibition of miR-31 Promotes Metastasis-Relevant Traits in vitro
The preceding observations demonstrated that miR-31 expression deprives metastatic
cells of attributes associated with high-grade malignancy. I next asked if miR-31 also prevents
the acquisition of aggressive traits by otherwise-non-metastatic human breast cancer cells. To do
so, I transiently inhibited miR-31 in non-invasive MCF7-Ras cells with either antisense
oligonucleotides or miRNA sponges. The latter are expression constructs that carry miRNA
recognition motifs in their 3’ UTR that bind and thus titer miRNAs (Ebert et al., 2007). Both
approaches inhibited miR-31 function by >4.5-fold (Supplementary Figure 7A). Suppression of
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miR-31 enhanced invasion by 20-fold and motility by five-fold, but cell viability was unaffected
by either inhibitor (Figure 3A and Supplementary Figure 7B).
Techniques for stable miRNA inhibition have been unavailable (Krützfeldt et al., 2006).
To address this problem, I modified elements derived from the transiently expressed miRNA
sponges, cloned them into a retroviral vector, and created MCF7-Ras cells that stably express the
modified miRNA sponges. The miR-31 sponge reduced miR-31 function by 2.5-fold, but did not
affect the activity of other known anti-metastatic miRNAs (Supplementary Figures 8A and 8B).
The relatively modest suppression of miR-31 conferred by stable sponge expression elicited
strong responses: invasion was enhanced by 12-fold, motility by eight-fold, and anoikis
resistance by 2.5-fold (Figure 3B and Supplementary Figure 8C). The miR-31 sponge failed to
alter in vitro proliferation (Supplementary Figure 8D).
When stably expressed in immortalized HMECs or tumorigenic but non-metastatic SUM-
149 human breast cancer cells, the miR-31 sponge elicited increased invasion, motility, and
anoikis resistance without affecting proliferation (Supplementary Figure 9 and data not shown).
Collectively, these data indicated that sustained miR-31 activity is necessary to prevent the
acquisition of aggressive traits by both tumor cells and untransformed breast epithelial cells.
Inhibition of miR-31 Promotes Metastasis in vivo
I exploited my ability to stably inhibit miRNAs in order to assess whether miR-31
activity is required to prevent metastasis in vivo. To do so, otherwise-non-metastatic MCF7-Ras
cells stably expressing the miR-31 sponge were orthotopically implanted into mice. Inhibition of
miR-31 failed to alter in vivo proliferation and primary tumor growth (Figure 3C and
Supplementary Figure 10A). Primary tumors derived from miR-31 sponge-expressing cells were
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poorly encapsulated and locally invasive, while control MCF7-Ras tumors appeared well-
confined and non-invasive (Figures 3D and 3E). Again, neo-vascularization did not differ
(Supplementary Figure 10B).
Strikingly, miR-31 sponge-expressing MCF7-Ras cells metastasized to the lungs in
significant numbers, while control tumor-bearing host lungs were largely devoid of tumor cells;
cells with impaired miR-31 activity formed 10-fold more lesions than did controls (Figure 3F).
Hence, continuous miR-31 function is required to prevent metastasis from an orthotopic site.
I asked if loss of miR-31 activity also promoted metastasis by intervening at steps of the
invasion-metastasis cascade subsequent to local invasion. Thus, I intravenously injected mice
with miR-31 sponge-expressing MCF7-Ras cells. Within one day, miR-31 inhibition enhanced
cell number in the lungs by six-fold; similarly, at later times after injection, miR-31 sponge-
expressing cells were 10-fold more prevalent in the lungs than were controls (Figure 3G). The
differing metastatic abilities of control and miR-31 sponge-expressing cells did not arise due to
failure of control cells to become lodged initially in the lung vasculature, as equal numbers of
cells from each cohort were present 10 minutes after injection (Figure 3G and Supplementary
Figure 11).
Suppression of miR-31 also affected lesion size four months after tail vein injection:
whereas control cells formed only small micrometastases, miR-31 sponge-expressing cells
produced macroscopic metastases (Figure 3G). Together, these data extended and reinforced my
ectopic expression studies by demonstrating that miR-31 affects local invasion, early post-
intravasation events, and metastatic colonization.
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miR-31 Directly Regulates a Cohort of Pro-Metastatic Genes
miR-31’s ability to impede multiple steps of the invasion-metastasis cascade might derive
from its ability to pleiotropically regulate genes involved in diverse aspects of metastatic
dissemination. To identify effectors of miR-31, I used two algorithms that predict the mRNA
targets of a miRNA – PicTar (Krek et al., 2005) and TargetScan (Grimson et al., 2007). Based on
the representation of miR-31 sites in their 3’ UTRs, >200 mRNAs were predicted to be regulated
by miR-31. Gene Ontology (Ashburner et al., 2000) revealed that these targets included a
disproportionately large number of genes encoding proteins with roles in motility-related
processes, such as cell adhesion, cytoskeletal remodeling, and cell polarity (data not shown).
Guided by this Gene Ontology analysis, I cloned the 3’ UTRs of 16 putative miR-31
targets from these overrepresented categories, including several implicated in tumor invasion
(Sahai and Marshall, 2002; McClatchey, 2003), into a luciferase construct. Reporter assays using
miR-31-expressing 231 cells revealed that miR-31 repressed six of the UTRs: frizzled3 (Fzd3),
integrin _5 (ITGA5), myosin phosphatase-Rho interacting protein (M-RIP), matrix
metallopeptidase 16 (MMP16), radixin (RDX), and RhoA (Figure 4A). Mutation of the putative
miR-31 site(s) in these six 3’ UTRs (Supplementary Table 3) abrogated responsiveness to miR-
31 (Figure 4B). In the case of RhoA, whose UTR contains two miR-31 sites separated by 152
nucleotides, mutation of either motif abolished miR-31-responsiveness (Figure 4B), suggesting
functional interaction between the sites (Grimson et al., 2007).
Endogenous Fzd3, ITGA5, MMP16, RDX, and RhoA protein levels were assayed in
miR-31-expressing 231 cells. miR-31 repressed the levels of these proteins by 40-60% (Figure
4C). miR-31’s effects on levels of the M-RIP protein could not be evaluated due to the lack of
appropriate antibodies. Also, miR-31 reduced the endogenous mRNA levels of these six targets
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by two-fold in SUM-159 cells, as well as Fzd3, ITGA5, MMP16, RDX, and RhoA mRNA levels
in 231 cells (Figure 4D). miR-31 did not affect CXCL12 mRNA levels – a computationally
predicted miR-31 target found not to be regulated by this miRNA – in either cell type (Figures
4A and 4D). These data indicated that miR-31 directly regulates endogenous Fzd3, ITGA5, M-
RIP, MMP16, RDX and RhoA expression in human breast cancer cells.
I determined if concomitant repression of Fzd3, ITGA5, M-RIP, MMP16, RDX, and
RhoA correlated with disease progression in clinical breast cancers by examining expression
profiling data from 295 primary breast tumors (Supplementary Table 4) (van de Vijver et al.,
2002). To do so, I constructed a miR-31 target signature based on coordinate differential
expression of these six genes. Within this cohort, high expression of the miR-31 target signature
was associated with metastasis, as well as poor survival, relative to signature-negative tumors;
five-year survival among patients negative for the target signature was 90%, while >35% of
target signature-positive patients succumbed to their disease over this interval (Figures 5A and
5B). Thus, coordinate repression of Fzd3, ITGA5, M-RIP, MMP16, RDX, and RhoA correlated
with more favorable outcome in clinical breast tumors.
To assess the functional contributions of these miR-31 targets to aggressive phenotypes, I
first examined if their inhibition affected the invasion or motility of 231 cells. Transfection with
siRNAs potently reduced target protein levels without affecting cell viability (Supplementary
Figures 12A and 12B). siRNAs targeting Fzd3, ITGA5, RDX, or RhoA reduced invasion and
motility, while siRNAs against M-RIP or MMP16 failed to affect these traits (Figure 5C and
Supplementary Figure 12C).
I asked if inhibition of these effectors compromised resistance to anoikis. siRNAs against
ITGA5, RDX, or RhoA sensitized 231 cells to anoikis; in contrast, siRNAs targeting Fzd3, M-
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RIP, or MMP16 had no effect on anoikis resistance (Figure 5D). Hence, suppression of Fzd3,
ITGA5, RDX, or RhoA impaired metastasis-relevant traits in vitro.
Re-Expression of Fzd3, ITGA5, RDX, and RhoA Reverses miR-31-Dependent Metastasis-
Relevant Phenotypes in vitro
To determine whether in vitro phenotypes associated with miR-31 expression could be
reversed via restoration of Fzd3, ITGA5, M-RIP, MMP16, RDX, or RhoA levels, I transfected
miR-31-expressing 231 cells with individual expression constructs rendered miRNA-insensitive
by deletion of their 3’ UTRs; this was not cytotoxic (Supplementary Figures 13A and 13B and
data not shown). In miR-31-expressing cells, Fzd3, ITGA5, RDX, or RhoA reversed, at least
partially, miR-31-imposed invasion and motility defects; in contrast, M-RIP or MMP16 had no
effect on these traits (Figure 5E and Supplementary Figure 13C). Surprisingly, re-expression of
RDX or RhoA completely rescued miR-31-mediated invasion and motility defects. Expression of
the six targets failed to enhance the invasion or motility of control 231 cells (Figure 5E and
Supplementary Figure 13C).
I evaluated if re-expression of any of the six targets rescued miR-31’s effects on anoikis.
ITGA5, RDX, or RhoA reversed, at least in part, anoikis susceptibility resulting from ectopic
miR-31; in contrast, Fzd3, M-RIP, or MMP16 failed to affect this trait (Figure 5F). In fact,
ITGA5 or RhoA completely rescued miR-31-dependent anoikis phenotypes. The six targets did
not enhance anoikis resistance in control 231 cells (Figure 5F). Hence, Fzd3, ITGA5, RDX, and
RhoA are functionally relevant effectors of miR-31 for conferring malignant traits in vitro.
65
Re-Expression of RhoA Partially Reverses miR-31-Imposed Metastasis Defects in vivo
RhoA afforded the most pronounced reversal of miR-31-mediated phenotypes. Thus, I
stably re-expressed miRNA-resistant RhoA in 231 cells that already had been infected with
either miR-31 or control vector (Supplementary Figures 14A and 14B). RhoA did not affect
proliferation in vitro, but did abrogate miR-31-imposed invasion, motility, and anoikis resistance
defects (Supplementary Figures 14C-14F).
To ascertain if restored RhoA levels reversed in vivo metastasis phenotypes ascribable to
miR-31, I orthotopically injected mice with 231 cells expressing combinations of miR-31, RhoA,
and control vectors. As observed previously, miR-31 enhanced primary tumor growth (Figure
6A). RhoA initially augmented primary tumor growth in the presence of ectopic miR-31, but
failed to do so in control 231 cells (Figure 6A). In consonance with my earlier findings, control
231 primary tumors were locally invasive, while miR-31-expressing tumors were non-invasive
(Figures 6B and 6C). In control 231 cells, ectopic RhoA failed to exacerbate the extent of local
invasion; in contrast, RhoA abolished the previously encapsulated appearance of miR-31-
expressing tumors and enabled invasion into surrounding normal tissue (Figures 6B and 6C).
Re-expression of RhoA restored lung metastasis in miR-31-expressing 231 cells to 75%
of control cell levels, while RhoA failed to enhance metastasis in control 231 cells (Figure 6D).
Thus, re-expression of RhoA partially, yet robustly, reverses metastasis-suppression imposed by
miR-31. The observed magnitude of rescue is surprising, as RhoA is only one member of a larger
cohort of metastasis-relevant genes repressed by miR-31.
By intravenously injecting mice with 231 cells expressing miR-31 and/or RhoA, I gauged
if RhoA-mediated reversal of miR-31-imposed metastasis defects was solely attributable to
effects on local invasion. While expression of miR-31 and/or RhoA failed to affect the initial
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lodging of tumor cells in the lung vasculature, the number of cells that persisted in the lungs
differed within one day of injection (Figure 6E and Supplementary Figure 15). As before, miR-
31 inhibited both the number of metastases formed and their eventual size (Figure 6E). While
expression of RhoA in control 231 cells failed to enhance metastasis, RhoA restored the number
of lung metastases to 60% of control cell levels in miR-31-expressing cells; however, RhoA did
not facilitate the formation of macroscopic metastases in cells with ectopic miR-31 (Figure 6E).
Together, these data indicated that miR-31’s ability to inhibit metastasis is attributable, in
significant part, to its capacity to inhibit RhoA. miR-31-mediated repression of RhoA affects
both local invasion and early post-intravasation events. However, these data also implied that the
full spectrum of miR-31’s effects on metastasis are elicited only via the coordinate repression of
multiple targets, as suppression of RhoA alone could not explain the complete impact of miR-31
on the number of metastases formed or its effects on metastatic colonization.
miR-31 Expression Correlates Inversely with Metastasis in Human Breast Tumors
Because established cell lines and xenograft studies cannot fully recapitulate clinical
malignancy, I extended my analyses by assaying miR-31 expression in specimens from 56
human breast cancer patients (Supplementary Table 5; Median follow-up = 59 months). Relative
to grade-matched estrogen receptor (ER)+ tumors, which are associated with more favorable
disease outcome (Sørlie et al., 2001), basal-like tumors exhibited 40% reduced miR-31; no
difference in miR-31 levels was observed between ER+ and HER2+ tumors (Supplementary
Figure 16).
When these 56 tumors were stratified based on clinical progression, I found that miR-31
expression was diminished in primary tumors that subsequently metastasized, when compared to
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normal breast tissue and primary tumors that did not recur; moreover, low miR-31 levels
correlated strongly with reduced distant disease-free survival relative to tumors with high miR-
31 (Figures 7A and 7B). Similarly, within this cohort of tumors, high RhoA expression was
associated with an increased incidence of distant metastasis (Supplementary Figure 17).
The association of low miR-31 levels with metastasis persisted independent of both
tumor grade and molecular subtype (Supplementary Figure 18). Such grade- and subtype-
independence is quite surprising, as clinically utilized prognostic markers for breast cancer
largely correlate with these parameters; furthermore, currently available markers do not identify
a worse-prognosis group within the more aggressive basal-like or HER2+ subtypes (Desmedt et
al., 2008). Thus, miR-31 may represent a marker for metastasis in a variety of breast cancer
subtypes; however, its utility as a prognostic indicator will depend on extension of these initial
observations.
I next assessed the heterogeneity of miR-31 expression in human primary breast tumors,
as well as distant metastases arising in the same patients. miR-31 was expressed in 65% of the
cells in these primary tumors; however, miR-31 was detected in only 12-30% of cells in patient-
matched distant metastases (Figure 7C). These data raise the possibility that selective pressures
operating over the course of breast cancer progression diminish the representation of miR-31-
expressing cells within the population of successfully metastasizing cells.
Finally, I asked if expression of ITGA5, RDX, and RhoA was also heterogeneous in
primary human breast tumors. RDX and RhoA were expressed in 60-75% of cells in the primary
tumors examined, while ITGA5 was detected in >80% of cells (Figure 7D). Distant metastases
were more homogeneous for the expression of RDX and RhoA than the primary tumors from
which they were derived, as >90% of cells in the metastases expressed RDX and RhoA (Figure
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7D). Similarly, >90% of cells in the metastases expressed ITGA5; however, the widespread
ITGA5 expression observed in the patient-matched primary tumors complicates interpretation of
its expression in distant metastases (Figure 7D).
MATERIALS AND METHODS
Plasmid Construction and Generation of Stable Cell Lines
The human miR-31 gene was PCR-amplified from genomic DNA and cloned into
pcDNA3.1 (Invitrogen), then subcloned into the BamHI and SalI sites of the pBABE-puro
retroviral vector (Morgenstern and Land, 1990). Synthetic miR-31, miR-126, miR-206, and miR-
335 binding site-containing Renilla luciferase reporter genes were constructed by annealing,
purifying, and cloning corresponding short oligonucleotides into the SacI and AgeI sites of the 3’
UTR of a pIS1 vector backbone provided by D. Bartel (Farh et al., 2005). Transient CMV-driven
miRNA sponge backbones were provided by P. Sharp; a control sponge containing tandem non-
targeting binding sites was identical to that utilized previously (Ebert et al., 2007), while the
miR-31 sponge was constructed by annealing, purifying, and cloning oligonucleotides containing
seven tandem “bulged” (at positions 9-12) miR-31 binding motifs into the XhoI and ApaI sites of
the CMV sponge backbone. For stable expression studies, the BamHI-ApaI fragments of the
miR-31 and control CMV sponge constructs were subcloned into the pBABE-puro retroviral
vector. Luciferase reporter genes driven by the 3’ UTRs of the indicated computationally
predicted miR-31 targets were created via PCR-based amplification from human genomic DNA,
and then cloned into AgeI, SacI, SpeI, and/or XbaI sites within the 3’ UTR of the pIS1 Renilla
luciferase reporter backbone. The indicated mutagenized miR-31 recognition site-containing
luciferase reporter genes were generated with a QuikChange II XL Site-Directed Mutagenesis
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Kit (Stratagene), in accordance with the manufacturer’s instructions. For transient
overexpression experiments, previously described constructs encoding Fzd3 (Deardorff et al.,
2001), ITGA5 (Kuwada and Li, 2000), M-RIP (Surks et al., 2003), MMP16 (Hotary et al., 2006),
RDX (Batchelor et al., 2004), and RhoA (Subauste et al., 2000) were provided by P. Klein, S.
Kuwada, H. Surks, S. Weiss, S. Crouch, and G. Bokoch, respectively. For stable overexpression
studies, RhoA was directly subcloned from pcDNA3 (Invitrogen) into the retroviral vector
pBABE-zeo (Morgenstern and Land, 1990).
All stable cell lines were generated via retroviral infection using HEK293T cells, as has
been previously described (Elenbaas et al., 2001).  GFP-labeled MDA-MB-231 and MCF7-Ras
cells were created via infection with pWZL-blast-EGFP.
Cell Culture
MDA-MB-231 and MCF7-Ras cells were obtained from the ATCC and cultured under
standard conditions. HMEC and HME cells have been described (Ma et al., 2007). SCP3 cells
were obtained from J. Massagué (Minn et al., 2005). SUM-149 and -159 cells were provided by
S. Ethier (Ma et al., 2007). D2 cells have been described (Morris et al., 1993). 67NR, 168FARN,
4TO7, and 4T1 cells were obtained from F. Miller (Aslakson and Miller, 1992).
miRNA Detection
Total RNA, inclusive of the small RNA fraction, was extracted from cultured cells with a
mirVana miRNA Isolation Kit (Ambion). RT-PCR-based detection of mature miR-31 and 5S
rRNA was achieved with a mirVana miRNA Detection Kit and gene-specific primers (Ambion).
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miRNA in situ Hybridization
miRNA expression was assessed from paraffin sections using a protocol adapted from
Silahtaroglu et al. (2007). Briefly, after a four hour pre-hybridization, a 5’ FITC-labeled
miRCURY LNA probe targeting miR-31 (Exiqon) was hybridized to proteinase K-treated 10 _m
sections at 55°C for 12 hours. Slides were then incubated with anti-FITC-HRP (PerkinElmer),
and the resulting signal was intensified with the TSA Plus Fluorescein System (PerkinElmer).
Invasion and Motility Assays
For invasion assays, 1.0 x 105 cells were seeded in a Matrigel-coated chamber with 8.0
_m pores (BD Biosciences); for motility assays, 5.0 x 104 cells were plated atop uncoated
membranes with 8.0 _m pores (BD Biosciences). Cells were seeded in serum-free media, and
translocated toward complete growth media for 20 hours. Fugene6 (Roche) was used to transfect
cells 24 hours prior to plating. 200 nM miRIDIAN miRNA Inhibitors (Dharmacon) were
employed to transiently inhibit miR-31. SMARTpool siRNAs against Fzd3, ITGA5, M-RIP,
MMP16, RDX, or RhoA (Dharmacon) were provided at 100 nM. Antisense oligonucleotides and
siRNAs were transfected 48 hours prior to seeding using Oligofectamine (Invitrogen).
Anoikis Assays
Anoikis resistance was evaluated by seeding 7.5 x 104 cells in ultra-low attachment plates
(Corning). After 24 hours of anchorage-independent culture, cells were resuspended in 0.4%
trypan blue (Sigma) and cell viability was assessed.
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Animal Studies
All research involving animals complied with protocols approved by the MIT Committee
on Animal Care. For spontaneous metastasis assays, age-matched female NOD/SCID mice
(propagated on-site) were bilaterally injected into the mammary fat pad with the indicated
number of tumor cells in 1:2 Matrigel (BD Biosciences) plus normal growth media. For
experimental metastasis assays, age-matched female NOD/SCID mice were injected with 5.0 x
105 cells (resuspended in PBS) via the tail vein. Metastasis was quantified using a fluorescent
microscope within three hours of specimen isolation.
Luciferase Assays
5.0 x 104 cells were co-transfected with 50 ng of the indicated pIS1 Renilla luciferase
construct and 50 ng of a pIS0 firefly luciferase normalization control. Lysates were collected 24
hours post-transfection, and Renilla and firefly luciferase activities were measured with a Dual-
Luciferase Reporter System (Promega).
Immunoblots
Lysates were resolved by electrophoresis, transferred to a PVDF membrane, and probed
with antibodies against _-actin (Santa Cruz), Fzd3 (Abcam), ITGA5 (Santa Cruz), MMP16
(Abcam), RDX (Cell Signaling), or RhoA (Santa Cruz).
miR-31 Target Signature
Expression profiling of 295 human breast tumors (van de Vijver et al., 2002) was used to
categorize tumors as miR-31 target signature-positive or -negative. Tumors were considered
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target signature-positive or -negative if the normalized expression of multiple of the six miR-31
targets herein identified resided in the top or bottom 15% of tumors in this cohort, respectively.
Immunohistochemistry
Detection of Ki-67 (Pharmingen), MECA-32 (U. of Iowa), ITGA5 (Santa Cruz), RDX
(Santa Cruz), or RhoA (Abcam) was performed on 5 _m paraffin sections using the indicated
antibodies, Vectastain Elite ABC kits (Vector), and ImmPACT DAB Substrate (Vector).
Human Breast Tumors
Primary breast tumors, distant metastases, and normal breast tissue were collected and
processed in compliance with a protocol approved by the Brigham and Women’s Hospital IRB.
Fresh tissue was harvested from patients, OCT-embedded, snap-frozen, and preserved at -80°C.
Recurrent cases were primary tumors from patients that developed distant metastases. For each
recurrent case, two non-recurrent cases were selected to control for date of diagnosis, molecular
subtype, lymph node status, and time of follow-up. Total RNA was isolated from 35 _m sections
via TRIzol extraction and a mirVana miRNA Isolation Kit. To discern if miR-31 levels correlate
with distant metastasis, primary tumors were classified as miR-31-positive or -negative. Tumors
were considered miR-31-positive or -negative if the normalized expression of miR-31 resided in
the top or bottom 30% of tumors in this cohort, respectively. Similarly, tumors were classified as
RhoA-high or -low if their RhoA levels were in the top or bottom 30% of tumors examined.
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Statistical Analyses
Data are presented as mean ± s.e.m. Unless otherwise noted, Student’s t-test was used for
comparisons, with P <0.05 considered significant.
Measurements of in vitro Cell Proliferation
In vitro proliferative kinetics were assayed by seeding 7.5 x 104 cells per well in 6-well
plates. Total cell number was assessed every two to three days, as indicated, by trypsinization
and manual counting with a hemocytometer.
Cell Viability Assays
The impact of transient transfection with various constructs and reagents on cell viability
was assessed by a trypan blue dye exclusion assay. Briefly, in parallel to the corresponding
invasion, motility, and anoikis assays, 2.0 x 105 cells were seeded in 6-well plates, and then
transfected with the indicated expression constructs, siRNAs, or antisense oligonucleotides, as
described in the Experimental Procedures. After 24 hours (expression constructs) or 48 hours
(siRNAs and antisense oligonucleotides), cells were trypsinized, resuspended in 0.4% trypan
blue staining solution (Sigma), and manually counted using a hemocytometer.
cDNA Synthesis and Real Time RT-PCR
Where indicated, cDNA was prepared from 200 ng of total RNA using the SuperScript
III First-Strand Synthesis System (Invitrogen), and target levels were assessed via SYBR Green-
based real time RT-PCR (Applied Biosystems).
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Oligonucleotide Sequences
Oligonucleotides employed in this study were: cloning miR-31 from genomic DNA,
ACAATACATAGCAGGACAGGAAGTAAGGAAGGTG and CATCTTCAAAAGCGGACACTCTAAGGAAGACTATGTTG; cloning
miR-145 from genomic DNA, TGCTACAGATGGGGCTGGATGCAGAA and TAAGCCCTCTTACCTCCAGGGACAGC;
miR-31 synthetic binding site, AATGGCGAGCTCAGGCAAGATGCTGGCATAGCTACCGGTAATGGC and
GCCATTACCGGTAGCTATGCCAGCATCTTGCCTGAGCTCGCCATT; cloning modified miRNA sponges to
pBABE-puro, AGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTG and AATGGCGTCGACTAGAAGGCACAGTCGAGGCT;
miR-126 synthetic binding site, GCCATTGAGCTCTCGTACCGTGAGTAATAATGCGACCGGTGCCATT and
AATGGCACCGGTCGCATTATTACTCACGGTACGAGAGCTCAATGGC; miR-206 synthetic binding site,
GCCATTGAGCTCTGGAATGTAAGGAAGTGTGTGGACCGGTGCCATT and AATGGCACCGGTCCACACACTTCCTTACATTCCAGAGCTCAATGGC;
miR-335 synthetic binding site, GCCAGTGAGCTCTCAAGAGCAATAACGAAAAATGTACCGGTGCCAGT and
ACTGGCACCGGTACATTTTTCGTTATTGCTCTTGAGAGCTCACTGGC; cloning Arp2/3s5 3’ UTR from genomic
DNA, TTAACCGAGCTCTCTGGCAGGAAGTGGAT and TTGGCCTCTAGAGAGTTTATAGAATTTCTGCACCAGTTTGC;
cloning CXCL12 3’ UTR from genomic DNA, TTAAGGACCGGTGCACAACAGCCAAAAAGGA and
TGGGCCACTAGTAAGCTCCATCACTAACAACTAATGA; cloning Ets-1 3’ UTR from genomic DNA,
TTAACCGAGCTCTGGCACTGAAGGGGCT and TCGGCCACCGGTATGAATGAAATTCTTTGT; cloning
Fzd3 3’ UTR from genomic DNA, TTGGCCGAGCTCTTTGTCTTGTCTAAGGT and
TTGGCCACCGGTAAGAAAGCTACCAATTCTTATTTG; cloning HoxC13 3’ UTR from genomic
DNA, TTAATAGAGCTCCCACCCACCCGCTGCT and TTAATAGAGCTCCCACCCACCCGCTGCT;
cloning ITGA5 3’ UTR from genomic DNA, TTAACCGAGCTCGTCCTCCCAATTTCAGACTC and
TTAACCACCGGTCTAGTTCTGGTCAGTGGGGGCACT; cloning JAZF1 3’ UTR from genomic DNA,
TTGGCCGAGCTCCATGCTGGTCATAACTG and TTAACCACCGGTGGGTCAGAGGCAGTTTA; cloning
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KLF13 3’ UTR from genomic DNA, TATATAACCGGTGCCCGCCACAGCCATGA and
TGCGGCCGCGCCCGGACTAGTAAAATAATGAATCATAAATTTTAT; cloning M-RIP 3’ UTR from genomic
DNA, TTAACCGAGCTCAGAGTCTGAAGGAAGGCCT and TTAAATACCGGTACCAAGAAAGGAACGAGCGGA;
cloning MMP16 3’ UTR from genomic DNA, TTAACCGAGCTCGCAGGAGTTTGTGGTAACTT and
TTGGCCACCGGTATCCACCACATTGTGTT; cloning NFAT5 3’ UTR from genomic DNA,
TTGGCCACCGGTAAATTCCACGAAGAAAATCCTG and TGGGCCTCTAGAAACTTTCAGTGTTTTATTTTTGACTGCAGCTG;
cloning Numb 3’ UTR from genomic DNA, TTCCGGACCGGTAAGCAATCATTATGGCTATGT and
TCGGCCACTAGTAAAAGCTTCTACCATGAACATT; cloning RDX 3’ UTR from genomic DNA,
TTGGCCACCGGTGAGCTGTTATTTTGCATATATG and TTGGCCACTAGTGAAGGCATGAGCTTTTGTCACTTTATTG;
cloning Ret 3’ UTR from genomic DNA, TTGGCCACCGGTCATTTCTTTGTGAAAGGT and
TTGGCCACTAGTGCAATGAAGAATGACAAGAAGCT; cloning RhoA 3’ UTR from genomic DNA,
TTAACCGAGCTCAACCTTGCTGCAAGCACA and TTGGCCACCGGTAGAAAACTGCCTTTATTCTATTAGTAGTTGG;
cloning YY1 3’ UTR from genomic DNA, TTGGCCGAGCTCAAAGAAGAGAGAAGACCCTTCT and
TTGGCCACCGGTCTTTAGGATTGCTATTTTATTGTTGCCCT; Fzd3 3’ UTR mutagenesis,
CTACAGTGAGATGTGATCGGCGCAAAGCCACCAGACCTTGGCTTCC and
GGAAGCCAAGGTCTGGTGGCTTTGCGCCGATCACATCTCACTGTAG; ITGA5 3’UTR mutagenesis,
CTGCAAAGATCTGTCCTCAGCCAAAAGAGAGATCCAAAAGAAGCCCCCAG and
CTGGGGGCTTCTTTTGGATCTCTCTTTTGGCTGAGGACAGATCTTTGCAG; M-RIP 3’ UTR
mutagenesis, GTTTGTTTTTTATTAAATCGGCGACAAAATCCCCGGCCCCTCTCC and
GGAGAGGGGCCGGGGATTTTGTCGCCGATTTAATAAAAAACAAAC; MMP16 3’ UTR mutagenesis,
GTGTTTATAACAAACAGAAATGATGTTACCGGCCAAAATTTTTCTGGC and
GCCAGAAAAATTTTGGCCGGTAACATCATTTCTGTTTGTTATAAACAC; RDX 3’ UTR mutagenesis,
GATATGATGGAATGCATCCCACCAGCGGAAAGCACTTACACCAGTTTGACTGTG and
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CACAGTCAAACTGGTGTAAGTGCTTTCCGCTGGTGGGATGCATTCCATCATATC; RhoA 3’ UTR site
one mutagenesis, CCTAAGATTACAAATCAGAAGTCAGGCGGCTACCAGTATTTAGAAGCCAAC and
GTTGGCTTCTAAATACTGGTAGCCGCCTGACTTCTGATTTGTAATCTTAGG; RhoA 3’ UTR site two
mutagenesis, GGCGCTAATTCAAGGAATTTCTTAACTCGCCGCTTCTTTCTAGAAAGAGAAACAGTGG
and CCAACTGTTTCTCTTTCTAGAAAGAAGCGGCGAGTTAAGAAATTCCTTGAATTAGCG CC;
CXCL12 RT-PCR, TGAGAGCTCGCTTTGAGTGACTGGGT and ATACCACCAGGACCTTCTGTGGATCGCA;
Fzd3 RT-PCR, TCCATCCCTGCACAATATAAGGCTTCCACA and TCTCAATGCATCAACATCGTAGAGGCCAAC;
GAPDH RT-PCR, TCACCAGGGCTGCTTTTAAC and GACAAGCTTCCCGTTCTCAG; ITGA5 RT-
PCR, AACTCATCATGGCCAGTGAGGGTAAGGGT and ATCCTTAATGGCTCAGACATTCGATCCCTCTACAACT;
M-RIP RT-PCR, AGGCAGAGCACATGGAGACCAATGCA and AGTCAGCCAGCCTTTCTTGAAATTCAGCA;
MMP16 RT-PCR, AGTACGGCTACCTTCCACCGACTGA and TACCTCTTGTCTGGTCAGGTACACCGCAT;
RDX RT-PCR, GAATCAGGAGCAGCTAGCAGCAGAACTT and TTGGTCTTTTCCAAGTCTTCCTGGGCTGCA;
RhoA RT-PCR, AGGTGGATGGAAAGCAGGTAGAGTTGGCT and AGGATGATGGGCACGTTGGGACAGA.
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FIGURES
Figure 1. miR-31 Levels Correlate Inversely with Metastatic Ability in Breast Cell Lines.
(A) RT-PCR for miR-31 in seven human breast cell lines. 5S rRNA was a loading control. NTC:
no template control. n = 3. (B) miR-31 RT-PCR in eight murine mammary cell lines. 5S rRNA
was a loading control. n = 3. (C) In situ hybridization for miR-31 (green) in animal-matched 4T1
cell primary mammary tumors and lung metastases; DAPI counterstain (blue). n = 4. (D)
Hematoxylin and eosin (H&E) stain of a 4T1 cell primary mammary tumor (top); box: invasive
front. miR-31 in situ hybridization in 4T1 cells located near the invasive front or the interior of
the primary tumors (bottom). n = 3.
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Figure 2. miR-31 Expression Inhibits Metastasis. (A) Invasion and motility assays after
transfection of MDA-MB-231 (231) cells with the indicated constructs. n = 3. (B) Anoikis assays
using 231 cells infected as indicated. n = 3. (C) Primary tumor growth upon orthotopic injection
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of 1.0 x 106 GFP-labeled 231 cells infected as indicated. The experiment was terminated after 13
weeks due to primary tumor burden. n = 5 per group per timepoint. (D) H&E stain of 231
primary tumors 62 days after orthotopic injection. (E) H&E stain of tissue adjacent to the
indicated 231 primary mammary tumors 62 days after injection. Arrows: disseminated tumor
cells in normal fat (a, b), muscle (c, d), and subcutis (e, f). (F) Images of murine lungs to
visualize GFP-labeled 231 cells 62 days after orthotopic implantation (left). H&E stain of lungs
from animals bearing the indicated tumors (right); arrows: metastatic foci. n = 5. (G) Images of
murine lungs to detect GFP-labeled 231 cells 88 days after tail vein injection (left). H&E stain of
lungs (right); arrows: metastatic foci. Asterisks: P >0.66. n = 5, except for 10 min and two hrs (n
= 4).
80
Figure 3. Inhibition of miR-31 Promotes Metastasis. (A) Invasion and motility assays using
MCF7-Ras cells transfected with the indicated transient miR-31 inhibitors. n = 3. (B) Anoikis
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assays with MCF7-Ras cells stably expressing the indicated sponge. n = 3. (C) Primary tumor
growth upon orthotopic implantation of 5.0 x 105 GFP-labeled MCF7-Ras cells infected as
indicated. The experiment was terminated after 16 weeks due to primary tumor burden. n = 5 per
group per timepoint. (D) H&E stain of MCF7-Ras primary tumors 47 days after orthotopic
injection. Arrows: regions of poor encapsulation. (E) H&E stain of tissue adjacent to the
indicated MCF7-Ras primary tumors 47 days post-injection. Arrows: disseminated tumor cells in
normal fat (a, c) and muscle (b, d). (F) Images of murine lungs to visualize GFP-labeled MCF7-
Ras cells 113 days after orthotopic injection (left). H&E stain of lungs from animals bearing the
indicated tumors (middle); arrows: metastatic foci. n = 5. (G) Images of murine lungs to detect
GFP-labeled MCF7-Ras cells 122 days after tail vein injection (left). H&E stain of lungs
(middle); arrow: metastasis. n = 4, except for one day (n = 3).
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Figure 4. miR-31 Directly Regulates a Cohort of Pro-Metastatic Genes. (A) Luciferase
activity in 231 cells infected with miR-31 or control vector after transfection of the indicated 3’
UTR-driven reporter constructs. n = 3. (B) Luciferase activity in the indicated 231 cells upon
transfection of miR-31 site mutant 3’ UTR-driven reporter constructs. wt: wild type; site 1: the
miR-31 motif at nt 145-151 of the RhoA 3’ UTR; site 2: the motif spanning nt 303-309.
Asterisks: P >0.80 relative to mutant-UTR + vector controls. n = 3. (C) Immunoblots for
endogenous Fzd3, ITGA5, MMP16, RDX, and RhoA in the indicated 231 cells. _-actin was a
loading control. Repression: protein levels in miR-31-expressing cells relative to vector controls.
(D) RT-PCR for endogenous CXCL12, Fzd3, ITGA5, M-RIP, MMP16, RDX, and RhoA.
GAPDH was a loading control. Asterisks: P <0.03 relative to vector controls. n = 3.
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Figure 5. Repression of Fzd3, ITGA5, RDX, and RhoA Underlies miR-31-Dependent
Phenotypes in vitro. (A) Kaplan-Meier curves for 295 human primary breast tumors depicting
metastasis-free survival, stratified based on expression of the six-gene miR-31 target signature.
P-value based on a logrank test. (B) Kaplan-Meier five-year survival curves for 295 breast
cancer patients, stratified based on miR-31 target signature expression in their primary tumors.
P-value based on a logrank test. (C) Invasion assays with miR-31-expressing or control 231 cells
transfected as indicated. Asterisks: P >0.19 relative to vector + siControl cells. n = 3. (D)
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Anoikis assays using 231 cells transfected with the indicated siRNAs. Asterisks: P >0.80 relative
to vector + siControl cells. n = 3. (E) Invasion assays using the indicated 231 cells transfected
with miRNA-resistant expression constructs. Asterisks: P >0.61 relative to miR-31 + mock cells.
n = 3. (F) Anoikis assays with the indicated 231 cells transfected as noted. Asterisks: P >0.11
relative to miR-31 + mock cells. n = 3.
85
Figure 6. Re-Expression of RhoA Partially Reverses miR-31-Imposed Metastasis Defects in
vivo. (A) Primary tumor growth upon orthotopic injection of 5.0 x 105 GFP-labeled 231 cells.
The experiment was terminated after 11 weeks due to primary tumor burden. Asterisks: P <0.02.
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n = 5 per group per timepoint. (B) H&E stain of 231 primary tumors 60 days after orthotopic
injection. (C) H&E stain of tissue adjacent to the indicated 231 primary mammary tumors 60
days after injection. Arrows: disseminated tumor cells in normal muscle (a, c, e, g) and fat (b, d,
f, h). (D) Images of murine lungs to visualize GFP-labeled 231 cells 60 days after orthotopic
injection (left). H&E stain of lungs from animals bearing the indicated tumors (right); arrows:
metastatic foci. n = 5. (E) Images of murine lungs to detect GFP-labeled 231 cells 86 days after
tail vein injection (left); arrows: micrometastatic lesions. Asterisks: P >0.87 relative to vector +
vector controls. n = 4, except for 2 weeks (n = 3).
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Figure 7. miR-31 Levels Correlate Inversely With Metastasis in Human Breast Tumors.
(A) miR-31 RT-PCR in 54 primary breast tumors. Normal: tissue from non-diseased individuals;
metastasis-positive and -free: tumors of the indicated distant metastasis outcome. 5S rRNA was a
loading control. n = 4 (normal); n = 14 (metastasis-positive); n = 40 (metastasis-free). (B)
Kaplan-Meier distant metastasis-free survival curves for 54 breast cancer patients, stratified
based on miR-31 levels in their primary tumors. P-value based on a chi-square test. (C) In situ
hybridization for miR-31 (green) in patient-matched primary breast tumors and distant
metastases (patient 1 = lung; 2 = pleura); DAPI counterstain (blue). n = 8 fields. (D)
Immunohistochemical detection of ITGA5, RDX, and RhoA in patient-matched primary breast
tumors and distant metastases (patient 1 = lung; 2 = pleura). n = 8 fields.
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SUPPLEMENTARY FIGURES
Supplementary Figure 1. miR-31 Does Not Affect MDA-MB-231 Cell Viability and
Proliferation in vitro. (A) RT-PCR for miR-31 in MDA-MB-231 (231) cells infected with
human miR-31 or control vector, as well as endogenous miR-31 levels in normal human
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mammary epithelial cells (HMECs). 5S rRNA was a loading control. NTC: no template control.
n = 3. (B) In vitro growth curves of 231 cells expressing miR-31 or control vector. Triplicate
wells from each cohort were counted for 14 days, as indicated. n = 3. (C) Invasion and motility
assays using 231 cells infected with miR-31 or vector control. n = 3. (D) Trypan blue dye
exclusion assay using 231 cells transfected with the indicated expression constructs for 24 hrs. n
= 3.
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Supplementary Figure 2. miR-31 Inhibits SUM-159 Invasion, Motility, and Anoikis
Resistance in vitro. (A) RT-PCR for miR-31 in SUM-159 (159) cells infected with miR-31 or
control vector, as well as endogenous miR-31 in normal HMECs. 5S rRNA was a loading
control. n = 3. (B) In vitro growth curves of 159 cells infected with miR-31 or vector control.
Triplicate wells from each cohort were counted for 14 days, as indicated. n = 3. (C) Invasion and
motility assays utilizing 159 cells expressing miR-31 or control vector. n = 3. (D) Anoikis assays
using 159 cells infected with miR-31 or vector control. Cells were cultured in anchorage-
independence for 24 hrs, and then cell viability was assessed by trypan blue stain. n = 3.
91
Supplementary Figure 3. miR-31 Does Not Impact MDA-MB-231 Primary Tumor Neo-
vascularization. (A) Ki-67 staining of primary mammary tumors derived from 231 cells
expressing miR-31 or control vector 62 days post-implantation. Cells were counterstained with
hematoxylin. n = 5. (B) MECA-32 stain of 231 cell primary mammary tumors expressing miR-
31 or control vector 62 days post-implantation. Arrows: intact intratumoral vessels. Cells were
counterstained with hematoxylin. n = 5.
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Supplementary Figure 4. miR-31 Promotes Primary Tumor Growth and Inhibits Both
Local Invasion and Lung Metastasis in a Single-Cell-Derived Population of MDA-MB-231
Cells. (A) RT-PCR for miR-31 in SCP3 cells overexpressing miR-31 or control vector, the
parental population of 231 cells infected as indicated, and endogenous miR-31 levels in normal
HMECs. 5S rRNA was a loading control. n = 3. (B) Primary tumor growth kinetics upon
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orthotopic injection of 1.0 x 106 GFP-labeled SCP3 cells infected as indicated. n = 5 per group
per timepoint. (C) Hematoxylin and eosin (H&E) stain of the indicated SCP3 primary tumors 32
days after orthotopic injection. (D) Fluorescent images of murine lungs to visualize the indicated
GFP-labeled SCP3 cells 61 days after orthotopic implantation (top panels). n = 5 per cohort per
timepoint.
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Supplementary Figure 5. miR-31 Promotes Primary Tumor Growth and Inhibits Local
Invasion in SUM-159 Cells. (A) Primary tumor burden 32 days after orthotopic injection of 1.0
x 106 SUM-159 cells infected as indicated. n = 5 per group per timepoint. (B) H&E stain of the
indicated SUM-159 primary tumors 32 days after orthotopic implantation.
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Supplementary Figure 6. miR-31 Fails to Alter the Initial Vascular Lodging of
Intravenously Injected MDA-MB-231 Cells and the Size of Eventually Established
Micrometastases. (A) Fluorescent images of murine lungs to visualize GFP-labeled 231 cells
expressing miR-31 or control vector 10 minutes subsequent to tail vein injection of 5.0 x 105
cells. (B) Fluorescent images of murine lungs to visualize the indicated GFP-labeled 231 cells
one month after intravenous injection.
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Supplementary Figure 7. Transient Inhibition of miR-31 Does Not Affect MCF7-Ras Cell
Viability. (A) Luciferase assays in MCF7-Ras cells upon transfection of the indicated transient
miRNA inhibitors. Cells were transfected with the inhibitors for 48 hrs, then co-transfected with
a Renilla luciferase reporter containing a miR-31 motif in its 3’ UTR and a control firefly
luciferase reporter. 24 hrs after transfection with the reporters, cell lysates were harvested and
luciferase activity was quantitated. n = 3. (B) Trypan blue dye exclusion assay employing
MCF7-Ras cells transfected with the indicated antisense oligonucleotides or miRNA sponges for
48 hrs. n = 3.
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Supplementary Figure 8. Modified miRNA Sponges Stably and Specifically Inhibit miR-31
in MCF7-Ras Cells. (A) Luciferase assays upon stable infection of MCF7-Ras cells with a
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modified miR-31 sponge or control sponge. Cells were co-transfected with a Renilla luciferase
reporter containing a miR-31 motif in its 3’ UTR and a control firefly luciferase reporter. 24 hrs
after transfection with the reporter genes, cell lysates were harvested and luciferase activity was
quantitated. n = 3. (B) Luciferase assays using MCF7-Ras cells stably infected with a miR-31 or
control sponge. Cells were co-transfected with a Renilla luciferase reporter containing either a
miR-126, miR-206, or miR-335 motif in its 3’ UTR and a control firefly luciferase reporter. 24
hrs after transfection with the reporters, lysates were harvested and luciferase activity quantified.
n = 3. (C) Invasion and motility assays using MCF7-Ras cells stably expressing a miR-31
sponge or control sponge. n = 3. (D) In vitro growth curves of MCF7-Ras cells infected with a
miR-31 sponge or control sponge. Triplicate wells from each cohort were counted for 14 days, as
indicated. n = 3.
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Supplementary Figure 9. miR-31 Inhibits HME and SUM-149 Invasion, Motility, and
Anoikis Resistance in vitro. (A) Luciferase assays upon infection of HME cells with a miR-31
or control sponge. Cells were co-transfected with a Renilla luciferase reporter containing a miR-
31 motif in its 3’ UTR and a control firefly luciferase reporter. 24 hrs after transfection with the
reporters, cell lysates were harvested and luciferase activity was quantitated. n = 3. (B) In vitro
growth curves of HME cells infected with a miR-31 or control sponge. Triplicate wells from
each cohort were counted for 14 days, as indicated. n = 3. (C) Invasion and motility assays using
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HME cells infected with the indicated sponges. n = 3. (D) Invasion and motility assays utilizing
SUM-149 cells infected with a miR-31 or control sponge. n = 3. (E) Anoikis assays with HME
cells infected as indicated. Cells were cultured in anchorage-independence for 24 hrs, and then
cell viability was assessed by trypan blue stain. n = 3. (F) Anoikis assays using SUM-149 cells
infected as indicated. Cells were cultured in anchorage-independence for 24 hrs then cell
viability was assessed via trypan blue stain. n = 3.
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Supplementary Figure 10. Loss of miR-31 Fails to Affect MCF7-Ras Cell Primary Tumor
Proliferation or Neo-vascularization. (A) Ki-67 staining of primary mammary tumors derived
from the indicated MCF7-Ras cells 47 days post-injection of 5.0 x 105 cells. Cells were
counterstained with hematoxylin. n = 5. (B) MECA-32 staining of primary mammary tumors
derived from MCF7-Ras cells expressing a miR-31 or control sponge 47 days after injection.
Arrows: intact intratumoral vessels. Cells were counterstained with hematoxylin. n = 5.
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Supplementary Figure 11. Loss of miR-31 Does Not Influence the Initial Vascular Lodging
of Intravenously Injected MCF7-Ras Cells. Fluorescent images of murine lungs to visualize
GFP-labeled MCF7-Ras cells expressing a miR-31 or control sponge 10 minutes after tail vein
injection of 5.0 x 105 cells.
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Supplementary Figure 12. Fzd3, ITGA5, RDX, and RhoA are Necessary for MDA-MB-231
Cell Motility. (A) Immunoblots for endogenous Fzd3, ITGA5, MMP16, RDX, and RhoA in
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control 231 cells transfected with the indicated siRNAs for 48 hours. _-actin was a loading
control.  Knockdown was >75% for all gene-specific siRNAs relative to siControl-treated cells.
(B) Trypan blue stain of 231 cells transfected with the indicated siRNAs for 48 hours. All P-
values are >0.80 relative to mock-treated vector control cells. n = 3. (C) Motility assays with
miR-31-expressing or control 231 cells transfected as indicated for 48 hrs. Asterisks: P <0.03
relative to siControl-treated vector control cells. n = 3.
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Supplementary Figure 13. Restored Expression of Fzd3, ITGA5, RDX, and RhoA Rescues
miR-31-Dependent Motility Phenotypes in MDA-MB-231 Cells. (A) Immunoblots for total
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Fzd3, ITGA5, MMP16, RDX, and RhoA in 231 cells stably expressing miR-31 and transfected
as indicated for 48 hrs. _-actin was a loading control. Overexpression was approximately five-
fold for all constructs relative to mock-treated controls. (B) Trypan blue stain of miR-31-
expressing or control 231 cells transfected as indicated for 24 hrs. All P-values are >0.86 relative
to mock-treated vector control cells. n = 3. (C) Motility assays using miR-31-expressing or
control 231 cells transfected as indicated for 24 hrs. Asterisks: P <0.02 relative to mock-treated
miR-31-expressing cells. n = 3.
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Supplementary Figure 14. Stable Re-Expression of RhoA Rescues miR-31-Mediated
Inhibition of MDA-MB-231 Cell Invasion, Motility, and Anoikis Resistance in vitro. (A) RT-
PCR for miR-31 in 231 cells infected with RhoA, miR-31, and/or control vectors. 5S rRNA was
a loading control. (B) Immunoblot for total RhoA in 231 cells infected with RhoA, miR-31,
and/or control vectors. _-actin was a loading control. Values: RhoA protein levels relative to
vector + vector controls. (C) In vitro growth curves of 231 cells infected with miR-31, RhoA,
and/or vector controls. Triplicate wells from each cohort were counted for 14 days, as indicated.
n = 3. (D) Invasion assays using 231 cells infected with miR-31, RhoA, and/or control vectors. n
= 3. (E) Motility assays with 231 cells infected with miR-31, RhoA, and/or vector controls. n =
3. (F) Anoikis assay with 231 cells infected as indicated. Cells were cultured in anchorage-
independence for 24 hrs, and then viability was assessed via trypan blue staining. n = 3.
108
Supplementary Figure 15. miR-31 and RhoA Fail to Affect the Initial Vascular Lodging of
Intravenously Injected MDA-MB-231 Cells. Fluorescent images of murine lungs to visualize
231 cells expressing miR-31, RhoA, and/or control vectors 10 minutes subsequent to tail vein
injection of 5.0 x 105 GFP-labeled cells.
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Supplementary Figure 16. miR-31 Levels in Primary Human Breast Tumors Partially
Correlate With Molecular Subtype. miR-31 levels in the indicated Grade II and Grade III
primary breast tumors, as assessed by RT-PCR. 5S rRNA was a loading control. n = 13 (ER+); n
= 19 (basal-like); n = 16 (HER2+).
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Supplementary Figure 17. RhoA Levels in Human Breast Tumors are Associated With
Distant Metastasis. Kaplan-Meier distant metastasis-free survival curves for 54 breast cancer
patients, stratified based on RhoA mRNA levels in their primary tumors. P-value based on a
logrank test.
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Supplementary Figure 18. miR-31 Expression in Primary Human Breast Carcinomas
Correlates with Metastatic Recurrence Independent of Tumor Grade and Subtype. (A)
miR-31 levels in primary breast tumors of the indicated grade and metastasis status, as assessed
by RT-PCR. 5S rRNA was a loading control. Normal: RNA derived from tissue of non-diseased
individuals; metastasis-positive and -free: RNA from primary tumors of the indicated distant
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metastasis outcome. n = 4 (normal); n = 6 (Grade I, metastasis-free); n = 1 (Grade I, metastasis-
positive); n = 9 (Grade II, metastasis-free); n = 5 (Grade II, metastasis-positive); n = 25 (Grade
III, metastasis-free); n = 9 (Grade III, metastasis-positive). (B) RT-PCR for miR-31 in primary
breast tumors of the indicated molecular subtype and metastasis status. 5S rRNA was a loading
control. Normal: RNA derived from tissue of non-diseased individuals; metastasis-positive and -
free: RNA from primary tumors of the indicated distant metastasis outcome. n = 4 (normal); n =
16 (ER-positive, metastasis-free); n = 4 (ER-positive, metastasis-positive); n = 10 (basal-like,
metastasis-free); n = 5 (basal-like, metastasis-positive); n = 13 (HER2-positive, metastasis-free);
n = 6 (HER2-positive, metastasis-positive).
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SUPPLEMENTARY TABLES
Supplementary Table 1. Known Expression Patterns of Candidate miRNAs in Human
Breast Tumors
miRNA Calin et al., 2004 Iorio et al., 2005 Zhang et al., 2006 Volinia et al., 2006
miR-31 downregulateda no change downregulated upregulated
miR-100 downregulated no change upregulated no change
miR-101 downregulated downregulated downregulated no change
miR-125b1 downregulated downregulated downregulated downregulated
miR-125b2 downregulated downregulated downregulated downregulated
miR-143 downregulated downregulated downregulated no change
miR-145 downregulated downregulated downregulated downregulated
miR-149 downregulated downregulated downregulated no change
miR-210 downregulated upregulated downregulated upregulated
miR-213 no change upregulated upregulated upregulated
aDownregulated, upregulated, and no change refer to expression of the indicated miRNA in
primary human breast tumor specimens relative to normal mammary tissue.
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Supplementary Table 2. Characteristics of Mammary Epithelial Cell Lines Employed in
this Study
Cell Line Origin Tumorigenica? Locally
invasivea?
Capable of forming
micrometastasesa?
Capable of forming
macrometastasesa?
HMEC Human; Primary
mammary epithelial cells
No No No No
HMLE Human; Experimentally
transformed
No No No No
HMLER Human; Experimentally
transformed
Yes No No No
MCF7-Ras Human; Pleural effusion Yes No No No
SUM-149 Human; Primary ductal
carcinoma
Yes No No No
SUM-159 Human; Primary carcinoma Yes Yes Yes No
MDA-MB-
231
Human; Pleural effusion Yes Yes Yes Yes
NMuMG Murine; Primary
mammary epithelial cells
No No No No
D2.OR Murine; Spontaneously
arising carcinoma
Yes Yes No No
D2.1 Murine; Spontaneously
arising carcinoma
Yes Yes Yes No
D2A1 Murine; Spontaneously
arising carcinoma
Yes Yes Yes Yes
67NR Murine; Spontaneously
arising carcinoma
Yes No No No
168FARN Murine; Spontaneously
arising carcinoma
Yes Yes No No
4TO7 Murine; Spontaneously
arising carcinoma
Yes Yes Yes No
4T1 Murine; Spontaneously
arising carcinoma
Yes Yes Yes Yes
aUpon orthotopic implantation into immune-deficient host mice (human cell lines) or a syngenic
background (murine cell lines).
115
Supplementary Table 3. Site-Specific Mutation of miR-31 Binding Sites in 3’ UTR
Reporter Constructs
3’ UTR Wild Type Sequence Mutagenized Sequence
Fzd3 TCTTGCCA TCGGCGCA
ITGA5 CTTGCCA CAAAAGA
M-RIP ATCTTGC ATCGGCG
MMP16 CTTGCCA CAAACAG
RDX CTTGCCA TCCACCA
RhoA (site 1)a ATCTTGC GGTAGGC
RhoA (site 2)b TCTTGC CGCCGC
aThe miR-31 motif at nucleotides 145-151 of the human RhoA 3’ UTR. bThe miR-31 motif
spanning nucleotides 303-309 of the RhoA 3’ UTR. Red: nucleotides altered in the mutagenized
reporter constructs.
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Supplementary Table 4. Fold-Change Values in 295 Human Breast Tumors (van de Vijver
et al., 2002)
Gene Fold-Change
(Range)
Fold-Change
(Quartile3 – Quartile1)
Fold-Change (Target Signature-
Positive vs. Signature-Negative)
Fzd3 7.21 1.62 2.75
ITGA5 11.56 1.61 3.38
M-RIP 8.24 1.37 2.32
MMP16 14.15 1.28 2.54
RDX 13.18 1.62 3.75
RhoA 5.7 1.43 2.39
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Supplementary Table 5. Annotation of Clinical Breast Tumor Specimens
#
Agea
Histological
Subtype
Molecular
Subtype Grade ER PR HER2
LN
Status
Metastatic
Recurrence?
Sites of
Metastasis
1 54 D HER II n n p n No None
2 57 D HER II n n p p Yes Viscera
3 85 D HER II n n p U Yes Pleura
4 63 D HER III n n p p No None
5 41 D HER III n n p n No None
6 44 D HER III n n n n No None
7 37 D HER III n n p n No None
8 55 D HER III n n p p No None
9 42 D HER III p n p p No None
10 45 D HER III n n p n No None
11 47 D HER III p p p p No None
12 56 D HER III n n p n No None
13 49 D HER III p p p n No None
14 53 D HER III n n p p Yes Viscera
15 45 D HER III n n p p Yes Viscera
16 62 D ERLG I p p n n No None
17 40 D ERLG I p n n p No None
18 37 D ERHG I p p n p No None
19 30 D ERHG II p p p p No None
20 37 D ERHG II p p n p No None
21 74 D ERHG II n n n n No None
22 64 D ERHG III p p p n No None
23 57 D ERHG III p p lp p No None
24 78 D ERHG III p p n p No None
25 55 D ERHG III p p n p Yes Bone only
26 57 D Basal II n n n n No None
27 41 D Basal III n n n n No None
28 40 D Basal III n n n n No None
29 49 D Basal III n n p n No None
30 78 D Basal III n n n n No None
31 48 D Basal III n n n n No None
32 48 D Basal III n n n n No None
33 65 D Basal III n n n n No None
34 U D Basal III n n n n No None
35 79 D Basal III n n n n Yes Bone only
36 42 D Basal III n n n p Yes Viscera
37 43 D Basal III n n n n Yes Viscera
38 53 D Basal III n n n n Yes Viscera
39 64 D Basal III n n n n Yes Viscera
40 72 D U III n n n n U U
41 71 L HER III p p p p No None
42 62 L ERLG I p p n n No None
43 81 L ERLG I p pl n p No None
44 62 L ERLG I p p n n No None
45 45 L ERLG II p p n p No None
46 45 L ERLG II p p n n No None
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47 60 L ERHG I p n n p Yes Bone only
48 46 L ERHG III p p lp p No None
49 32 M HER II p p p p No None
50 44 M HER II p pl p p Yes Viscera
51 44 M HER II p p p p Yes Viscera
52 46 M ERLG II p p n p Yes Bone only
53 58 M ERHG II p p n p No None
54 38 M ERHG III pl pl n p Yes Viscera
55 48 M Basal III p p n p No None
56 68 M Basal III n n p p No None
aAt time of initial presentation. ER = Estrogen receptor; PR = Progesterone receptor; LN =
lymph node; U = Unknown; D = Ductal; L = Lobular; M = Mixed type; ERLG = ER-positive
low-grade; ERHG = ER-positive high-grade; p = positive; n = negative; pl = positive-low; lp =
low-positive.
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INTRODUCTION
As described in Chapter One, microRNAs (miRNAs) are an evolutionarily conserved
family of regulatory RNAs that inhibit their mRNA targets post-transcriptionally, leading to
modulation of diverse biological processes including the development and progression of cancer
(Ambros, 2004; Bartel, 2009; Ventura and Jacks, 2009). An individual miRNA is capable of
regulating dozens of distinct mRNAs (Selbach et al., 2008; Baek et al., 2008), and it is thought
that pleiotropic suppression of multiple downstream effectors may underlie the phenotypic
changes observed upon perturbing the levels of certain miRNAs (Zhao et al., 2007; van Rooij et
al., 2007; Thai et al., 2007; Rodriguez et al., 2007; Johnnidis et al., 2008; Ventura et al., 2008). It
remains unclear, however, whether these consequences depend on simultaneous deregulation of
the entire repertoire of targets of a given miRNA or instead the altered activity of only a small
subset of effectors.
Metastases, which are responsible for 90% of human cancer deaths, arise via a complex
series of events, collectively termed the invasion-metastasis cascade (Fidler, 2003; Gupta and
Massagué, 2006), as has been previously outlined in Chapter One. In order to metastasize, cells
in a primary tumor must become motile, degrade surrounding extracellular matrix (local
invasion), intravasate into the vasculature, retain viability during transit through the circulation,
extravasate into the parenchyma of a distant tissue, survive in this foreign microenvironment to
form micrometastases, and finally thrive in their new milieu and establish macroscopic
secondary tumors (colonization) (Fidler, 2003). Colonization is the rate-limiting step of the
invasion-metastasis cascade, yet the molecular underpinnings of this process are poorly
understood (Gupta and Massagué, 2006).
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As described in Chapter Two, I recently determined that expression of the miRNA miR-
31 was both necessary and sufficient to inhibit the metastasis of human breast cancer xenografts,
and that miR-31 levels correlated inversely with metastatic relapse in breast carcinoma patients
(Valastyan et al., 2009). I attributed these effects to miR-31’s ability to pleiotropically suppress a
cohort of pro-metastatic targets; however, I did not identify a minimal set of downstream
effectors whose concomitant re-expression is sufficient to fully override miR-31’s influences on
metastasis. For this reason, I undertook to determine whether the impact of miR-31 on metastasis
could be explained by its ability to pleiotropically modulate a defined subset of its >200
predicted targets.
RESULTS
Individual Suppression of ITGA5, RDX, or RhoA Impairs Metastasis-Relevant Traits in
vitro and Metastatic Capacity in vivo
I previously demonstrated that miR-31 regulates six mRNAs that encode proteins with
roles in cell motility and tumor progression: frizzled3 (Fzd3), integrin-_5 (ITGA5), matrix
metallopeptidase 16 (MMP16), myosin phosphatase-Rho interacting protein (M-RIP), radixin
(RDX), and RhoA (Valastyan et al., 2009). To begin to address whether miR-31-imposed
inhibition of one or more of these effectors might be responsible for mediating miR-31’s anti-
metastatic influences, I stably suppressed these six mRNAs individually in otherwise-metastatic
MDA-MB-231 human breast cancer cells (“231 cells”) using short hairpin RNAs (shRNAs). 231
cells are largely devoid of endogenous miR-31 and robustly express these six effectors;
moreover, ectopic miR-31 impairs metastasis by these cells (Valastyan et al., 2009).
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For each gene, I derived multiple cell lines that stably expressed a distinct shRNA
targeting unique sequences in the encoded mRNA in order to minimize confounding influences
from shRNA off-target effects (Supplementary Figures 1A and 2A). At least one shRNA against
each of the six effectors reduced its target’s level by a factor comparable to that elicited by miR-
31 expression (Valastyan et al., 2009). This allowed me to reasonably approximate the
consequences of miR-31’s actions on each individual downstream effector.
These shRNA-expressing 231 cells were subjected to in vitro assays that model traits
important for metastasis. I observed that individual suppression of ITGA5, RDX, or RhoA
reduced invasion, motility, and resistance to anoikis-mediated cell death in vitro; in contrast, the
Fzd3, MMP16, or M-RIP shRNAs failed to substantially affect these behaviors (Supplementary
Figures 1B-1D and 2B-2D). For shRNAs that conferred measurable responses, the magnitude of
these responses was directly correlated with the extent of knock-down achieved, suggesting that
these effects arose as a specific consequence of reduced levels of the targeted protein. Inhibition
of Fzd3, ITGA5, MMP16, M-RIP, RDX, or RhoA failed to affect in vitro proliferation
(Supplementary Figures 1E and 2E). Also, the responses evoked by the ITGA5, RDX, and RhoA
shRNAs could not be ascribed to saturation of the miRNA biogenesis machinery, as mature
levels of eight control miRNAs were unaffected in these cells (Supplementary Figure 3).
I determined whether suppression of these six mRNAs altered metastatic capacity in vivo
by intravenously injecting the shRNA-expressing 231 cells into mice. One month later, cells
bearing shRNAs targeting ITGA5, RDX, or RhoA had generated 80%, 85%, and 55% fewer lung
metastases than controls, respectively; however, downregulation of Fzd3, MMP16, or M-RIP did
not affect the number of metastases spawned (Supplementary Figure 4). Thus, inhibition of
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ITGA5, RDX, or RhoA – but not Fzd3, MMP16, or M-RIP – affects in vitro surrogates of
metastatic capacity as well as in vivo metastasis.
Individual Re-Expression of ITGA5, RDX, or RhoA Partially Reverses miR-31-Imposed
Metastasis Defects in vivo
To extend these analyses, I stably re-expressed miRNA-insensitive versions of the
mRNAs encoding Fzd3, ITGA5, MMP16, M-RIP, RDX, or RhoA individually in 231 cells that
already expressed either miR-31 or control vector (Supplementary Figure 5A). This allowed me
to gauge the ability of each of these effectors – when re-expressed – to reverse miR-31’s impact
on in vivo metastasis. When introduced into the venous circulation of mice, miR-31-expressing
cells formed 85% fewer lung metastases than controls one month post-injection (Supplementary
Figure 5B), consistent with my prior findings (Valastyan et al., 2009). Individual re-expression
of ITGA5, RDX, or RhoA restored the number of lung metastases in miR-31-expressing cells to
55%, 50%, and 65% of control levels, respectively; in contrast, Fzd3, MMP16, or M-RIP failed
to increase lesion number (Supplementary Figure 5B). Overexpression of ITGA5, RDX, or
RhoA did not further enhance metastasis in control 231 cells (Supplementary Figure 5B),
suggesting that signaling from these pathways was already saturated in 231 cells, as has
previously been established for RhoA-controlled networks (Pillé et al., 2005). Together, these
findings implied that although miR-31 is capable of suppressing numerous mRNA species, its
ability to regulate only a subset of these effectors appears to be crucial for its capacity to impair
metastasis.
In support of this notion, when stably re-expressed in 231 cells, Fzd3, MMP16, or M-RIP
failed to reverse miR-31-imposed attenuation of invasion, motility, and anoikis resistance in vitro
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(Supplementary Figure 6); in contrast, my prior work revealed that restored levels of ITGA5,
RDX, or RhoA rescued, at least partially, miR-31-evoked defects in these phenotypes (Valastyan
et al., 2009). Based on these in vitro and in vivo re-expression data, as well as the above-
described in vitro and in vivo loss-of-function findings, I focused my subsequent analyses on the
ability of inhibition of ITGA5, RDX, and RhoA to account for miR-31’s anti-metastatic
activities.
Individual Suppression of ITGA5, RDX, or RhoA Impairs Metastasis, But Fails to
Phenocopy the Full Spectrum of miR-31’s Anti-Metastatic Activities in vivo
To this end, I investigated the consequences of suppressing ITGA5, RDX, or RhoA
individually in an orthotopic injection assay. Accordingly, I implanted 231 cells expressing
shRNAs targeting either ITGA5, RDX, or RhoA into the mammary fat pads of mice.
Suppression of ITGA5 or RhoA did not affect primary tumor growth; conversely, inhibition of
RDX reduced the size of resulting mammary tumors (Figure 1A). After normalizing for
differences in primary tumor growth, cells expressing shRNAs against ITGA5, RDX, or RhoA
formed 85%, 70%, and 50% fewer lung metastases than controls 2.5 months after injection,
respectively (Figure 1B). Thus, inhibition of ITGA5, RDX, or RhoA each impedes metastasis;
however, this assay did not reveal the particular step(s) of the invasion-metastasis cascade that
were impaired due to suppression of ITGA5, RDX, or RhoA.
In my previous work, I observed that miR-31 impinges upon three steps of the invasion-
metastasis cascade in vivo: local invasion, early post-intravasation events (intraluminal viability,
extravasation, and/or initial survival in distant tissues), and colonization (Valastyan et al., 2009).
Consequently, I evaluated whether the individual suppression of ITGA5, RDX, or RhoA was
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sufficient to recapitulate one or more of miR-31’s multiple effects on the metastatic process. I
found that 231 cells containing shRNAs against either ITGA5, RDX, or RhoA formed primary
tumors that appeared histologically invasive and were indistinguishable from controls (Figure
1C). Thus, inhibition of ITGA5, RDX, or RhoA alone does not abolish local invasion in vivo.
Putative effects on early post-intravasation events were examined by quantifying shRNA-
expressing 231 cells in the lungs one day after intravenous injection. Cells with either suppressed
ITGA5 or RhoA were 40% and 30% less prevalent than controls, respectively; however, RDX
knock-down did not reduce persistence in the lungs (Figure 1D). These effects were not
attributable to a differential ability of the cells to become lodged initially in the lung
microvasculature, as equal numbers of cells were detected in the lungs 10 minutes after
intravenous injection (Supplementary Figure 7). These data indicated that inhibition of either
ITGA5 or RhoA impairs early post-intravasation events in vivo.
To investigate potential effects on colonization (i.e., the capacity of disseminated single
cells to yield large, multi-cellular metastases), the sizes of lung metastases in intravenously
injected animals was analyzed three months after implantation. 231 cells expressing either
ITGA5 or RDX shRNAs formed only small micrometastases, while RhoA shRNA-containing
cells generated macroscopic metastases comparable to those spawned by control cells (Figure
1E). Hence, suppression of either ITGA5 or RDX alone prevents colonization in vivo.
Together, these observations revealed that while individual suppression of ITGA5, RDX,
or RhoA impairs one or more steps of the invasion-metastasis cascade, inhibition of any one of
these proteins alone is unable to phenocopy the full spectrum of miR-31’s impact on metastasis.
This suggested that miR-31 may achieve its influences on multiple distinct stages of the
metastatic process via concomitant suppression of several downstream effectors. Provocatively,
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my loss-of-function analyses indicated that ITGA5, RDX, and RhoA act during at least partially
distinct steps of the invasion-metastasis cascade (e.g., RhoA affected early post-intravasation
events but not colonization, while RDX had no impact on early post-intravasation events but
altered colonization); hence, their concurrent regulation provides a plausible mechanism by
which miR-31 might elicit its multiple anti-metastatic effects.
Simultaneous Re-Expression of ITGA5, RDX, and RhoA Abrogates miR-31-Imposed
Metastasis Suppression in vivo
To test this hypothesis, I stably re-expressed miRNA-insensitive mRNAs encoding
ITGA5, RDX, and RhoA together in combination – along with either miR-31 or control vector –
in 231 cells. When these cells were orthotopically injected into mice, miR-31 enhanced primary
tumor growth, recapitulating my prior findings (Valastyan et al., 2009); simultaneous re-
expression of ITGA5, RDX, and RhoA failed to alter the size of miR-31-containing or control
primary tumors (Figure 2A). Despite their ability to generate larger primary tumors, miR-31-
expressing 231 cells were impaired by >80% in their ability to spawn lung metastases (Figure
2B). ITGA5, RDX, and RhoA did not enhance metastasis in control 231 cells; however,
concomitant re-expression of ITGA5, RDX, and RhoA in 231 cells containing miR-31
completely abrogated miR-31-imposed metastasis suppression (Figure 2B). These data implied
that the impact of miR-31 on in vivo metastasis can be explained by miR-31’s capacity to inhibit
a cohort of three downstream effectors. This was quite surprising, as computational algorithms
predict that miR-31 regulates >200 mRNAs, many of which encode proteins that function in
metastasis-relevant processes (Krek et al., 2005; Grimson et al., 2007).
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Re-Expression of ITGA5, RDX, and/or RhoA Affords Both Unique and Partially
Overlapping Reversal of miR-31-Evoked Inhibition of Spontaneous Metastasis in vivo
Since the combined re-expression of ITGA5, RDX, and RhoA entirely abolished miR-31-
evoked metastasis suppression, I also determined whether these three effectors were able to
reverse a subset of miR-31’s influences on metastasis when re-expressed either individually or in
different combinations. Thus, I created 231 cells stably expressing miR-31 or control vector plus
all possible permutations of zero, one, two, or three of these miR-31 targets (all rendered
miRNA-resistant) (Supplementary Figure 8). miR-31, ITGA5, RDX, and RhoA failed to affect
cell proliferation in vitro (Supplementary Figure 9A). However, individual re-expression of
ITGA5, RDX, or RhoA rescued, at least partially, in vitro defects in invasion, motility, and
anoikis resistance conferred by ectopic miR-31; the extent of reversal was more pronounced
when multiple effectors were re-expressed in combination (Supplementary Figures 9B-9D).Thus,
ITGA5, RDX, and RhoA control in vitro behaviors important for metastasis downstream of miR-
31.
To assay the respective abilities of all possible combinations of re-expressed ITGA5,
RDX, and/or RhoA to reverse miR-31’s influences on in vivo metastasis, 231 cells expressing
miR-31, ITGA5, RDX, and/or RhoA were orthotopically implanted into mice. miR-31 generally
promoted primary tumor growth, while restored levels of ITGA5, RDX, and RhoA failed to
consistently affect the growth of primary tumors (Figure 3A and Supplementary Table 1). miR-
31 reduced the incidence of metastatic lesions in the lungs by >90% (Figure 3B). When
individually re-expressed in miR-31-containing cells, ITGA5, RDX, or RhoA increased
metastasis to 40%, 45%, and 65% of control levels, respectively; re-expression of any two of
these targets in miR-31-positive cells yielded 85% as many metastases as controls (Figure 3B).
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As before, concomitant re-expression of ITGA5, RDX, and RhoA in cells containing miR-31
restored the number of lung metastases to 100% of that observed in controls (Figure 3B). Hence,
these three effectors make distinct contributions to in vivo metastasis that can collaborate to
explain miR-31’s influence on this process; however, these observations failed to delineate the
specific step(s) of the invasion-metastasis cascade affected by various combinations of re-
expressed ITGA5, RDX, and/or RhoA.
miR-31 affects three steps of the invasion-metastasis cascade in vivo: local invasion,
early post-intravasation events, and colonization (Valastyan et al., 2009). To investigate whether
ITGA5, RDX, and RhoA – when overexpressed – could synergize to reverse miR-31’s effects on
local invasion, I examined the histological appearance of primary tumors that developed in
orthotopically injected mice. Whereas control 231 cell tumors displayed clear evidence of
invasion, miR-31-expressing tumors were well-confined (Figure 3C), as I previously
documented (Valastyan et al., 2009). While ITGA5, RDX, and RhoA did not alter invasion in
control 231 cell tumors, combined re-expression of these three targets abolished the previously
well-encapsulated phenotype of miR-31-expressing tumors (Figure 3C). miR-31-containing cells
with restored levels of either RDX or RhoA alone formed primary tumors that appeared invasive,
though reversal of miR-31-imposed invasion defects was incomplete; ITGA5 did not affect
encapsulation (Figure 3C). These observations revealed that miR-31-dependent attenuation of
local invasion can be attributed to miR-31’s ability to regulate RDX and RhoA. Ostensibly, in
light of my shRNA studies (Figure 1C), RDX and RhoA function redundantly – either with one
another or with additional, still-unidentified miR-31 targets – to promote invasion in vivo.
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Re-Expression of ITGA5, RDX, and/or RhoA Affords Both Unique and Partially
Overlapping Reversal of miR-31-Mediated Inhibition of Experimental Metastasis in vivo
I also examined whether re-expression of these three targets could reverse the impact of
miR-31 on early post-intravasation events. To do so, I introduced 231 cells into the venous
circulation of mice and assayed the number of cells in the lungs one day after injection.
Consistent with my previous findings (Valastyan et al., 2009), miR-31-expressing cells were
five-fold impaired in their ability to persist in the lungs (Figure 4A), indicating that miR-31
impeded one or more early post-intravasation events. ITGA5, RDX, and RhoA failed to affect
early post-intravasation events in control 231 cells (Figure 4A). In contrast, individual re-
expression of either ITGA5 or RhoA restored the number of miR-31-expressing cells in the lungs
to 50% of control levels; RDX did not augment the ability of cells containing miR-31 to persist
in the lungs at this timepoint (Figure 4A). Simultaneous re-introduction of ITGA5 and RhoA in
miR-31-expressing cells sufficed to completely override miR-31-imposed obstruction of early
post-intravasation events (Figure 4A). These effects were not a consequence of an altered ability
of ITGA5-, RDX-, RhoA-, and/or miR-31-expressing cells to become lodged initially in the lung
microvasculature, as equal numbers of cells were detected in the lungs 10 minutes after
intravenous injection (Supplementary Figure 10). These data provided evidence that miR-31-
evoked suppression of early post-intravasation events can be ascribed to miR-31’s ability to
modulate ITGA5 and RhoA.
Three months after intravenous injection, control 231 cells generated large macroscopic
metastases while miR-31-expressing cells yielded only small micrometastases (Figure 4B).
Hence, miR-31 prevented disseminated tumor cells from re-initiating their proliferative program
at the site of metastasis, in consonance with miR-31’s reported influence on colonization
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(Valastyan et al., 2009). Concomitant re-expression of ITGA5, RDX, and RhoA in miR-31-
containing cells abrogated miR-31-imposed suppression of colonization, yet overexpression of
these three targets in control 231 cells failed to increase lesion size (Figure 4B). Individually
restored levels of either ITGA5 or RDX in miR-31-expressing cells reversed miR-31’s effects on
colonization; RhoA did not affect this parameter (Figure 4B). Thus, the ability of miR-31 to
inhibit colonization can derive from its capacity to suppress ITGA5 and RDX.
In this same assay, miR-31-expressing 231 cells formed 20-fold fewer lung metastases
than controls (Figure 4C). When individually re-expressed in miR-31-containing cells, ITGA5,
RDX, or RhoA increased the number of metastases formed to 60%, 60%, and 50% of control
levels, respectively (Figure 4C). Restored levels of pairwise combinations of these three targets
in miR-31-expressing cells enhanced lesion number to >70% of controls; importantly,
simultaneous re-expression of ITGA5, RDX, and RhoA in miR-31-containing cells completely
abolished miR-31-mediated metastasis suppression (Figure 4C). Taken together, the preceding
experiments indicated that the impact of miR-31 on metastasis can be entirely explained by miR-
31’s capacity to regulate ITGA5, RDX, and RhoA; these three targets act at partially overlapping
steps of the invasion-metastasis cascade downstream of miR-31 in vivo (Table 1).
The Effects of ITGA5, RDX, and RhoA Re-Expression on miR-31-Evoked Metastasis-
Relevant Phenotypes are Not Confined to 231 Cells
It remained possible that the ability of ITGA5, RDX, and RhoA to override miR-31’s
actions arose due to some peculiarity of the 231 cell system. To address this, I extended my
analyses to SUM-159 human breast cancer cells. Like 231 cells, SUM-159 cells lack endogenous
miR-31, are highly aggressive in vitro, and display impaired invasion, motility, and anoikis
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resistance upon ectopic miR-31 (Valastyan et al., 2009). I created SUM-159 cells stably
expressing all 16 potential combinations of either miR-31 or control vector plus miRNA-resistant
mRNAs encoding ITGA5, RDX, and/or RhoA; all lines displayed comparable in vitro
proliferative kinetics (Supplementary Figures 11A and 11B). Consistent with my observations in
231 cells, individual re-expression of ITGA5, RDX, or RhoA in miR-31-containing SUM-159
cells rescued, at least partially, in vitro defects in invasion, motility, and anoikis resistance
attributable to ectopic miR-31; as before, the extent of rescue was more pronounced when
multiple effectors were concomitantly re-expressed (Supplementary Figures 11C-11E). Hence,
the ability of ITGA5, RDX, and RhoA re-expression to override the actions of miR-31 is not
confined to 231 cells.
MATERIALS AND METHODS
Plasmid Construction
miR-31 was expressed from pBABE-puro, as I have elaborated upon (Valastyan et al.,
2009). Constructs encoding Fzd3 (Deardorff et al., 2001), ITGA5 (Kuwada and Li, 2000),
MMP16 (Hotary et al., 2006), M-RIP (Surks et al., 2003), RDX (Batchelor et al., 2004), and
RhoA (Subauste et al., 2000) – but lacking endogenous 3’ UTR sequences and thus rendering
them miRNA-resistant – were subcloned into pBABE-hygro, pBABE-neo, pBABE-hygro,
pBABE-hygro, pBABE-hygro, and pBABE-zeo, respectively (Elenbaas et al., 2001). shRNAs
targeting Fzd3, ITGA5, MMP16, M-RIP, RDX, and RhoA were expressed from pLKO.1-puro
(Open Biosystems).
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Cell Culture
Green fluorescent protein (GFP)-labeled 231 cells have been described (Valastyan et al.,
2009). SUM-159 cells were provided by S. Ethier (Ma et al., 2007). Stable expression was
achieved via retroviral (expression constructs) or lentiviral (shRNAs) transduction, followed by
selection with puromycin, neomycin, hygromycin, and/or zeocin (Elenbaas et al., 2001).
Animal Studies
All research involving animals complied with protocols approved by the MIT Committee
on Animal Care. Age-matched NOD/SCID (propagated on-site) or nude (Taconic) mice were
utilized in the xenograft studies, as indicated. For spontaneous metastasis assays, the indicated
female mice were bilaterally injected into the mammary fat pads with 1.0 x 106 tumor cells
resuspended in 1:2 Matrigel (BD Biosciences) plus normal growth media. In spontaneous
metastasis assays employing nude mice, primary tumor diameter was measured every seven days
using precision calipers; tumor volume was calculated according to the formula V = (4/3)∏r3. For
experimental metastasis assays, the indicated mice were injected intravenously with 5.0 x 105
tumor cells (in PBS) via the tail vein. Lung metastasis was quantified using a fluorescent
dissecting microscope within three hours of specimen isolation. Tumor histology was assessed
by staining paraffin-embedded tissue sections with hematoxylin and eosin (H&E).
Statistical Analysis
Data are presented as mean ± s.e.m; Student’s two-tailed t-test was used for comparisons,
with P <0.05 considered significant.
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Immunoblotting
Lysates were resolved by NuPAGE gel electrophoresis (Invitrogen), transferred to a
PVDF membrane, and probed with antibodies against _-actin (Santa Cruz), ITGA5 (Santa Cruz),
RDX (Cell Signaling), or RhoA (Abcam).
miRNA Detection and RT-PCR
Total RNA, including small RNAs, was extracted from the indicated 231 cells with a
mirVana MicroRNA Isolation Kit (Ambion). RT-PCR-based detection of mature microRNAs
and the 5S rRNA was achieved via use of a mirVana MicroRNA Detection Kit and gene-specific
primer sets (Ambion). For detection of Fzd3, GAPDH, ITGA5, MMP16, M-RIP, RDX, and
RhoA transcript levels, cDNA was prepared from 200 ng of total RNA using the SuperScript III
First-Strand Synthesis System (Invitrogen), and quantitated by SYBR Green real time RT-PCR
(Applied Biosystems).
Invasion and Motility Assays
For invasion assays, 1.0 x 105 cells were plated in Matrigel-coated chambers with 8.0 _m
pores (BD Biosciences); for motility assays, 5.0 x 104 cells were seeded atop uncoated
membranes with 8.0 _m pores (BD Biosciences). Cells were seeded in serum-free media, and
translocated toward complete growth media for 20 hours. Non-invaded or non-migrated cells
were then physically removed; successfully translocated cells were visualized using a Diff-Quick
Staining Set (Dade) and counted.
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Anoikis Assays
Anoikis resistance was evaluated by seeding 7.5 x 104 cells in ultra-low attachment plates
(Corning). After 24 hours, cells were resuspended in 0.4% trypan blue (Sigma) and the
proportion of viable cells was quantified using a hemocytometer.
Measurements of in vitro Cell Proliferation
Unless otherwise denoted, proliferative kinetics were assayed by seeding 1.0 x 105 cells per well
in 6-well plates. Total cell number was assessed every two to three days by trypsinization and
manual counting with a hemocytometer. Alternatively, cell proliferation was measured by
seeding 5.0 x 102 or 1.0 x 103 cells per well in 96-well plates and utilizing a CellTiter96 AQueous
One Solution MTS Cell Proliferation Assay (Promega); cells were incubated with the MTS
reagent for 1.5 hours, then total cell number was quantitated by measuring absorbance at 492 nm
on a 96-well plate reader.
Oligonucleotide Sequences
Oligonucleotides employed in this study were: subcloning Fzd3 into pBABE-hygro,
TGGCGAGAATTCATGGCTATGACTTGGATTGTCTTCTCTCTTTGGCCCT and TTGCGGGTCGACTTAAGCACTGGTTCCATCTTCTTCAATAACCCGA;
subcloning ITGA5 into pBABE-neo, TTATAAGTCGACATGGGGAGCCGGACGCCAGAGTCCCCTCT and
TTTATAGTCGACTCAGGCATCAGAGGTGGCTGGAGGCTTGAGCTGA; subcloning MMP16 into pBABE-hygro,
AACCACTTTGTCGACATGATCTTACTCACATTCAGCACTGGAAGACGG and AACCACTTTGTCGACTCACACCCACTCTTGCATAGAGCGTTTACAGTAC;
subcloning M-RIP into pBABE-hygro, AACCACTTTGAATTCATGTCGGCAGCCAAGGAGAAC and
AACCACTTTGTCGACTCAGGTATCCCACGAGACCTGCTCAATTAC; subcloning RDX into pBABE-hygro,
TGGCACGGATCCATGCCGAAACCAATCAACGTAAGAGTAACTACAATG  and GGTCGAGTCGACTCACATTGCTTCAAACTCATCGATACGCTGCT;
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Fzd3 RT-PCR, TCCATCCCTGCACAATATAAGGCTTCCACA and TCTCAATGCATCAACATCGTAGAGGCCAAC; GAPDH RT-
PCR, TCACCAGGGCTGCTTTTAAC and GACAAGCTTCCCGTTCTCAG; ITGA5 RT-PCR, AACTCATCATGGCCAGTGAGGGTAAGGGT
and ATCCTTAATGGCTCAGACATTCGATCCCTCTACAACT; MMP16 RT-PCR, AGTACGGCTACCTTCCACCGACTGA and
TACCTCTTGTCTGGTCAGGTACACCGCAT; M-RIP RT-PCR, AGGCAGAGCACATGGAGACCAATGCA and
AGTCAGCCAGCCTTTCTTGAAATTCAGCA; RDX RT-PCR, GAATCAGGAGCAGCTAGCAGCAGAACTT and
TTGGTCTTTTCCAAGTCTTCCTGGGCTGCA; RhoA RT-PCR, AGGTGGATGGAAAGCAGGTAGAGTTGGCT and
AGGATGATGGGCACGTTGGGACAGA.
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FIGURES
Figure 1. Individual Suppression of ITGA5, RDX, or RhoA Impairs Metastasis in vivo. (A)
Primary tumor growth upon orthotopic injection of the indicated GFP-labeled 231 cells into
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NOD/SCID mice. The assay was terminated after 11 weeks due to primary tumor burden. n = 5
per timepoint. (B) Fluorescent images of murine lungs to visualize 231 cells 76 days after
orthotopic implantation (top panels). Quantification of metastatic burden (bottom panel). n = 5.
(C) H&E stain of 231 cell primary mammary tumors 57 days after injection (top panels).
Quantification of local invasion (bottom panel). n = 5. All P-values are >0.67 relative to
shLuciferase. (D) Prevalence of GFP-labeled 231 cells in the lungs one day after intravenous
introduction into NOD/SCID mice. n = 4. (E) Fluorescent images of murine lungs to visualize
231 cells 89 days after intravenous injection. Arrows: micrometastases. shRNAs utilized in these
assays: shITGA5 #4, shRDX #3, and shRhoA #5. All error bars represent mean ± s.e.m.
143
Figure 2. Simultaneous Re-Expression of ITGA5, RDX, and RhoA Abrogates miR-31-
Imposed Metastasis Suppression in vivo. (A) Primary tumor growth upon orthotopic injection
of the indicated GFP-labeled 231 cells into NOD/SCID mice. The assay was terminated after 11
weeks due to primary tumor burden. n = 5 per timepoint. (B) Fluorescent images of murine lungs
to visualize 231 cells 67 days after orthotopic implantation (top panels). Quantification of
metastatic burden (bottom panel). n = 5. All error bars represent mean ± s.e.m.
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Figure 3. Re-Expression of ITGA5, RDX, and/or RhoA Affords Both Unique and Partially
Overlapping Reversal of miR-31-Evoked Inhibition of Spontaneous Metastasis in vivo. (A)
Primary tumor growth upon orthotopic implantation of the indicated GFP-labeled 231 cells into
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nude mice. The assay was terminated after 13 weeks due to primary tumor burden. n = 5. (B)
Fluorescent images of murine lungs to visualize 231 cells 88 days after orthotopic injection (top
panels). Quantification of metastatic burden (bottom panel). n = 5. (C) H&E stain of 231 cell
primary mammary tumors 54 days after injection. Quantification of local invasion (bottom
panel). n = 5. All error bars represent mean ± s.e.m.
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Figure 4. Re-Expression of ITGA5, RDX, and/or RhoA Affords Both Unique and Partially
Overlapping Reversal of miR-31-Mediated Inhibition of Experimental Metastasis in vivo.
(A) Prevalence of the indicated GFP-labeled 231 cells in the lungs one day after intravenous
introduction into NOD/SCID mice. n = 4. (B) Fluorescent images of murine lungs to visualize
231 cells 84 days after tail vein injection. (C) Lung metastatic burden 84 days subsequent to
intravenous injection. n = 5. All error bars represent mean ± s.e.m.
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SUPPLEMENTARY FIGURES
Supplementary Figure 1. Suppression of ITGA5, RDX, or RhoA Impairs Metastasis-
Relevant Traits in vitro. (A) Immunoblots for total ITGA5, RDX, or RhoA in the indicated
MDA-MB-231 (231) cells. _-actin was a loading control. (B) Invasion assays using the indicated
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231 cells. n = 3. (C) Motility assays employing 231 cells infected as denoted. n = 3. (D) Anoikis
assays with the indicated 231 cells. n =3. (E) In vitro proliferation of the indicated 231 cells. n =
3. Asterisks: P <0.05 relative to shLuciferase. All error bars represent mean ± s.e.m.
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Supplementary Figure 2. Suppression of Fzd3, MMP16, or M-RIP Does Not Affect
Metastasis-Relevant Traits in vitro. (A) Real time RT-PCR for Fzd3, MMP16, and M-RIP in
the indicated 231 cells. GAPDH was a loading control. n = 3. (B) Invasion assays using the
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indicated 231 cells. n = 3. (C) Motility assays employing 231 cells infected as denoted. n = 3.
(D) Anoikis assays with the indicated 231 cells. n =3. All P-values are >0.65 relative to
shLuciferase. (E) In vitro proliferation of the indicated 231 cells, as measured by an MTS assay.
n = 3. All error bars represent mean ± s.e.m.
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Supplementary Figure 3. shRNA Expression Does Not Interfere with MicroRNA
Biogenesis. Real time RT-PCR for various mature microRNAs in the indicated 231 cells. 5S
rRNA was a loading control. n = 3. All P-values are >0.32 relative to shLuciferase. shRNAs
utilized in these assays: shITGA5 #4, shRDX #3, and shRhoA #5. All error bars represent mean
± s.e.m.
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Supplementary Figure 4. Suppression of ITGA5, RDX, or RhoA Impairs in vivo
Metastasis, while Inhibition of Fzd3, MMP16, or M-RIP Fails to Impact this Phenotype.
Quantification of metastatic burden in the lungs of nude mice one month after intravenous
injection of the indicated green fluorescent protein (GFP)-labeled 231 cells. n = 5. shRNAs
utilized in these assays: shFzd3 #1, shITGA5 #4, shMMP16 #2, shM-RIP #2, shRDX #3, and
shRhoA #5. All error bars represent mean ± s.e.m.
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Supplementary Figure 5. Re-Expression of ITGA5, RDX, or RhoA Partially Reverses miR-
31-Imposed Metastasis Suppression in vivo, while Re-Expression of Fzd3, MMP16, or M-
RIP Fails to Rescue this Phenotype. (A) Real time RT-PCR for miR-31, Fzd3, ITGA5,
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MMP16, M-RIP, RDX, and RhoA in the indicated 231 cells. 5S rRNA (for miR-31) and
GAPDH (for Fzd3, ITGA5, MMP16, M-RIP, RDX, and RhoA) were loading controls. n = 3. (B)
Quantification of metastatic burden in the lungs of nude mice one month after intravenous
injection of the indicated GFP-labeled 231 cells. n = 5. Asterisks: P <0.05 relative to miR-31 +
vector. All error bars represent mean ± s.e.m.
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Supplementary Figure 6. Re-Expression of Fzd3, MMP16, or M-RIP Fails to Reverse miR-
31-Imposed Metastasis-Relevant Phenotypes in vitro. (A) In vitro proliferation of the
indicated 231 cells, as measured by an MTS assay. n = 3. (B) Invasion assays using the indicated
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231 cells. n = 3. (C) Motility assays employing 231 cells infected as denoted. n = 3. (D) Anoikis
assays with the indicated 231 cells. n =3. All P-values indicated no significant difference
between miR-31 + vector and miR-31 + Fzd3, miR-31 + MMP16, or miR-31 + M-RIP in any of
these assays. All error bars represent mean ± s.e.m.
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Supplementary Figure 7. Suppression of ITGA5, RDX, or RhoA Fails to Affect the Initial
Vascular Lodging of Intravenously Injected 231 Cells in vivo. Fluorescent images of murine
lungs to visualize GFP-labeled 231 cells 10 minutes subsequent to tail vein injection into
NOD/SCID mice (top panels). Quantification of the relative prevalence of these cells in the lungs
(bottom panel). n = 3. All P-values are >0.56 relative to shLuciferase. shRNAs utilized in these
assays: shITGA5 #4, shRDX #3, and shRhoA #5. All error bars represent mean ± s.e.m.
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Supplementary Figure 8. Generation of 231 Cells Stably Expressing miR-31, ITGA5, RDX,
and/or RhoA. (A) RT-PCR (top two rows) or immunoblots (bottom four rows) for total miR-31,
ITGA5, RDX, or RhoA in the indicated 231 cells. 5S rRNA and _-actin were loading controls
for the RT-PCR and immunoblots, respectively. (B) Real time RT-PCR for miR-31, ITGA5,
RDX, and RhoA in the indicated 231 cells. 5S rRNA (for miR-31) and GAPDH (for ITGA5,
RDX, and RhoA) were loading controls. n = 3. All error bars represent mean ± s.e.m.
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Supplementary Figure 9. Concomitant Re-Expression of ITGA5, RDX, and RhoA Reverses
miR-31-Imposed Metastasis-Relevant Phenotypes in 231 Cells in vitro. (A) In vitro
proliferation of the indicated 231 cells. n = 3. (B) Invasion assays using the indicated 231 cells. n
= 3. (C) Motility assays employing 231 cells infected as denoted. n = 3. (D) Anoikis assays with
the indicated 231 cells. n =3. All error bars represent mean ± s.e.m.
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Supplementary Figure 10. miR-31, ITGA5, RDX, and RhoA Fail to Affect the Initial
Vascular Lodging of Intravenously Injected 231 Cells in vivo. Fluorescent images of murine
lungs to visualize GFP-labeled 231 cells 10 minutes subsequent to tail vein injection into
NOD/SCID mice (top panels). Quantification of the relative prevalence of these cells in the lungs
(bottom panel). n = 2. All P-values are >0.52 relative to vector + vector + vector + vector. All
error bars represent mean ± s.e.m.
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Supplementary Figure 11. Concomitant Re-Expression of ITGA5, RDX, and RhoA
Reverses miR-31-Imposed Metastasis-Relevant Phenotypes in SUM-159 Cells in vitro. (A)
Real time RT-PCR for miR-31, ITGA5, RDX, and RhoA in the indicated SUM-159 cells. 5S
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rRNA (for miR-31) and GAPDH (for ITGA5, RDX, and RhoA) were loading controls. n = 3. (B)
In vitro proliferation of the indicated SUM-159 cells, as measured by an MTS assay. n = 3. (C)
Invasion assays using the indicated SUM-159 cells. n = 3. (D) Motility assays employing SUM-
159 cells infected as denoted. n = 3. (E) Anoikis assays with the indicated SUM-159 cells. n =3.
All error bars represent mean ± s.e.m.
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SUPPLEMENTARY TABLES
Supplementary Table 1. Effects of miR-31, ITGA5, RDX, and RhoA on Primary Tumor
Size
Cell Line Relative Final Tumor Volumea p-valuea
vector + vector + vector + vector 1.0 ± 0.06b -
vector + vector + vector + ITGA5 3.06 ± 1.90 >0.33
vector + vector + RDX + vector 0.73 ± 0.24 >0.33
vector + RhoA + vector + vector 0.80 ± 0.19 >0.36
vector + vector + RDX + ITGA5 3.30 ± 0.91 >0.06
vector + RhoA + vector + ITGA5 0.26 ± 0.06 <0.01
vector + RhoA + RDX + vector 0.74 ± 0.24 >0.34
vector + RhoA + RDX + ITGA5 0.84 ± 0.20 >0.48
miR-31 + vector + vector + vector 2.08 ± 0.37 <0.05
miR-31 + vector + vector + ITGA5 1.78 ± 0.27 <0.05
miR-31 + vector + RDX + vector 0.52 ± 0.19 >0.06
miR-31 + RhoA + vector + vector 1.35 ± 0.64 >0.61
miR-31 + vector + RDX + ITGA5 2.10 ± 0.34 <0.04
miR-31 + RhoA + vector + ITGA5 1.50 ± 0.18 <0.05
miR-31 + RhoA + RDX + vector 5.16 ± 1.58 <0.05
miR-31 + RhoA + RDX + ITGA5 2.30 ± 0.07 <0.01
aRelative to vector + vector + vector + vector. bAll error bars represent mean ± s.e.m.
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INTRODUCTION
As discussed in Chapter One, metastases are responsible for 90% of human cancer deaths
and arise via a complex, multi-step process termed the invasion-metastasis cascade (Fidler, 2003;
Gupta and Massagué, 2006). In order to metastasize, cancer cells in a primary tumor must first
acquire the capacity for motility, invade locally, intravasate into the systemic circulation,
maintain viability during transit through the vasculature, extravasate into the parenchyma of a
distant tissue, survive in this foreign microenvironment to form micrometastases, and finally re-
initiate their proliferative program and establish macroscopic secondary tumors (metastatic
colonization) (Fidler, 2003). Metastatic colonization is the rate-limiting step of the invasion-
metastasis cascade, yet relatively few molecular mediators of this process have been identified
(Gupta and Massagué, 2006).
MicroRNAs (miRNAs) are emerging as a class of critically important regulators of tumor
metastasis. These evolutionarily conserved RNAs modulate gene expression at a post-
transcriptional level via the pleiotropic suppression of sequence-complementary mRNA targets
(Ambros, 2004; Bartel, 2004; Bartel, 2009). As indicated in Chapter One, a crucial role for
miRNAs in tumor development has been firmly established by the identification of numerous
miRNAs that function as bona fide oncogenes or tumor suppressor genes (Calin and Croce,
2006; Esquela-Kerscher and Slack, 2006; Sotiropoulou, 2009; Ventura and Jacks, 2009).
Additionally, certain miRNAs have been more specifically implicated in the regulation of
metastatic progression (Valastyan and Weinberg, 2009).
One such anti-metastatic miRNA is miR-31. As described in Chapter Two, I recently
determined that miR-31 levels were inversely associated with the propensity for metastatic
relapse in human breast carcinoma patients (Valastyan et al., 2009a). Moreover, miR-31
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expression was both necessary and sufficient to inhibit metastasis in human breast cancer
xenografts (Valastyan et al., 2009a). I attributed these effects to miR-31’s capacity to intervene
during at least three distinct steps of the invasion-metastasis cascade, doing so via the pleiotropic
suppression of a cohort of pro-metastatic target genes (Valastyan et al., 2009a). Subsequently, as
detailed in Chapter Three, I discovered that the anti-metastatic consequences of ectopic miR-31
expression could be entirely reversed by the concomitant overexpression of three downstream
effectors of this miRNA – integrin _5 (ITGA5), radixin (RDX), and RhoA (Valastyan et al.,
2009b).
Importantly, these earlier studies relied upon ectopic expression or overexpression of
miR-31 and these target mRNAs, rather than modulation of the endogenous gene products. For
this reason, I undertook to determine whether the concurrent suppression of the endogenous
mRNAs encoding ITGA5, RDX, and RhoA was sufficient to phenocopy the impacts of ectopic
miR-31 expression on metastasis. Success in this endeavor would indicate that these three
proteins indeed function to promote metastasis and furthermore would implicate the pleiotropic
suppression of ITGA5, RDX, and RhoA as a potential mechanism by which miR-31 antagonizes
the metastatic phenotype.
RESULTS
Simultaneous Suppression of ITGA5, RDX, and RhoA Impairs Metastasis-Relevant Traits
in vitro
I previously demonstrated that the metastatic potential of human breast cancer xenografts
could be potently suppressed by the ectopic expression of miR-31, and that the concomitant re-
expression of three downstream effectors of this miRNA – ITGA5, RDX, and RhoA – sufficed
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to override the anti-metastatic actions of miR-31 (Valastyan et al., 2009a; Valastyan et al.,
2009b). These prior analyses relied, however, upon overexpression of ITGA5, RDX, and RhoA
via viral expression vectors, rather than on modulation of the endogenous mRNAs encoding
these proteins. Consequently, I wished to determine whether the simultaneous downregulation of
endogenous ITGA5, RDX, and RhoA levels could phenocopy the effects of miR-31 expression
on metastasis.
To this end, I created otherwise-metastatic MDA-MB-231 human breast cancer cells
(“231 cells”) that concurrently expressed shRNAs targeting the endogenous mRNAs encoding
ITGA5, RDX, and RhoA. Multiple sequence-independent hairpins were tested for their efficacy
in suppressing the targeted molecules (Supplementary Figure 1 and data not shown).
Importantly, cell lines generated upon sequential infection with several distinct combinations of
shRNAs against these three proteins exhibited reductions in endogenous ITGA5, RDX, and
RhoA levels reminiscent of the 50%-60% decreases in these three factors previously observed
upon ectopic expression of miR-31 in 231 cells (Valastyan et al., 2009a). Accordingly, I focused
my subsequent analyses on those cell lines that concomitantly displayed between two- and three-
fold suppression of ITGA5, RDX, and RhoA.
Non-specific, deleterious effects have been observed in cells expressing large quantities
of shRNA molecules, ostensibly due to competition for shared components of the miRNA
biogenesis machinery that might impair, in turn, the actions of a broad spectrum of important but
otherwise functionally unrelated endogenous cellular miRNAs (Grimm et al., 2006).
Reassuringly, however, the processing of eight control miRNAs was unaffected in 231 cells
simultaneously expressing ITGA5, RDX, and RhoA shRNAs (Supplementary Figure 2). Hence,
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saturation of the miRNA biogenesis machinery was unlikely to have confounded my
interpretations.
These shRNA-expressing 231 cells were first subjected to in vitro assays that gauge cell-
biologic attributes required for metastasis. Coordinate suppression of ITGA5, RDX, and RhoA
reduced invasion through an artificial extracellular matrix (Figure 1A), cell motility (Figure 1B),
and resistance to anoikis-mediated cell death (Figure 1C) in vitro. Among the different
combinations of sequence-independent hairpins against ITGA5, RDX, and RhoA, the magnitude
of the observed biological response correlated with the extent of knockdown achieved,
suggesting that these outcomes arose as specific consequences of reduced levels of the targeted
proteins. Importantly, concomitant suppression of ITGA5, RDX, and RhoA failed to alter in
vitro proliferation kinetics (Supplementary Figure 3), indicating the absence of significant
cytostatic or cytotoxic effects due to the expression of these shRNAs. Together, these data
confirmed that ITGA5, RDX, and RhoA control in vitro behaviors critical for the acquisition of
metastatic competence.
Concomitant Suppression of ITGA5, RDX, and RhoA Phenocopies miR-31-Evoked
Inhibition of Spontaneous Metastasis in vivo
While the preceding experiments demonstrated that the concurrent suppression of
ITGA5, RDX, and RhoA impaired metastasis-relevant phenotypes in 231 cells in vitro, the
consequences of concomitantly inhibiting these three proteins on the in vivo behavior of
carcinoma cells remained unclear. Accordingly, I determined whether the simultaneous
suppression of ITGA5, RDX, and RhoA impaired in vivo metastasis in a manner comparable to
that triggered by ectopic miR-31 expression. In order to do so, I orthotopically implanted into the
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mammary fat pads of mice 231 cells expressing either shRNAs against the mRNAs encoding
these three factors or, alternatively, a miR-31 expression vector. Consistent with my prior
findings (Valastyan et al., 2009a; Valastyan et al., 2009b), miR-31 enhanced primary mammary
tumor growth by 1.5-fold; in contrast, the combined shRNA-evoked suppression of ITGA5,
RDX, and RhoA failed to affect primary tumor size (Figure 2A).
After normalizing for differences in primary mammary tumor growth, miR-31-expressing
231 cells formed 95% fewer lung metastases than did controls in this assay; similarly, the
coordinate shRNA-conferred knockdown of ITGA5, RDX, and RhoA inhibited the incidence of
pulmonary metastatic lesions by 95% (Figure 2B). Cells concurrently expressing additional
combinations of shRNAs against alternative complementary sequences in the three targeted
mRNAs yielded identical results, implying that these effects were attributable specifically to the
ability of these shRNAs to reduce the levels of ITGA5, RDX, and RhoA (Supplementary Figure
4). Hence, the concomitant downregulation of endogenous ITGA5, RDX, and RhoA levels
closely phenocopied miR-31-imposed inhibition of metastasis in this xenograft assay.
Concurrent Knockdown of ITGA5, RDX, and RhoA Phenocopies the Influences of miR-31
on Local Invasion, Early Post-Intravasation Events, and Metastatic Colonization in vivo
Remaining unresolved, however, were the particular step(s) of the invasion-metastasis
cascade that were impaired due to the combined suppression of ITGA5, RDX, and RhoA in 231
cells. In my previous work, I observed that miR-31 impinges on three distinct steps of the
invasion-metastasis cascade in vivo: local invasion, one or more early post-intravasation events
(intraluminal viability, extravasation, and/or initial survival in distant tissues), and metastatic
colonization (Valastyan et al., 2009a; Valastyan et al., 2009b). Consequently, I evaluated
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whether the coordinate shRNA-mediated suppression of ITGA5, RDX, and RhoA was sufficient
to recapitulate one or more of miR-31’s multiple effects on various discrete steps of the
metastatic process.
To assess potential impacts on local invasion, I examined the histopathological
appearance of orthotopically implanted primary mammary tumors. As before (Valastyan et al.,
2009a; Valastyan et al., 2009b), control 231 cells formed invasive primary tumors, while miR-31
expression resulted in primary mammary tumors with a well-encapsulated phenotype (Figure
3A). Cells containing shRNAs directed against ITGA5, RDX, and RhoA formed non-invasive
primary mammary tumors that were indistinguishable at a histopathological level from the
tumors generated by miR-31-expressing cells (Figure 3A and Supplementary Figure 5A).
Therefore, the concurrent suppression of ITGA5, RDX, and RhoA phenocopied the in vivo
influences of miR-31 on local invasion.
Possible effects on early post-intravasation events were investigated by quantifying 231
cells in the lungs one day after intravenous injection via the tail vein. As anticipated (Valastyan
et al., 2009a; Valastyan et al., 2009b), miR-31-expressing cells were five-fold impaired in terms
of their ability to persist in the lungs at one day post-injection; cells with coordinately suppressed
ITGA5, RDX, and RhoA levels owing to the simultaneous expression of shRNAs against these
three mRNAs were also five-fold less prevalent than controls at this timepoint (Figure 3B and
Supplementary Figure 5B). These outcomes were not attributable to differing abilities of the cells
to become lodged initially in the lung microvasculature, as equal numbers of cells from each
group were detected in the lungs 10 minutes after intravenous injection (Supplementary Figure
6). Instead, these observations indicated that the combined inhibition of ITGA5, RDX, and RhoA
phenocopied the effects of miR-31 on early post-intravasation events in the lungs in vivo.
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To evaluate putative effects on metastatic colonization, the sizes of subsequently arising
lung metastases in intravenously injected mice were assessed at three months post-implantation.
As expected (Valastyan et al., 2009a; Valastyan et al., 2009b), whereas control 231 cells
generated robust macroscopic lung metastases, miR-31-expressing cells formed only small
micrometastases (Figure 3C). Similarly, cells containing shRNAs concomitantly targeting
ITGA5, RDX, and RhoA failed to spawn macroscopic metastases and generated only small
micrometastases (Figure 3C and Supplementary Figure 5C). Hence, the simultaneous
suppression of ITGA5, RDX, and RhoA phenocopied the in vivo consequences of miR-31
expression with respect to metastatic colonization.
Simultaneous Suppression of ITGA5, RDX, and RhoA Phenocopies miR-31-Mediated
Inhibition of Experimental Metastasis in vivo
In this same intravenous injection assay, miR-31-expressing 231 cells formed 95% fewer
lung metastases than did controls, while the concomitant shRNA-mediated suppression of
ITGA5, RDX, and RhoA decreased the number of pulmonary metastatic lesions by 90% (Figure
4 and Supplementary Figure 7). Together, the preceding experiments indicated that the
concurrent shRNA-mediated suppression of endogenous ITGA5, RDX, and RhoA levels was
sufficient to phenocopy the full spectrum of miR-31’s described influences on in vivo metastasis,
including the effects of this miRNA on local invasion, early post-intravasation events, and
metastatic colonization.
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The Ability of Concomitant Suppression of ITGA5, RDX, and RhoA to Phenocopy the
Influences of miR-31 on Metastasis-Relevant Traits is Not Confined to 231 Cells
It remained possible that the ability of concomitantly suppressed ITGA5, RDX, and
RhoA to phenocopy miR-31’s anti-malignant actions arose due to some peculiarity of 231 cells.
To address this, I extended my analyses to SUM-159 human breast cancer cells. Like 231 cells,
SUM-159 cells are highly aggressive in vitro and exhibit reduced invasiveness, motility, and
anoikis resistance upon ectopic miR-31 expression (Valastyan et al., 2009a). I created SUM-159
cells that concurrently expressed shRNAs targeting the endogenous mRNAs encoding ITGA5,
RDX, and RhoA, again utilizing multiple sequence-independent hairpins against an individual
transcript (Supplementary Figure 8A). Of note, sequential infection with several distinct
combinations of shRNAs against these three proteins resulted in reductions in endogenous
ITGA5, RDX, and RhoA levels quite similar to the 50%-60% decreases in these three factors
elicited by ectopic miR-31 expression in aggressive human breast cancer cells (Valastyan et al.,
2009a). The simultaneous knockdown of ITGA5, RDX, and RhoA failed to alter the in vitro
proliferative kinetics of SUM-159 cells (Supplementary Figure 8B), thus excluding potential
confounding effects related to this parameter. Consistent with my observations in 231 cells, the
concomitant suppression of ITGA5, RDX, and RhoA in SUM-159 cells impaired several in vitro
surrogate markers of metastatic capacity, namely invasiveness through an artificial extracellular
matrix (Supplementary Figure 8C), cell motility (Supplementary Figure 8D), and anoikis
resistance (Supplementary Figure 8E). Thus, the ability of the simultaneous shRNA-conferred
suppression of ITGA5, RDX, and RhoA to phenocopy the consequences of ectopic miR-31
expression on various cell-biologic attributes required for metastasis was not confined to 231
cells.
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MATERIALS AND METHODS
Cell Culture, Plasmids, and Creation of Stable Cell Lines
GFP-labeled MDA-MB-231 cells were described (Valastyan et al., 2009a). SUM-159
cells were provided by S. Ethier, and cultured under conditions that I have delineated (Valastyan
et al., 2009a). miR-31 was expressed from pBABE-puro (Ma et al., 2007). Short hairpin RNAs
(shRNAs) targeting the mRNAs encoding Luciferase, ITGA5, RDX, or RhoA were expressed
from pLKO.1-puro (Open Biosystems); the sequences of these shRNAs hairpins are: shITGA5
#3, CCACTGTGGATCATCATCCTA; shITGA5 #4, CCTCAGGAACGAGTCAGAATT;
shITGA5 #5, CTCCTATATGTGACCAGAGTT; shRDX #3, GCCAGAGATGAAACCAAGAAA;
shRDX #4, GCAGACAATTAAAGCTCAGAA; shRDX #5, GCTAAATTCTTTCCTGAAGAT;
shRhoA #5, GAAAGCAGGTAGAGTTGGCTT. Stable expression of the indicated plasmids
was achieved via sequential retroviral or lentiviral transduction, followed by selection with
puromycin (Morgenstern and Land, 1990; Elenbaas et al., 2001). In the case of the Luciferase
shRNA hairpin, target cells were subjected to either a single complete infection protocol
(“shLuc” cells) or, alternatively, to three sequential complete infection protocols (“shLuc +
shLuc + shLuc” cells); the latter strategy allowed me to obtain control cells containing
approximately the same total number of shRNA molecules as were present in the shITGA5 +
shRDX + shRhoA cells.
Invasion and Motility Assays
In the invasion assays, 1.0 x 105 cells were seeded in Matrigel-coated chambers with 8.0
_m pores (BD Biosciences); in the motility assays, 5.0 x 104 cells were plated atop uncoated
membranes with 8.0 _m pores (BD Biosciences). Cells were seeded in serum-free media, and
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then were allowed to translocate toward complete growth media for 20 hours. Non-invaded or
non-migrated cells were then physically removed by scraping. Successfully translocated cells
were subsequently visualized using a Diff-Quick Staining Set (Dade) and manually counted
under a light microscope.
Anoikis Assays
Anoikis resistance was measured by seeding 7.5 x 104 cells in 6-well ultra-low
attachment plates (Corning). After 24 hours, cells were resuspended in 0.4% trypan blue (Sigma)
and the proportion of viable cells was quantified using a hemocytometer.
Xenograft Studies
All animal studies complied with protocols approved by the MIT Committee on Animal
Care. Age-matched NOD/SCID mice (propagated on-site) were employed in all xenograft
experiments. For spontaneous metastasis assays, female mice were subjected to bilateral
orthotopic injections into the mammary fat pads with 1.0 x 106 tumor cells resuspended in 1:2
Matrigel (BD Biosciences) plus normal growth media. For experimental metastasis assays, male
mice were intravenously injected with 5.0 x 105 tumor cells (resuspended in PBS) via the tail
vein. Lung metastasis was quantified at the indicated timepoints using a fluorescent dissecting
microscope; these analyses were performed within three hours of specimen isolation. Tumor and
lung histology was assessed by staining paraffin-embedded tissue sections with hematoxylin and
eosin (H&E). In my studies, metastatic foci less than 50 _m in average diameter were classified
as micrometastases; in contrast, macroscopic metastases were defined as metastatic lesions
greater than 50 _m in average diameter.
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Statistical Analyses
Data are presented as mean ± SEM from a representative experiment; each assay was
independently repeated at least three times. Student’s t-test was utilized for comparisons between
groups, with P <0.05 considered statistically significant.
Real Time RT-PCR
Total RNA, including small RNAs, was isolated with a mirVana MicroRNA Isolation Kit
(Ambion). RT-PCR-based detection of mature miRNAs and the 5S rRNA was achieved via
utilization of a mirVana MicroRNA Detection Kit and gene-specific primer sets (Ambion). For
detection of GAPDH, ITGA5, RDX, and RhoA transcript levels, cDNA was prepared from 500
ng of total RNA using the SuperScript III First-Strand Synthesis System (Invitrogen), and
subsequently quantified by SYBR Green real time RT-PCR (Applied Biosystems) using
oligonucleotides that I have described previously (Valastyan et al., 2009b).
Immunoblotting
Cell lysates were resolved by NuPAGE gel electrophoresis (Invitrogen), transferred to a
PVDF membrane, and probed with antibodies recognizing _-actin (Santa Cruz), ITGA5 (Santa
Cruz), RDX (Cell Signaling), or RhoA (Abcam).
Measurements of in vitro Cell Proliferation
Unless otherwise indicated, cellular proliferation was evaluated by seeding 1.0 x 105 cells
per well in 6-well plates. Total cell number was assessed every two to three days by
trypsinization and manual counting with a hemocytometer. Alternatively, proliferative kinetics
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were measured by seeding 5.0 x 102 cells per well in 96-well plates and then employing a
CellTiter96 AQueous One Solution MTS Cell Proliferation Assay (Promega); cells were incubated
with the MTS reagent for 1.5 hours, then total cell number was quantitated by measuring
absorbance at 492 nm on a 96-well plate reader.
Oligonucleotide Sequences
Oligonucleotides employed in this study were: GAPDH RT-PCR, TCACCAGGGCTGCTTTTAAC
and GACAAGCTTCCCGTTCTCAG; ITGA5 RT-PCR, AACTCATCATGGCCAGTGAGGGTAAGGGT and
ATCCTTAATGGCTCAGACATTCGATCCCTCTACAACT; RDX RT-PCR, GAATCAGGAGCAGCTAGCAGCAGAACTT and
TTGGTCTTTTCCAAGTCTTCCTGGGCTGCA; RhoA RT-PCR, AGGTGGATGGAAAGCAGGTAGAGTTGGCT and
AGGATGATGGGCACGTTGGGACAGA.
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FIGURES
Figure 1. Simultaneous Suppression of ITGA5, RDX, and RhoA Impairs Metastasis-
Relevant Traits in vitro. (A) Invasive capacity of 231 cells through Matrigel in a Boyden
chamber transwell assay. n = 3. (B) Transwell motility assays employing 231 cells. n = 3. (C)
Sensitivity of 231 cells to anoikis-mediated cell death after 24 hours of suspension culture. n = 3.
Luc = Luciferase. Asterisks: P <0.05 relative to shLuc + shLuc + shLuc. Data are presented as
mean ± SEM from a representative experiment; each assay was independently repeated at least
three times.
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Figure 2. Concomitant Suppression of ITGA5, RDX, and RhoA Phenocopies miR-31-
Evoked Inhibition of Spontaneous Metastasis in vivo. (A) Primary mammary tumor growth
kinetics upon orthotopic implantation of 231 cells. The experiment was terminated after seven
weeks due to primary tumor burden. n = 4. (B) Fluorescent images of murine lungs to visualize
231 cells 49 days after orthotopic injection (top panels). Quantification of metastatic burden
(bottom panel). Arrows: micrometastases. n = 4. Luc = Luciferase. shRNAs utilized: shITGA5
#5, shRDX #5, and shRhoA #5. Data are presented as mean ± SEM from a representative
experiment; each assay was independently repeated three times.
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Figure 3. Concurrent Knockdown of ITGA5, RDX, and RhoA Phenocopies the Influences
of miR-31 on Local Invasion, Early Post-Intravasation Events, and Metastatic Colonization
in vivo. (A) H&E staining of 231 cell primary mammary tumors 34 days after orthotopic
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implantation (top panels). Quantification of local invasion (bottom panel). n = 4. (B) Prevalence
of 231 cells in the lungs one day after intravenous introduction. n = 4. (C) Fluorescent images of
murine lungs to visualize 231 cells 84 days after tail vein injection (top panels). H&E staining of
lungs from animals implanted with the indicated tumor cells (bottom panels). Arrows:
micrometastases. n = 5. Luc = Luciferase. shRNAs utilized: shITGA5 #5, shRDX #5, and
shRhoA #5. Data are presented as mean ± SEM from a representative experiment; each assay
was independently repeated three times.
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Figure 4. Simultaneous Suppression of ITGA5, RDX, and RhoA Phenocopies miR-31-
Mediated Inhibition of Experimental Metastasis in vivo. Lung metastatic burden 84 days
subsequent to intravenous injection of the indicated 231 cells. n = 5. Luc = Luciferase. shRNAs
utilized: shITGA5 #5, shRDX #5, and shRhoA #5. Data are presented as mean ± SEM from a
representative experiment; this assay was independently repeated three times.
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SUPPLEMENTARY FIGURES
Supplementary Figure 1. shRNA-Mediated Concurrent Suppression of ITGA5, RDX, and
RhoA. (A) Real time RT-PCR for integrin _5 (ITGA5), radixin (RDX), and RhoA in the
indicated MDA-MB-231 (231) cells. GAPDH was a loading control. n = 3. (B) Immunoblots for
endogenous ITGA5, RDX, and RhoA in 231 cells infected as denoted. _-actin was a loading
control. Short hairpin RNAs (shRNAs) utilized: shITGA5 #5, shRDX #5, and shRhoA #5. Luc =
Luciferase. Data are presented as mean ± SEM from a representative experiment; each assay was
independently repeated three times.
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Supplementary Figure 2. shRNA Expression Does Not Interfere With MicroRNA
Biogenesis. Real time RT-PCR analysis of various mature microRNAs in the indicated 231 cells.
5S rRNA was a loading control. n = 3. Luc = Luciferase. All P-values are >0.12 relative to shLuc
+ shLuc + shLuc. Data are presented as mean ± SEM from a representative experiment; this
assay was independently repeated three times.
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Supplementary Figure 3. Simultaneous Suppression of ITGA5, RDX, and RhoA Does Not
Affect Proliferative Kinetics in vitro. In vitro proliferation rates of the indicated 231 cells. n =
3. Luc = Luciferase. No statistically significant differences were observed relative to shLuc +
shLuc + shLuc. Data are presented as mean ± SEM from a representative experiment; this assay
was independently repeated three times.
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Supplementary Figure 4. Concomitant Suppression of ITGA5, RDX, and RhoA
Phenocopies miR-31-Evoked Inhibition of Spontaneous Metastasis in vivo. (A) Relative
primary tumor mass 49 days after orthotopic implantation of the indicated 231 cells. The assay
was terminated after seven weeks due to primary tumor burden. n = 4. (B) Fluorescent images of
murine lungs to visualize 231 cells 49 days after orthotopic injection (top panels). Quantification
of metastatic burden (bottom panel). Arrows: micrometastases. n = 4. Luc = Luciferase. Data are
presented as mean ± SEM from a representative experiment; each assay was independently
repeated three times.
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Supplementary Figure 5. Simultaneous Knockdown of ITGA5, RDX, and RhoA
Phenocopies the Influences of miR-31 on Local Invasion, Early Post-Intravasation Events,
and Metastatic Colonization in vivo. (A) Hematoxylin and eosin staining of 231 cell primary
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mammary tumors 34 days after orthotopic implantation (top panels). Quantification of local
invasion (bottom panel). n = 5. (B) Prevalence of the indicated 231 cells in the lungs one day
after intravenous introduction. n = 4. (C) Fluorescent images of murine lungs to visualize 231
cells 84 days after tail vein injection. Arrows: micrometastases. n = 5. Luc = Luciferase. Data are
presented as mean ± SEM from a representative experiment; each assay was independently
repeated three times.
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Supplementary Figure 6. Coordinate Suppression of ITGA5, RDX, and RhoA Fails to
Affect the Initial Vascular Lodging of Intravenously Injected Cells in vivo. Fluorescent
images of murine lungs to visualize the indicated 231 cells 10 minutes subsequent to tail vein
injection (top panels). Quantification of the relative prevalence of these cells in the lungs (bottom
panel). n = 3. Luc = Luciferase. All P-values are >0.77 relative to shLuc + shLuc + shLuc. Data
are presented as mean ± SEM from a representative experiment; this assay was independently
repeated three times.
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Supplementary Figure 7. Concurrent Suppression of ITGA5, RDX, and RhoA Phenocopies
miR-31-Mediated Inhibition of Experimental Metastasis in vivo. Lung metastatic burden 84
days subsequent to intravenous injection. n = 5. Luc = Luciferase. Data are presented as mean ±
SEM from a representative experiment; this assay was independently repeated three times.
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Supplementary Figure 8. Simultaneous Suppression of ITGA5, RDX, and RhoA Impairs
Metastasis-Relevant Traits in SUM-159 Cells in vitro. (A) Real time RT-PCR for ITGA5,
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RDX, and RhoA in the indicated SUM-159 cells. GAPDH was a loading control. n = 3. (B) In
vitro proliferation of SUM-159 cells, as measured by an MTS assay. n = 3. (C) Invasive capacity
of SUM-159 cells through Matrigel in a Boyden chamber transwell assay. n = 3. (D) Transwell
motility assays employing SUM-159 cells. n = 3. (E) Sensitivity of SUM-159 cells to anoikis-
mediated cell death after 24 hours of suspension culture. n = 3. Luc = Luciferase. Asterisks: P
<0.05 relative to shLuc + shLuc + shLuc. Data are presented as mean ± SEM from a
representative experiment; each assay was independently repeated at least three times.
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INTRODUCTION
Distant metastases, rather than the primary tumors from which these malignant lesions
originate, are responsible for greater than 90% of human cancer-associated mortality (Fidler,
2003; Gupta and Massagué, 2006). Consequently, as was discussed previously in Chapter One,
our ability to effectively manage and treat human neoplasias is dependent on our capacity to
either prevent or reverse the process of metastasis.
It has been widely believed that agents that effectively target any step of the invasion-
metastasis cascade – the complex process whereby tumor cells disseminate from their primary
site of growth, travel to a distant organ, and then survive and thrive within an ectopic
microenvironment – should be capable of conferring measurable therapeutic responses in human
cancer patients with advanced disease (Fidler, 2003; Gupta and Massagué, 2006). However,
existing clinical data reveal little anti-metastatic benefit upon the administration of compounds
designed to block the initial escape of neoplastic cells from primary tumors (Coussens et al.,
2002; Steeg, 2006; Smith and Theodorescu, 2009). This finding can be rationalized by the
observation that many cancer patients already harbor significant numbers of disseminated tumor
cells in their bloodstream, bone marrow, and distant organ sites when they initially present with
their disease (Nagrath et al., 2007; Hüsemann et al., 2008; Pantel et al., 2008); hence, the
putative precursor cells of overt metastases can disseminate relatively early during the course of
tumor progression. Consequently, it is now increasingly appreciated that effective anti-metastatic
therapeutics must be capable of impairing the survival and proliferation of already-disseminated
tumor cells. Unfortunately, few examples of compounds exemplifying these attributes have been
identified (Steeg, 2006; Smith and Theodorescu, 2009). Instead, many anti-metastatic agents
currently in pre-clinical or clinical testing impede the initial dissemination of neoplastic cells
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without influencing the behavior of already-seeded metastases (Coussens et al., 2002; Steeg,
2006; Smith and Theodorescu, 2009; Ma et al., 2010).
As described in Chapter One, microRNAs (miRNAs) have recently emerged as crucial
regulators of a variety of physiologic and pathologic processes (Bartel, 2009), including
carcinoma development and subsequent metastatic progression (Ventura and Jacks, 2009;
Valastyan and Weinberg, 2009). As I have outlined in Chapter Two and Chapter Three, miR-31
is a pleiotropically acting miRNA that functions as a potent suppressor of breast cancer
metastasis without exerting inhibitory influences on primary tumor growth (Valastyan et al.,
2009a; Valastyan et al., 2009b). Data presented in Chapter Two and Chapter Three indicate that
the anti-metastatic activities of miR-31 are attributable to its ability – when constitutively
expressed – to impair at least three distinct steps of the invasion-metastasis cascade: local
invasion, one or more early post-intravasation events (intraluminal viability, extravasation,
and/or initial survival in the parenchyma of a distant tissue), and metastatic colonization
(Valastyan et al., 2009a; Valastyan et al., 2009b). Thus, constitutive miR-31 expression impeded
the post-intravasation survival and proliferation of disseminated tumor cells. These prior findings
– when coupled with the clinical data concerning requirements for effective anti-metastatic
therapeutic strategies enumerated above – prompted me to investigate whether the temporally
controlled, acute re-activation of miR-31 in already-established metastases might elicit anti-
metastatic therapeutic responses in vivo.
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RESULTS
Re-Activation of miR-31 Triggers the Regression of Already-Established Experimental
Metastases in vivo
In order to determine the consequences of acutely restoring miR-31 function, I utilized a
doxycycline (dox)-inducible miR-31 expression vector system (Supplementary Figure 1A). As
anticipated (Valastyan et al., 2009a), when these vectors were introduced into otherwise-
metastatic MDA-MB-231 human breast cancer cells (“231 cells”) – which are essentially devoid
of endogenous miR-31 expression (Valastyan et al., 2009a) – I observed dox-dependent
inhibition of several in vitro surrogate markers of metastatic proficiency (invasion through an
artificial extracellular matrix, cell motility, and resistance to anoikis-mediated cell death)
(Supplementary Figures 1B-1D). In contrast, acute induction of miR-31 expression failed to alter
the in vitro proliferative kinetics of 231 cells (Supplementary Figure 1E). These findings
established that my dox-inducible system closely recapitulated the previously observed
influences of constitutive miR-31 expression on malignant cellular behaviors.
I next exploited my ability to precisely control the timing of miR-31 re-expression in
carcinoma cells to gauge the impact of restoring miR-31 function in already-disseminated 231
cells at various timepoints subsequent to their implantation in vivo. To this end, I intravenously
injected these cells into mice and then re-activated miR-31 at various intervals post-implantation
via dox administration. More specifically, I re-expressed miR-31 either (1) at no point during the
study, (2) for the entire duration of the experiment, (3) only after the formation of small
micrometastases at one month following implantation, (4) subsequent to the creation of
moderately sized macroscopic metastases at two months after injection, or (5) only following the
establishment of very large macroscopic metastases at three months post-implantation (Figure
205
1A). I then assayed the effects of miR-31-based therapeutic intervention on lung metastatic
burden.
Consistent with my prior findings (Valastyan et al., 2009a), in the absence of miR-31
expression, the implanted 231 cells formed numerous robustly growing macroscopic metastases
within three months of their intravenous introduction; also anticipated was the observation that
persistent expression of miR-31 for the entire duration of the assay substantially impaired both
the overall number of pulmonary metastases and their metastatic colonization efficiency (i.e., the
proportion of disseminated metastatic cells that were capable of re-initiating their proliferative
program in order to form macroscopic malignant lesions) (Figures 1B-1D). These differences in
metastatic potential were not attributable to a failure of the dox-treated cells to become lodged
initially in the lung microvasculature, as equal numbers of cells from each group were detected
in the lungs 10 minutes subsequent to intravenous injection (Supplementary Figure 2).
Of interest, I discovered that if miR-31 was not expressed for the first month after
intravenous implantation in order to permit the formation of small micrometastases by the 231
cells – but was then re-introduced for the following two months of the experiment – strong anti-
metastatic responses were still evoked (Figures 1B-1D). I also evaluated the consequences of re-
activating miR-31 in already-robustly growing macroscopic metastases; quite remarkably, even
when miR-31 was expressed for only the final seven days of a three-month xenograft assay, a
significant reduction was observed in both the total number of metastatic foci and the relative
prevalence of macroscopic metastases among these pulmonary lesions (Figures 1B-1D). Taken
together, these findings suggested that an intervention approach involving the re-activation of
miR-31 in already-established metastases sufficed to elicit anti-metastatic therapeutic responses
in vivo.
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Acute Re-Expression of miR-31 Reverses the Invasiveness of Primary Mammary Tumors
and Elicits the Regression of Already-Established Spontaneous Metastases in vivo
The intravenous injection strategy utilized above affords a means by which to compare
post-extravasation proliferation kinetics due to the synchronous nature of initial dissemination in
this assay. However, this approach does not recapitulate the full sequence of events required for
de novo metastasis formation in vivo, because it circumvents the initial steps of local invasion
and intravasation (Fidler, 2003; Gupta and Massagué, 2006). Accordingly, in order to measure
the effects of the temporally controlled re-activation of miR-31 on the entirety of the invasion-
metastasis cascade, I next implanted the dox-inducible miR-31-expressing cells orthotopically
into the mammary fat pads of mice. The expression of this miRNA was then restored at defined
intervals subsequent to implantation.
In particular, miR-31 was re-expressed either (1) at no point during the experiment, (2)
for the entire course of the study, (3) only after a relatively modest number of metastatic cells
had already reached the lungs at one month post-injection, (4) subsequent to the formation of a
large number of pulmonary metastases at six weeks after implantation, or (5) only following the
establishment of a near-saturating metastatic burden in the lungs at two months subsequent to
injection (Figure 2A). Importantly, at all three of the timepoints selected for intervention, the
implanted carcinoma cells had already formed primary mammary tumors that displayed
extensive histopathological evidence of local stromal invasion (Valastyan et al., 2009a). The
consequences of miR-31-dependent therapeutic intervention on both primary mammary tumor
development and subsequent metastatic progression were then assessed.
Re-activation of miR-31 at any of the assayed timepoints failed to alter the growth
kinetics of 231 cell primary mammary tumors (Figure 2B). The absence of an effect on primary
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tumor size did not arise due to a failure in the dox-mediated upregulation of miR-31 in these
orthotopically implanted cells (Supplementary Figure 3). Moreover, the miR-31 molecules
produced upon dox-controlled induction were indeed functionally active, as gauged by their
ability to suppress endogenous levels of the known (Valastyan et al., 2009a; Valastyan et al.,
2009b) miR-31 downstream target genes integrin _5 (ITGA5), radixin (RDX), and RhoA in vivo
(Supplementary Figure 4). Notably, together these observations indicated that acute re-
expression of miR-31 did not elicit general cytostatic or cytotoxic responses in carcinoma cells
growing in vivo; stated differently, the effects of miR-31 re-activation on already-established
metastases – as described above and again below – could not be ascribed to generic, context-
independent anti-proliferative or pro-apoptotic influences.
Despite the lack of significant changes in their overall sizes, histological examination of
these 231 cell primary mammary tumors revealed stark differences upon the acute re-
introduction of miR-31. Consistent with my prior observations (Valastyan et al., 2009a), control
cells yielded primary mammary tumors that demonstrated clear histopathological evidence of
invasion into the surrounding stroma; in contrast, those primary tumors formed by cells that
expressed miR-31 for the entire duration of the experiment had a well-encapsulated appearance
and were largely non-invasive (Figures 2C and 2D). Interestingly, if miR-31 was not expressed
for the first month of the experiment in order to allow for the formation of poorly encapsulated
primary mammary tumors – but was then re-activated for the remainder of the study – the
histopathological appearance of these primary tumors was converted from an invasive phenotype
to a largely non-invasive phenotype (Figures 2C and 2D). Similarly, reversal of the invasive
histological presentation of 231 cell primary mammary tumors was observed when miR-31 was
re-expressed beginning at six weeks post-implantation (Figures 2C and 2D). In contrast,
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however, I found no discernible change in primary mammary tumor histology when miR-31 was
re-expressed for only the final seven days of a two-month xenograft experiment (Figures 2C and
2D). Taken together, these data revealed that acute re-activation of miR-31 in already-established
primary mammary tumors was capable of reversing their invasiveness in vivo.
In this same orthotopic injection experiment, I also determined the effects of acutely re-
expressing miR-31 on the formation of distant metastases. In these studies, systemic
administration of dox to the animals resulted in the induction of miR-31 expression in implanted
carcinoma cells present at both their initial site of injection in the mammary fat pads and in those
tumors cells that had already disseminated to distant organ sites. For this reason – in contrast to
the situation encountered in my intravenous implantation assays – it is likely that any anti-
metastatic therapeutic responses observed in this orthotopic injection strategy reflect a
combination of the influences of re-introduced miR-31 on the initial escape of neoplastic cells
from primary mammary tumors and the ability of this miRNA to affect the fate of already-
disseminated tumor cells.
As anticipated (Valastyan et al., 2009a), in the absence of miR-31 expression, the 231
cells formed large numbers of pulmonary metastases within two months of orthotopic
implantation; also expected was my finding that metastasis was strongly impaired when miR-31
was expressed for the entire duration of the assay (Figures 2E and 2F). Notably, if miR-31 was
not expressed for the first month of the experiment – thereby permitting the establishment of
pulmonary micrometastases – but was then re-activated for the remaining one month of the
assay, a substantial reduction in metastasis formation was observed (Figures 2E and 2F). In
contrast, however, re-expression of miR-31 only at later timepoints failed to diminish the number
of pulmonary metastatic foci in a statistically significant manner (Figures 2E and 2F).
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Consequently, these data indicated that acute re-activation of miR-31 in already-established
primary tumors and distant metastases was sufficient to evoke anti-metastatic therapeutic
benefits in vivo, with these effects occurring in the absence of potentially confounding influences
on the proliferation and survival of the corresponding primary mammary tumors.
Re-Activation of miR-31 Triggers Cell Cycle Arrest and Apoptosis in Already-Established
Metastases in vivo
I next undertook to determine the cellular mechanisms underlying the anti-metastatic
therapeutic responses observed upon acute re-expression of miR-31. To do so, I performed
immunohistochemical staining on tissue sections derived from animals bearing the dox-inducible
231 cells for established markers of neo-vascularization, cell cycle progression, and apoptotic
cell death. Re-activation of miR-31 failed to impact vascular density within the pulmonary
metastases (Supplementary Figure 5). However, regardless of the timepoint at which miR-31
expression was induced, restoring the function of this miRNA diminished the proportion of
disseminated tumor cells in the lungs that were actively dividing (Figures 3A and 3B). Moreover,
an increased rate of apoptosis was elicited when miR-31 was re-activated specifically in already-
macroscopic metastases (Figures 3C and 3D). Importantly, these anti-proliferative and pro-
apoptotic responses were not attributable to general cytostatic or cytotoxic influences stemming
from acute miR-31 expression, since re-activation of miR-31 in 231 cell primary mammary
tumors failed to impair either cell cycle progression or cell viability (Figures 3E and 3F); in fact,
miR-31 re-expression enhanced the proportion of cells in these primary mammary tumors that
were actively dividing, in consonance with my previous findings (Valastyan et al., 2009a).
Collectively, these observations revealed that miR-31 was capable of utilizing multiple distinct
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cellular mechanisms to antagonize the metastatic outgrowth of already-disseminated tumor cells
in vivo; additionally, these therapeutic responses arose specifically within the context of the
foreign microenvironment afforded by a metastatic locus.
Given the striking reductions in total metastatic burden observed upon miR-31 re-
activation, I was surprised by the relatively modest effects on cell cycle arrest and apoptosis
triggered by miR-31 re-expression. I reasoned that this might derive from impaired dox-
dependent activation of miR-31 in the remaining – ostensibly unaffected – metastatic foci. To
address this possibility, I attempted to detect dox-refractory subpopulations within dox-treated
tumor cells by performing in situ hybridizations for miR-31 in tissue sections prepared from
animals bearing the dox-inducible 231 cells. Indeed, disseminated tumor cells in the lungs that
had been exposed to dox for one month or longer were greatly impaired in their ability to
properly induce miR-31 expression in response to dox administration (Figures 3G and 3H).
Moreover, when the proportion of cells that expressed miR-31 in response to dox treatment was
compared between animal-matched primary mammary tumors and pulmonary metastases, I
found that a lower percentage of cells in the distant metastases appropriately induced miR-31 in
response to dox treatment relative to the dox-dependent re-expression that occurred in the
primary breast tumors from which these malignant lesions were initially spawned
(Supplementary Figure 6). Thus, it appeared that a substantial fraction of the residual pulmonary
metastases present in the lungs of animals bearing the dox-inducible miR-31-expressing cells
achieved a selective advantage by losing their ability to properly re-activate miR-31 in response
to dox treatment. Additionally, the presence of a significant dox-unresponsive subpopulation
provided a plausible rationale for the observed only partial induction of cell cycle arrest and
apoptosis upon the administration of dox.
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Acute Restoration of Endogenous miR-31 Function Prevents the Outgrowth of Already-
Established Experimental Metastases and Reduces Overall Metastatic Burden in vivo
It remained possible that the observed anti-metastatic therapeutic benefits resulting from
acute miR-31 re-expression arose due to some peculiarity of either 231 cells or my miR-31
ectopic expression strategy. To address these possibilities, I evaluated the consequences of
acutely restoring endogenous miR-31 function in an appropriate independent cell line; this was
achieved by creating a dox-repressible modified miR-31 miRNA sponge vector system. miRNA
sponges function as competitive inhibitors of miRNA activity by sequestering miRNAs, thereby
diverting them from their endogenous mRNA targets (Ebert et al., 2007; Valastyan et al., 2009a).
The dox-repressible miR-31 sponge system was introduced into otherwise-non-metastatic
MCF7-Ras human breast cancer cells – a cell line that expresses endogenous miR-31 and in
which constitutive miR-31 sponge expression confers metastatic competence (Valastyan et al.,
2009a). Indeed, miR-31 activity was impaired specifically in the absence of dox treatment
(Supplementary Figure 7A). As anticipated (Valastyan et al., 2009a), this inhibition of
endogenous miR-31 function enhanced various in vitro surrogate markers of metastatic capacity
(invasion, motility, and anoikis resistance) without impacting the proliferative rates of these cells
in vitro (Supplementary Figures 7B-7E).
Moreover, when these dox-repressible miR-31 sponge-expressing MCF7-Ras cells were
injected intravenously into mice, acute restoration of endogenous miR-31 function in already-
established micrometastases both reduced the total number of metastatic foci and prevented the
successful outgrowth of remaining lesions into large macroscopic metastases (Figure 4). These
influences were not attributable to differing abilities of these various cells to lodge initially in the
lung microvasculature (Supplementary Figure 8). Robust repression of the miR-31 sponge
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persisted for the entire duration of the assay in a dox-dependent manner (Supplementary Figure
9). Assessed collectively, these findings revealed that the anti-metastatic therapeutic responses
observed upon acute restoration of miR-31 function in already-seeded metastases did not arise
solely in 231 cells, nor were these effects confined to approaches in which miR-31 was
ectopically re-expressed.
MATERIALS AND METHODS
Plasmid Construction
The reverse tetracycline-controlled transactivator (rtTA) was expressed from the
FUdeltaGW lentiviral vector (Maherali et al., 2008), while the lentiviral vector pTK365 carried
the tetracycline-controlled transactivator (tTA) (Haack et al., 2004). miR-31 and the miRNA
sponge constructs were expressed from the pTK380 lentiviral vector (Haack et al., 2004). The
pISO firefly luciferase normalization control plasmid and the pIS1 Renilla luciferase reporter
containing a synthetic miR-31 binding site motif in its 3’ UTR have been described previously
(Valastyan et al., 2009a).
Cell Culture and Reagents
GFP-labeled 231 cells and MCF7-Ras cells have been described (Valastyan et al.,
2009a). Stable expression of the indicated plasmids was achieved via lentiviral transduction
(Valastyan et al., 2009b). 1.0 _g/mL dox (Sigma) was provided directly in the culture medium
for in vitro studies; in the in vivo analyses, dox was added to sucrose-supplemented (10 mg/mL)
drinking water at a final concentration of 2.0 mg/mL.
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Xenograft Studies
All animal studies complied with protocols approved by the MIT Committee on Animal
Care. NOD/SCID mice (propagated on-site) were employed in all xenograft experiments. For
spontaneous metastasis assays, female mice were subjected to bilateral orthotopic injections into
the mammary fat pads with 1.0 x 106 tumor cells resuspended in 1:2 Matrigel (BD Biosciences)
plus normal growth media. For experimental metastasis assays, male mice were intravenously
injected with 5.0 x 105 tumor cells (resuspended in PBS) via the tail vein. Where indicated, cells
were pre-treated with 1.0 _g/mL dox 72 hours prior to injection. Lung metastasis was quantified
at the indicated timepoints using a fluorescent dissecting microscope; these analyses were
performed within three hours of specimen isolation.
Immunohistochemistry
Tumor and lung histology was assessed by staining paraffin-embedded tissue sections
with hematoxylin and eosin (H&E). Detection of CD31 (Cell Signaling), cleaved-caspase3 (Cell
Signaling), and phosphorylated-histone H3 (phospho-H3) (Cell Signaling) was performed on 10
_m sections using the indicated antibodies, Vectastain Elite ABC kits (Vector), and ImmPACT
DAB Substrate (Vector).
miRNA in situ Hybridization
miRNA expression was assessed from paraffin-embedded tissue sections using a protocol
adapted from Silahtaroglu (Silahtaroglu et al., 2007). Briefly, after a four hour pre-hybridization,
5’ FITC-labeled miRCURY LNA probes targeting miR-31 (Exiqon) were hybridized to
proteinase K-treated 10 _m sections at 55°C for 12 hours. Slides were then incubated with anti-
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FITC-HRP (PerkinElmer), and the resulting signal was intensified via utilization of the TSA Plus
Fluorescein System (PerkinElmer).
Statistical Analyses
Data are presented as mean ± s.e.m. Student’s t-test was utilized for all comparisons, with
P <0.05 considered statistically significant.
Real Time RT-PCR
Total RNA, including small RNAs, was extracted from the indicated cells or
homogenized primary mammary tumor tissue xenografts with a mirVana MicroRNA Isolation
Kit (Ambion). RT-PCR-based detection of mature miR-31 and the U6 snRNA was achieved via
use of Taqman MicroRNA Assays (Applied Biosystems). For detection of the levels of GAPDH,
ITGA5, RDX, RhoA, and the dox-repressible miRNA sponge transcripts, cDNA was prepared
from 500 ng of total RNA using the SuperScript III First-Strand Synthesis System (Invitrogen),
and then quantitated by SYBR Green real time RT-PCR (Applied Biosystems).
Invasion and Motility Assays
For invasion assays, 1.0 x 105 cells were seeded in a Matrigel-coated chamber with 8.0
_m pores (BD Biosciences); for motility assays, 5.0 x 104 cells were plated on top of uncoated
membranes with 8.0 _m pores (BD Biosciences). Cells were seeded in serum-free media, and
translocated toward complete growth media for 20 hours. Where indicated, cells were pre-treated
with 1.0 _g/mL dox 48 hours prior to initiating the experiment.
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Anoikis Assays
Anoikis resistance was evaluated by seeding 7.5 x 104 cells in ultra-low attachment plates
(Corning). After 24 hours of anchorage-independent culture, cells were resuspended in 0.4%
trypan blue (Sigma) and cell viability was assessed via manual counting with a hemocytometer.
Where indicated, cells were pre-treated with 1.0 _g/mL dox 48 hours prior to initiating the
experiment.
Measurements of in vitro Cell Proliferation
Proliferative kinetics were assayed by seeding 1.0 x 103 cells per well in 96-well plates
and utilizing a CellTiter96 AQueous One Solution MTS Cell Proliferation Assay (Promega). Cells
were incubated with the MTS reagent for 1.5 hours, and then total cell number was quantitated
by measuring absorbance at 492 nm on a 96-well plate reader. Where indicated, cells were pre-
treated with 1.0 _g/mL dox 48 hours prior to initiating the experiment; these cells were then re-
treated with dox on day four of the assay.
Luciferase Reporter Gene Assays
5.0 x 104 cells were co-transfected with 50 ng of a miR-31 binding motif-containing pIS1
Renilla luciferase construct and 50 ng of a pIS0 firefly luciferase normalization control using
Fugene6 (Roche). Lysates were collected 24 hours post-transfection, and Renilla and firefly
luciferase activities were measured with a Dual-Luciferase Reporter System (Promega). Where
indicated, cells were pre-treated with 1.0 _g/mL dox 48 hours prior to initiating the experiment.
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Oligonucleotide Sequences
Oligonucleotides employed in this study were: Subcloning miRNA sponges to the dox-
repressible vector, TTGGTACCGAGCTCGGATCCAC and AATGGTGTGTCGACTAGAAGGCACAGTCGAGGCTGATCAG;
Subcloning miR-31 to the dox-inducible vector, TTGGTTTCCAGGATCCACAATACATAGCAGGACAGGAAGTAAGGAAGGTG and
TTGGTTTCCAGTCGACCATCTTCAAAAGCGGACACTCTAAGGAAGACTATGTTG; GAPDH RT-PCR, TCACCAGGGCTGCTTTTAAC
and GACAAGCTTCCCGTTCTCAG; ITGA5 RT-PCR, AACTCATCATGGCCAGTGAGGGTAAGGGT and
ATCCTTAATGGCTCAGACATTCGATCCCTCTACAACT; RDX RT-PCR, GAATCAGGAGCAGCTAGCAGCAGAACTT and
TTGGTCTTTTCCAAGTCTTCCTGGGCTGCA; RhoA RT-PCR, AGGTGGATGGAAAGCAGGTAGAGTTGGCT and
AGGATGATGGGCACGTTGGGACAGA; miRNA sponge vector RT-PCR, ATCCACCGGTCGCCACCATGGTGAGCAA and
TGGTGCAGATGAACTTCAGGGTCAGCTT.
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FIGURES
Figure 1. Acute Re-Activation of miR-31 Triggers the Regression of Already-Established
Experimental Metastases in vivo. (A) Schematic depicting the dox-mediated intervention
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strategy for miR-31 re-expression upon intravenous injection of 5.0 x 105 of the indicated GFP-
labeled 231 cells. Images document the normal progression of control cells in this assay. (B)
Fluorescent images of murine lungs to visualize 231 cells 88 days after intravenous implantation.
(C) Quantification of total metastatic burden in the lungs 88 days following intravenous
injection. n = 5. (D) Quantification of the prevalence of macroscopic metastases in the lungs 88
days subsequent to intravenous introduction. n = 5. Arrows: micrometastases. Asterisks: P <0.05
relative to rtTA-miR-31 cells (no dox treatment). Data are presented as mean ± s.e.m.
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Figure 2. Acute Re-Expression of miR-31 Reverses the Invasiveness of Primary Mammary
Tumors and Elicits the Regression of Already-Established Spontaneous Metastases in vivo.
(A) Overview of the dox-controlled intervention strategy for miR-31 re-expression upon
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orthotopic implantation of 1.0 x 106 of the indicated GFP-labeled 231 cells. (B) Masses of 231
cell primary mammary tumors 56 days subsequent to injection. (C) H&E staining of primary
mammary tumors 56 days after orthotopic implantation. (D) Quantification of primary mammary
tumor local invasion 56 days following orthotopic injection. n = 5. (E) Fluorescent images of
murine lungs to visualize disseminated 231 cells 56 days after orthotopic implantation. (F)
Quantification of total metastatic burden in the lungs 56 days after orthotopic injection. n = 5.
Asterisks: P <0.04 relative to rtTA-miR-31 cells (no dox treatment). Data are presented as mean
± s.e.m.
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Figure 3. Acute Restoration of miR-31 Function in Already-Established Metastases Leads
to Metastasis-Specific Cell Cycle Arrest and Apoptosis in vivo. (A) 231 cell lung metastases
88 days after intravenous injection, immunohistochemically stained for phospho-H3. (B)
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Quantification of phospho-H3 staining in pulmonary metastases 88 days post-intravenous
implantation. n = 5. (C) 231 cell lung metastases 88 days subsequent to intravenous injection,
immunohistochemically stained for cleaved-caspase3. (D) Quantification of cleaved-caspase3
staining in pulmonary metastases 88 days following intravenous introduction. n = 5. (E)
Quantification of phospho-H3 immunohistochemical staining in 231 cell primary mammary
tumors at 56 days post-orthotopic injection. n = 5. (F) Quantification of cleaved-caspase3
immunohistochemical staining in 231 cell primary mammary tumors 56 days subsequent to
orthotopic implantation. n = 5. (G) In situ hybridizations for miR-31 (green) in lung metastases
formed by intravenously injected 231 cells 88 days following implantation. DAPI counterstain
(blue). (H) Quantification of miR-31 staining in pulmonary metastases 88 days after intravenous
injection. n = 5. Asterisks: P <0.03 relative to rtTA-miR-31 cells (no dox treatment). Data are
presented as mean ± s.e.m.
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Figure 4. Acute Restoration of Endogenous miR-31 Function Prevents the Outgrowth of
Already-Established Experimental Metastases and Reduces Overall Metastatic Burden in
vivo. (A) Schematic depicting the dox-mediated intervention strategy for the re-activation of
endogenous miR-31 function – achieved via repression of a modified miR-31 miRNA sponge –
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upon intravenous injection of 5.0 x 105 of the indicated GFP-labeled MCF7-Ras cells. Images
document the normal progression of MCF7-Ras cells expressing a miR-31 sponge for the entire
duration of this assay. (B) Fluorescent images of murine lungs to visualize MCF7-Ras cells 117
days after intravenous implantation. (C) Quantification of total metastatic burden in the lungs
117 days following intravenous injection. n = 5. (D) Quantification of the prevalence of
macroscopic metastases in the lungs 117 days subsequent to intravenous introduction. n = 5.
Arrows: micrometastases. Asterisks: P <0.03 relative to tTA-miR-31 sponge cells (no dox
treatment). Data are presented as mean ± s.e.m.
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SUPPLEMENTARY FIGURES
Supplementary Figure 1. The Temporally Controlled Re-Activation of miR-31 Impairs
Metastasis-Relevant Traits in vitro. (A) Real time RT-PCR for miR-31 in the indicated 231
cells. The U6 snRNA was a loading control. n = 3. (B) Invasion assays using the indicated 231
cells. n = 3. (C) Motility assays employing 231 cells infected as denoted. n = 3. (D) Anoikis
assays with the indicated 231 cells. n =3. (E) Proliferation of the indicated 231 cells in vitro. n =
3. Asterisks: P <0.03 relative to rtTA-miR-31 cells (no dox treatment). Data are presented as
mean ± s.e.m.
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Supplementary Figure 2. miR-31 Expression and Doxycycline Treatment Fail to Affect the
Initial Vascular Lodging of Intravenously Injected MDA-MB-231 Cells in vivo. (A)
Fluorescent images of murine lungs to visualize GFP-labeled 231 cells 10 minutes subsequent to
intravenous injection. (B) Quantification of the relative prevalence of these cells in the lungs. n =
2. All P-values are >0.35 relative to rtTA-miR-31 cells (no dox treatment). Data are presented as
mean ± s.e.m.
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Supplementary Figure 3. miR-31 Expression is Successfully Induced in Response to
Doxycycline Treatment in vivo. Real time RT-PCR for miR-31 in orthotopically implanted
primary mammary tumors derived from the indicated 231 cells. The U6 snRNA was a loading
control. n = 3. Data are presented as mean ± s.e.m.
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Supplementary Figure 4. Endogenous Integrin _5, Radixin, and RhoA Expression is
Suppressed Upon Doxycycline-Mediated Re-Activation of miR-31 in vivo. (A) Real time RT-
PCR for ITGA5 in primary mammary tumors formed by the indicated 231 cells. GAPDH was a
loading control. n = 3. (B) Real time RT-PCR for RDX in 231 cell primary mammary tumors.
GAPDH was a loading control. n = 3. (C) Real time RT-PCR for RhoA in primary mammary
tumors derived from the indicated 231 cells. GAPDH was a loading control. n = 3. Asterisks: P
<0.03 relative to rtTA-miR-31 cells (no dox treatment). Data are presented as mean ± s.e.m.
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Supplementary Figure 5. Acute Re-Introduction of miR-31 Fails to Impact Vascular
Density Within Already-Established Metastases in vivo. (A) 231 cell lung metastases 88 days
after intravenous injection, immunohistochemically stained for CD31. (B) Quantification of
CD31 staining 88 days following intravenous implantation. n = 5. All P-values are >0.30 relative
to rtTA-miR-31 cells (no dox treatment). Data are presented as mean ± s.e.m.
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Supplementary Figure 6. Selective Loss of Proper miR-31 Induction in Response to
Doxycycline Treatment in Pulmonary Metastases in vivo. (A) In situ hybridizations for miR-
31 (green) in animal-matched primary mammary tumors and lung metastases formed by
orthotopically injected 231 cells 56 days following implantation. DAPI counterstain (blue). (B)
Quantification of miR-31 staining in animal-matched primary mammary tumors and lung
metastases at 56 days post-injection. n = 5. Asterisks: P <0.02 relative to the corresponding
primary tumor. Data are presented as mean ± s.e.m.
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Supplementary Figure 7. The Temporally Controlled Re-Activation of Endogenous miR-31
Function Impairs Metastasis-Relevant Traits in vitro. (A) Luciferase activity in the indicated
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MCF7-Ras cells 24 hours after transfection of a reporter construct driven by a miR-31 3’ UTR
binding site motif. n = 3. (B) Invasion assays using the indicated MCF7-Ras cells. n = 3. (C)
Motility assays employing MCF7-Ras cells infected as denoted. n = 3. (D) Anoikis assays with
the indicated MCF7-Ras cells. n =3. (E) Proliferation of the indicated MCF7-Ras cells in vitro. n
= 3. Asterisks: P <0.02 relative to tTA-miR-31 sponge cells treated with dox. Data are presented
as mean ± s.e.m.
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Supplementary Figure 8. miR-31 Sponge Expression and Doxycycline Treatment Do Not
Affect the Initial Vascular Lodging of Intravenously Injected MCF7-Ras Cells in vivo. (A)
Fluorescent images of murine lungs to visualize GFP-labeled MCF7-Ras cells 10 minutes
subsequent to intravenous injection. (B) Quantification of the relative prevalence of these cells in
the lungs. n = 2. All P-values are >0.35 relative to dox-treated tTA-miR-31 sponge cells. Data
are presented as mean ± s.e.m.
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Supplementary Figure 9. MicroRNA Sponge Expression is Successfully Repressed in
Response to Doxycycline Treatment in vivo. Real time RT-PCR for miRNA sponge expression
in primary mammary tumors derived from the indicated MCF7-Ras cells. GAPDH was a loading
control. n = 3. Data are presented as mean ± s.e.m.
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INTRODUCTION
As described in Chapter One, metastases are responsible for 90% of human cancer-
associated mortality (Fidler, 2003; Gupta and Massagué, 2006). These malignant growths arise
through the completion of a series of ordered events, whereby cancer cells that were initially
confined within a primary tumor become motile, invade through their surrounding extracellular
matrix, intravasate into the lumen of a blood vessel, survive during transit through the systemic
circulation, arrest at a distant organ site, extravasate into the parenchyma of that secondary locus,
adapt to survive within this foreign microenvironment to form micrometastases, and finally
succeed in colonizing the metastatic site in order to generate clinically detectable macroscopic
metastases (Fidler, 2003; Gupta and Massagué, 2006).
Over the last decade, much attention has been devoted to elucidating molecular regulators
of metastatic progression – a point that was initially discussed in Chapter One. In fact, a number
of genomics-based approaches have recently been undertaken in an endeavor to enumerate novel
regulators of the invasion-metastasis cascade (Clark et al., 2000; van’t Veer et al., 2002;
Ramaswamy et al., 2003; Kang et al., 2003; Minn et al., 2005a; Bos et al., 2009). While these
studies have identified interesting candidate regulators of the metastatic process – some of which
appear to hold promise as clinically useful prognostic biomarkers for aggressive disease (Gupta
and Massagué, 2006) – our knowledge of the molecular circuitry that governs metastasis still
remains fragmentary. Accordingly, alternative approaches that serve to elucidate previously
unappreciated molecular mediators of metastasis are required in order to more fully comprehend
the complex etiology of metastatic disease.
Past strategies for identifying novel genetic determinants of metastatic propensity have
largely centered upon either serial in vivo selection for highly metastatic variants in experimental
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animal models followed by gene expression profiling of the selected variant populations (Clark
et al., 2000; Kang et al., 2003; Minn et al., 2005a; Bos et al., 2009) or, alternatively, gene
expression profiling of clinical human tumor specimens (van’t Veer et al., 2002; Ramaswamy et
al., 2003). One severe limitation of these prior approaches stems from the fact that these
strategies fail to preserve and assay the extensive – and functionally critical (Gupta and
Massagué, 2006) – heterogeneity that is intrinsically present within tumor cell populations.
Stated differently, because these strategies either (1) eliminate potentially important genetic
diversity through serial in vivo selection and/or (2) are constrained by their ability to measure
only the genetic makeup of the few most prevalent clones present within a much more
substantially heterogeneous cell population, they have almost certainly failed to identify
numerous critically important metastasis-regulatory factors.
In response to the shortcomings of these past approaches, I outline here a novel
alternative strategy for the elucidation of key modulators of metastatic progression. More
specifically, I describe an experimental system that can be deployed to implicate genetic factors
that contribute to various aspects of metastatic progression in an unbiased manner. Importantly,
this novel experimental tool is capable of both maintaining and investigating the profound
phenotypic heterogeneity and genetic diversity that pre-exists within tumor cell populations, thus
providing a means by which to identify multiple distinct combinations of genetic alterations that
succeed in driving a common cell-biologic phenotype – including genomic changes that arise
only in relatively rare sub-populations.
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RESULTS
Single-Cell Clones Derived from the Parental Bulk Population of MDA-MB-231 Cells
Display Extensive Functional Heterogeneity and Genetic Diversity
MDA-MB-231 cells (“231 cells”) are an established line of human breast carcinoma cells
that were isolated from the pleural effusion of a patient afflicted with widespread metastatic
disease (Cailleau et al., 1978). 231 cells are known to possess a strong capacity to form primary
tumors when grown as xenografts in mice; moreover, these implanted primary tumors efficiently
seed distant metastases (Kang et al., 2003; Minn et al., 2005a; Minn et al., 2005b; Bos et al.,
2009). Importantly, the work of others has demonstrated that the bulk 231 cell population is
comprised of a rich assemblage of functionally distinct sub-clones (Kang et al., 2003; Minn et
al., 2005b). Additionally, these different sub-populations have been shown to possess at least
some degree of genetic diversity, as the expression levels of several genes of interest were
retrospectively found to differ between various functionally distinct clones (Kang et al., 2003;
Minn et al., 2005b). I therefore hypothesized that widespread genomic differences might exist
between the various 231 cell sub-clones, and also that these genetic differences might dictate the
observed phenotypic heterogeneity of the sub-clones. Consequently, I reasoned that detailed
study of these genetically and functionally diverse clones might afford a means by which to
implicate previously unappreciated modulators of biological processes of interest in an unbiased
manner.
Accordingly, in order to establish an experimental system capable of identifying novel
regulators of metastasis-relevant phenotypes, I isolated 30 single-cell clones (SCCs) from a
parental bulk population of green fluorescent protein (GFP)-labeled 231 cells. Because a
relatively large number of SCCs were obtained, I postulated that my collection of SCCs
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contained representatives from a number of the distinct sub-populations that pre-exist within the
parental bulk 231 cell line. Of note, these might include functionally interesting, yet rare, sub-
populations whose genetic makeup would be entirely masked by the genomic attributes of more
prevalent clones when traditional bulk analyses (e.g., microarray expression profiling) were
conducted using the heterogeneous parental 231 cell population. Hence, by isolating a large
number of SCCs from this initially heterogeneous cell line, I was able to obtain a diverse array of
SCCs whose individual genetic constitutions could subsequently be interrogated and whose
individual functional attributes were perhaps likely to vary widely.
Indeed, these 30 SCCs exhibited extensive morphological diversity, even when grown
under standard culture conditions (data not shown). Moreover, the 30 SCCs were found to
possess a wide range of capacities for in vitro cell proliferation, in vivo primary tumor growth, in
vitro cell motility, and in vivo metastasis formation (Figure 1). As expected, the majority of the
various SCCs proliferated at the same rate as the parental bulk 231 cell population in vitro
(Figure 1B), thus providing a rationale for how a number of genetically distinct sub-populations
can be stably maintained within these cultures. However, the proliferative kinetics of 10 of the
SCCs were significantly slower than the doubling rate of the parental bulk 231 cell population
(Figure 1B), perhaps suggesting that these isolates were likely to have been generated de novo
and persist only transiently in 231 cell cultures. Alternatively, selective pressures may exist that
operate to ensure the continuous presence of these slow-proliferating clones.
Another surprising observation stemmed from the finding that 22 of the 30 isolated SCCs
were more weakly tumorigenic in vivo than was the parental bulk 231 cell population, while only
one of the SCCs formed significantly larger tumors than parental bulk 231 cells (Figure 1C).
These findings could be interpreted as being consistent with the notion that only a minority of the
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cells present in an initial tumor cell population have a robust capacity to seed new tumors – in
consonance with the “tumor-initiating cell” hypothesis (Brabletz et al., 2005; Rosen and Jordan,
2009). Alternatively, these data might simply indicate that extensive intercellular heterogeneity
is an important pre-requisite for tumor formation.
Additionally, the 30 SCCs displayed extensive phenotypic variability in terms of their in
vitro cell motility (Figure 1D) and in vivo metastatic capacity (Figure 1E). In fact, four SCCs
were found to be significantly more motile than the parental bulk 231 cells, while three SCCs
possessed impaired migratory capacity relative to that of the parental bulk 231 cell population
(Figure 1D). Analogously, five SCCs displayed heightened in vivo metastatic propensity, while
four SCCs were significantly less competent to seed metastases, relative to the parental bulk 231
cell population. Assessed collectively, the preceding observations revealed that my collection of
30 SCCs exhibited an extensive range of functional diversity.
I investigated whether the observed phenotypic heterogeneity between the SCCs might be
accompanied by substantial genetic differences at a genome-wide level. Accordingly, I
performed microarray gene expression profiling on those 13 SCCs that displayed significant
phenotypic differences (SCC-2, SCC-4, SCC-5, SCC-7, SCC-12, SCC-13, SCC-18, SCC-19,
SCC-20, SCC-21, SCC-23, SCC-27, and SCC-29). Indeed, while evidence of their common
ancestry from a single human tumor was evident, I observed numerous differences between the
global mRNA expression profiles of these various SCCs (data not shown). Hence, when taken
together, these data revealed that the widespread genetic and functional diversity that existed
among the various clones present in this initial heterogeneous tumor cell population was
maintained and subsequently assayed by deriving a large number of SCCs from the parental bulk
population of 231 cells and then performing parallel functional and genomic analyses.
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The SCC Experimental System Can be Utilized to Identify Novel Regulators of Metastasis-
Relevant Processes in vitro
Because the acquisition of a motile phenotype is a critical pre-requisite for metastasis
formation that can be accurately modeled in vitro (Gupta and Massagué, 2006), I asked whether
the SCC system might be capable of implicating certain genetic factors as novel regulators of in
vitro cell motility. Accordingly, I utilized data obtained from the functional assays and
microarray expression profiling described above to compile a roster of genes whose expression
levels were significantly correlated with migratory potential across the seven SCCs displaying
either weakly motile behavior (SCC-7, SCC-19, and SCC-29) or strongly motile behavior (SCC-
2, SCC-4, SCC-13, and SCC-18) (Figure 1D). These different SCCs displayed a >40-fold overall
range in motility in vitro (Figure 1D). From these analyses, I identified 88 genes whose levels
were significantly associated with this parameter (data not shown). Collectively, these findings
indicated that the SCC system can indeed be used to enumerate candidate regulators of a
metastasis-relevant process.
A subset of 12 of these 88 identified differentially expressed genes was selected for
further study on the basis of (1) the lack of previous reports concerning their potential role in cell
migration and (2) the magnitude of their differential expression between the weak-motility and
high-motility SCCs (Figure 2A and data not shown). Of these 12 genes, the differential
expression patterns observed on the microarrays were indeed verified by independent RT-PCR-
based analyses in the cases of eight of the 12 candidates: a disintegrin-like and metalloproteinase
with thrombospondin type 1 motif 12 (ADAMTS12), DEAD box protein 4 (DDX4), forkhead-
related transcription factor F2 (FOXF2), phosphatase and actin regulator 2 (PHACTR2), plexin
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C1 (PLXNC1), RhoJ, transcription factor EC-like (TFEC), and zinc finger matrin type 4
(ZMAT4) (Figures 2B-2I).
Among these eight independently confirmed, differentially expressed candidates, RhoJ –
a cdc42-like small GTPase with no described role in cancer (Jaffe and Hall, 2005; Heasman and
Ridley, 2008) – was of particular interest, given its >90% downregulation in all four of the high-
motility SCCs (SCC-2, SCC-4, SCC-13, and SCC-18) (Figure 2G). In contrast, RhoJ levels in
two of the three low-motility SCCs (SCC-19 and SCC-29) were comparable to those expressed
by the parental bulk population of 231 cells, while the levels of RhoJ were modestly
downregulated in the third low-motility SCC (SCC-7) relative to the parental bulk population of
231 cells (Figure 2G). Thus, RhoJ expression levels were inversely associated with migratory
capacity.
In light of this strong correlation, I hypothesized that RhoJ might play a functional role in
impeding cell motility. Therefore, I investigated the consequences of perturbing RhoJ expression
levels. To this end, I infected otherwise-weakly motile SCCs with short hairpin RNAs (shRNAs)
against RhoJ. More specifically, two distinct lines of low-motility SCCs (SCC-19 and SCC-29)
were individually infected with five sequence-independent hairpins targeting alternative
complementary sequences located within the RhoJ transcript; most of these shRNAs succeeded
in reducing endogenous RhoJ expression levels by >70% (Supplementary Figure 1). When cells
containing the various RhoJ shRNAs were subjected to in vitro motility assays, I found that RhoJ
knockdown enhanced the migratory capacity of these otherwise-weakly motile SCCs between
approximately two-fold and five-fold (Figures 3A and 3B). In fact, the magnitude of the
observed biological response was correlated with the extent of RhoJ knockdown achieved by the
introduced shRNAs, suggesting that these effects on cell migration were specifically attributable
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to diminished RhoJ expression; moreover, the only RhoJ-targeting hairpins that did not enhance
motility were those that failed to successfully downregulate RhoJ levels. Taken together, these
findings indicated that RhoJ expression is necessary to prevent the acquisition of a motile
phenotype.
To further extend these observations, I ectopically expressed RhoJ in each of the four
otherwise-highly motile SCCs (Supplementary Figure 2). In the cases of two of these four SCCs
(SCC-4 and SCC-18), ectopic RhoJ expression impaired in vitro motility by >75% (Figure 3C).
In contrast, however, RhoJ expression failed to diminish the migratory capacity of the other two
high-motility SCCs (SCC-2 and SCC-13) (Figure 3C). These data therefore suggested that RhoJ
expression is sufficient to impede cell motility in certain otherwise-aggressive breast cancer
cells, but that alternative lines of high-motility breast cancer cells are impervious to the
influences of ectopically expressed RhoJ and thus might modulate their motile behaviors via
RhoJ-independent pathways. In fact, these observations provided empirical support for one of the
stated goals of the SCC experimental system: namely, that this system would be capable of
identifying multiple alternative genetic pathways that each were capable of fostering the same
ultimate phenotypic output – instead of simply selecting for a single combination of genetic
insults that drive that phenotype, as is typically accomplished by previously described
approaches (Clark et al., 2000; Kang et al., 2003; Minn et al., 2005a; Bos et al., 2009).
Assessed collectively, these observations supported the notion that RhoJ can function to
inhibit the in vitro motility of breast carcinoma cells. Moreover, the identification of RhoJ as a
bona fide regulator of cell motility provided a proof-of-concept concerning the viability and
utility of the SCC experimental system as a tool for the identification of novel regulators of
metastasis-relevant processes of interest.
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The SCC Experimental System Can be Utilized to Identify Candidate Novel Regulators of
Metastatic Capacity in vivo
Encouraged by the successful identification of a previously unappreciated modulator of
in vitro cell motility via deployment of the SCC system, I attempted to utilize this experimental
tool to elucidate novel regulators of in vivo metastatic capacity. Upon sub-cutaneous
implantation, the 30 SCCs displayed a >110-fold range in in vivo metastatic potential (Figure
1E). Among the 30 SCCs, four possessed weak metastatic abilities (SCC-4, SCC-18, SCC-19,
and SCC-21) and five had a high proclivity to form metastases (SCC-5, SCC-12, SCC-20, SCC-
23, and SCC-27), as compared to the parental bulk 231 cell population (Figure 1E). Microarray
expression profiling succeeded in identifying a cohort of 314 differentially expressed genes
whose levels were significantly correlated with the demonstrated metastatic abilities of these
SCCs (data not shown). Thus, the SCC experimental system was capable of identifying
candidate regulators of in vivo metastatic ability.
I focused on a subset of these candidates for follow-up analyses. This group of 35 genes
was highlighted due to (1) the lack of previous reports concerning their potential role in
metastasis and (2) the magnitude of their differential expression between the weakly metastatic
and highly metastatic SCCs (Figure 4A and data not shown). From this group of candidate genes,
independent RT-PCR analyses indeed verified the expression level changes observed in the
initial microarray studies for 15 of these potential modulators of in vivo metastasis (Figures 4B-
4P).
More specifically, CD33, cystatin F (CST7), interleukin 7 (IL7), leucine rich repeat and
coiled-coil domain containing 1 (LRRCC1), matrix metallopeptidase 12 (MMP12),
paraneoplastic antigen MA2 (PNMA2), PR domain containing 16 (PRDM16), syndecan 2
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(SDC2), spectrin repeat containing nuclear envelope 1 (SYNE1), synaptotagmin-like 5 (SYTL5),
tektin 1 (TEKT1), transmembrane protein 200A (TMEM200A), transmembrane
phosphoinositide 3-phosphatase and tensin homolog 2 (TPTE2), testis-specific transcript Y-
linked 15 (TTTY15), and Unc5B exhibited expression level changes that were associated with
the known differential metastatic abilities of these nine SCCs (Figures 4B-4P). Hence, the SCC
experimental system has implicated these gene products as possible regulators of in vivo
metastatic capacity. Detailed investigation of the functional relevance of these various candidates
for the process of in vivo tumor metastasis represents a topic of ongoing study and awaits
definitive resolution.
MATERIALS AND METHODS
Cell Culture and Plasmid Construction
GFP-labeled 231 cells have been described (Valastyan et al., 2009a). shRNAs targeting
the mRNA encoding RhoJ were expressed from the lentiviral vector pLKO.1-puro (Open
Biosystems). The RhoJ cDNA was expressed from the pBABE-puro retroviral vector
(Morgenstern and Land, 1990). Stable expression of the indicated plasmids was achieved via
lentiviral or retroviral transduction, followed by selection with puromycin (Morgenstern and
Land, 1990; Elenbaas et al., 2001; Valastyan et al., 2009b).
Measurements of in vitro Cell Proliferation
Proliferative kinetics were assayed by seeding 1.0 x 103 cells per well in 96-well plates
and utilizing a CellTiter96 AQueous One Solution MTS Cell Proliferation Assay (Promega).
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Subsequently, cells were incubated with the MTS reagent for 1.5 hours, and then total cell
number was quantitated by measuring absorbance at 492 nm on a 96-well plate reader.
in vitro Motility Assays
For motility assays, 5.0 x 104 cells were plated atop uncoated membranes with 8.0 _m
pores (BD Biosciences). Cells were seeded in serum-free media, and translocated toward
complete growth media for 20 hours. Non-migrated cells were then physically removed by
scraping. Successfully translocated cells were subsequently visualized using a Diff-Quick
Staining Set (Dade) and manually counted under a light microscope.
Xenograft Studies
All animal studies complied with protocols approved by the MIT Committee on Animal
Care. Male NOD/SCID mice (propagated on-site) were employed in the xenograft experiments.
Mice were subjected to bilateral sub-cutaneous injections with 1.0 x 106 tumor cells resuspended
in 1:2 Matrigel (BD Biosciences) plus normal growth media. Lung metastasis was subsequently
quantified at the indicated timepoints using a fluorescent dissecting microscope; these analyses
were performed within three hours of specimen isolation.
Microarray Gene Expression Profiling
Microarray analyses were conducted using 4x44k human whole-genome multiplex cDNA
expression arrays (Agilent). Cy3-labeled cRNA was hybridized to individual microarrays, and
raw intensity values were measured with an Agilent DNA microarray scanner at 532 nm. One-
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color chip-normalized intensity readings for each of the assayed SCCs were then converted to
fold-change values relative to the parental bulk 231 cell population.
Statistical Analyses
Data are presented as mean ± s.e.m. Student’s t-test was utilized for all comparisons, with
P <0.05 considered statistically significant.
Real Time RT-PCR
Total RNA was extracted from the indicated cells with a mirVana MicroRNA Isolation
Kit (Ambion). For detection of the levels of the indicated transcripts, cDNA was prepared from
500 ng of total RNA using the SuperScript III First-Strand Synthesis System (Invitrogen), and
then quantitated by SYBR Green real time RT-PCR (Applied Biosystems).
Oligonucleotide Sequences
Oligonucleotides employed in this study were: ADAMTS12 RT-PCR,
CAAGAGTGACCTCAATCCTGTTCATCACG and ATGTCTGCCCACAGGCTCACAGTCAT; CD33 RT-PCR,
GTTCCACAGAACCCAACAACTGGTATCTTTC and TGACCCTGTGGTAGGGTGGGTGTCATT; CST7 RT-PCR,
ACTCTGCTGGCCTTCTGCTGCCTGGTCTTGA and TATCTGAACTAGGGCCCTTGTGATGCGGGA; DDX4 RT-PCR,
AGTGGCACAGGTAATGGTGATACTTCTCA and AGATGGAGTCCTCATCCTCAGGTGGA; FOXF2 RT-PCR,
TCATCGTCATGGCCATCCAGAGCTC and CTCCTCGAACATGAACTCGCTGGC; GAPDH RT-PCR,
TCACCAGGGCTGCTTTTAAC and GACAAGCTTCCCGTTCTCAG; IL7 RT-PCR,
CTGATCCTTGTTCTGTTGCCAGTAGCATCA and GTGGAGATCAAAATCACCAGTGCTATTCA; LRRCC1 RT-PCR,
ACCAAAGTCACTCAGAAGACAACACTTACCAG and GTTTGTGAACCATAACTTCGAGTTGTCCT; MMP12 RT-PCR,
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TGACATACGTGGCATTCAGTCCCTGTAT and CTGGCTTCAATTTCATAAGCAGCTTCAATGCCA; PHACTR2 RT-PCR,
CACAGCGATGGTAAGAGACACCGT and CAAGTCTTTGAGGAATCCACATCAGGAGGT; PLXNC1 RT-PCR,
CTTGATCCATTCCGACCTGACATCCGT and GAATTCTCCTCACCTCTTTCCCAGCTGTTAG; PNMA2 RT-PCR,
TGTGACTGTCTTTGAGTGACCTAGTCTGGGAC and TATCCCCGTAACCATCAGTGACTTCTGCTCA; PRDM16 RT-PCR,
CACCTCAAGAAGCACGAGCACGAGAACGCA and ACACTGGGCACTGCCGTCCACGATCTGCATGT; RhoJ RT-PCR,
ACACTTGCTCGGACTGTATGACACCG and TGCGAGCTTCACACCATGCTC; SDC2 RT-PCR,
GACGCTGAATATACAGAACAAGATACCTGCTCAG and AGGTCATAGCTTCCTTCATCCTTCTTTCTC; SYNE1 RT-PCR,
TCTCCATCAATCTCTGCAGCCCTGAGTTCA and TACTCTGAGTTGGGATTCCAACAGCTCATG; SYTL5 RT-PCR,
TGTTCTCGGCACTGATGTTGTCCGACAGTC and TGTTGACCGTCTAAGTCCAAGCTATAGCTC; TEKT1 RT-PCR,
AGACCACAAGAAAATCTCAAAGCGATGTG and TGCACCAGGTCAATGCCAATGCGCTTCT; TFEC RT-PCR,
AGCAGCAACTTGGTGGTGTACTACTGG and CAATGGAGAAAGGCAATGACCACCTG; TMEM200A RT-PCR,
GAATGAAGGCGGTGTGGTGGTTCGCTTCT and CTTAGCGTGTGAATGTCAATGACTGTGGA; TPTE2 RT-PCR,
ATGACGGTCCACCTCTGTATGATGATGTGA and GCCAAAAAGTATCTCCACAGCAAATTCTGG; TTTY15 RT-PCR,
CAAGTTAGAAACTGTTCAGGGCCAACTTACCT and GTATGTTGGTTCAGTCTAGAAAGGCAGGGA; Unc5B RT-PCR,
ACGCTGCTCGACTCTAAGAACTGCACAGAT and CAGCAGATGAGTCAGTGATGTCTGTGTCGA; ZMAT4 RT-PCR,
CTGAAAGGATCTAAACACCAGACCAACCTG and GGATAGAGGTGGTTTACATCACACTCATTGAGG; Subcloning RhoJ
to pBABEpuro, TTGGTTTCCAGGATCCATGAACTGCAAAGAGGGAACTGACAGCAG and
TTGGTTTCCAGAATTCTCAGATAATTGAACAGCAGCTGTGACCCTCAG.
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FIGURES
Figure 1. Single-Cell Clones Derived from the Parental Bulk Population of MDA-MB-231
Cells Display Extensive Functional Heterogeneity. (A) Summary of the functional diversity
that exists among the 30 isolated MDA-MB-231 (231) cell single-cell clones (SCCs). (B)
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Proliferative kinetics of the 30 SCCs in vitro. n =3. (C) Primary tumor sizes 60 days after sub-
cutaneous implantation of the 30 SCCs in vivo. n = 4. (D) Images of successfully migrated cells
20 hours after seeding in vitro for the indicated SCCs (top panels). Quantification of in vitro
motility for the 30 SCCs (bottom panel). n = 3. (E) Fluorescent images of murine lungs to
visualize the indicated SCCs 60 days after sub-cutaneous injection in vivo (top panels).
Quantification of in vivo metastatic burden for the 30 SCCs (bottom panel). n = 4. Data are
presented as mean ± s.e.m.
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Figure 2. The SCC Experimental System Can be Utilized to Identify Novel Candidate
Regulators of Metastasis-Relevant Processes in vitro. (A) Microarray expression profiling data
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for eight selected candidate genes from the seven SCCs that displayed either high-motility
(green) or low-motility (red) phenotypes in vitro. Fold-change values are presented relative to the
parental bulk 231 cell population. (B) Real time RT-PCR for ADAMTS12 in the indicated SCCs.
GAPDH was a loading control. n = 3. (C) DDX4 levels in the indicated SCCs, as gauged by real
time RT-PCR. GAPDH was a loading control. n = 3. (D) Real time RT-PCR for FOXF2 in the
indicated SCCs. GAPDH was a loading control. n = 3. (E) PHACTR2 levels in the indicated
SCCs, as gauged by real time RT-PCR. GAPDH was a loading control. n = 3. (F) Real time RT-
PCR for PLXNC1 in the indicated SCCs. GAPDH was a loading control. n = 3. (G) RhoJ levels
in the indicated SCCs, as gauged by real time RT-PCR. GAPDH was a loading control. n = 3.
(H) Real time RT-PCR for TFEC in the indicated SCCs. GAPDH was a loading control. n = 3.
(I) ZMAT4 levels in the indicated SCCs, as gauged by real time RT-PCR. GAPDH was a
loading control. n = 3. Data are presented as mean ± s.e.m.
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Figure 3. RhoJ Expression Can be Both Necessary and Sufficient to Impair Cell Motility in
vitro. (A) Migration assays utilizing the indicated SCCs. n =3. Asterisks: P <0.05 relative to
shLuciferase cells. (B) Migration assays employing SCCs infected as denoted. n =3. Asterisks: P
<0.05 relative to shLuciferase cells. (C) Migration assays utilizing the indicated SCCs. n =3.
Asterisks: P <0.02 relative to vector control cells. Data are presented as mean ± s.e.m.
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Figure 4. The SCC Experimental System Can be Utilized to Identify Novel Candidate
Regulators of Metastatic Capacity in vivo. (A) Microarray expression profiling data for 15
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selected candidate genes from the nine SCCs that displayed either highly metastatic (green) or
weakly metastatic (red) phenotypes in vivo. Fold-change values are presented relative to the
parental bulk 231 cell population. (B) Real time RT-PCR for CD33 in the indicated SCCs.
GAPDH was a loading control. n = 3. (C) CST7 levels in the indicated SCCs, as gauged by real
time RT-PCR. GAPDH was a loading control. n = 3. (D) Real time RT-PCR for IL7 in the
indicated SCCs. GAPDH was a loading control. n = 3. (E) LRRCC1 levels in the indicated
SCCs, as gauged by real time RT-PCR. GAPDH was a loading control. n = 3. (F) Real time RT-
PCR for MMP12 in the indicated SCCs. GAPDH was a loading control. n = 3. (G) PNMA2
levels in the indicated SCCs, as gauged by real time RT-PCR. GAPDH was a loading control. n
= 3. (H) Real time RT-PCR for PRDM16 in the indicated SCCs. GAPDH was a loading control.
n = 3. (I) SDC2 levels in the indicated SCCs, as gauged by real time RT-PCR. GAPDH was a
loading control. n = 3. (J) Real time RT-PCR for SYNE1 in the indicated SCCs. GAPDH was a
loading control. n = 3. (K) SYTL5 levels in the indicated SCCs, as gauged by real time RT-PCR.
GAPDH was a loading control. n = 3. (L) Real time RT-PCR for TEKT1 in the indicated SCCs.
GAPDH was a loading control. n = 3. (M) TMEM200A levels in the indicated SCCs, as gauged
by real time RT-PCR. GAPDH was a loading control. n = 3. (N) Real time RT-PCR for TPTE2
in the indicated SCCs. GAPDH was a loading control. n = 3. (O) TTTY15 levels in the indicated
SCCs, as gauged by real time RT-PCR. GAPDH was a loading control. n = 3. (P) Real time RT-
PCR for Unc5B in the indicated SCCs. GAPDH was a loading control. n = 3. Data are presented
as mean ± s.e.m.
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SUPPLEMENTARY FIGURES
Supplementary Figure 1. Quantification of the Extent of Knockdown Achieved Upon
Transduction of RhoJ-Targeting shRNAs. (A) Real time RT-PCR analysis for RhoJ in the
indicated single-cell clones (SCCs). GAPDH was a loading control. n = 3. (B) RhoJ expression
levels in the indicated SCCs, as gauged by RT-PCR. GAPDH was a loading control. n = 3. Data
are presented as mean ± s.e.m.
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Supplementary Figure 2. Quantification of Total RhoJ Levels in Cells Infected with a
RhoJ-Encoding cDNA. (A) Real time RT-PCR analysis for RhoJ in the indicated SCC. GAPDH
was a loading control. n = 3. (B) RhoJ expression levels in the indicated SCC, as gauged by RT-
PCR. GAPDH was a loading control. n = 3. (C) Real time RT-PCR analysis for RhoJ in the
indicated SCC. GAPDH was a loading control. n = 3. (D) RhoJ expression levels in the indicated
SCC, as gauged by RT-PCR. GAPDH was a loading control. n = 3. Data are presented as mean ±
s.e.m.
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This thesis has focused on defining genetic events that drive the complex cell-biologic
processes that underlie metastatic progression in human breast carcinoma cells. To this end, two
independent lines of study were conducted. First, I succeeded in identifying a human microRNA
(miRNA) that regulated tumor metastasis and subsequently investigated the mechanistic
underpinnings of these phenotypic influences. I was able to accomplish this by creating various
novel cell line models that perturbed the functional levels of miR-31 and/or certain downstream
effectors of this miRNA. Second, I developed a novel experimental system capable of
elucidating molecular regulators of metastasis in an unbiased fashion; this tool was utilized to
uncover previously unexplored genes of possible relevance to metastatic progression. In order to
do so, I devised a genomics-based approach that preserved and assayed the intrinsic genetic
diversity and functional heterogeneity that pre-exists within tumor cell populations. In this
chapter, I will discuss the implications of my work for the larger field of cancer research and I
will consider potential future directions that stem from my previous observations.
miR-31 Functions as a Negative Regulator of Breast Cancer Metastasis
Experiments described in Chapter Two revealed that expression of the human miRNA
miR-31 is both necessary and sufficient to inhibit breast cancer metastasis. In humans, miR-31 is
encoded by a single genomic locus and is normally expressed in a variety of tissues and cell
types (Grimson et al., 2007; Landgraf et al., 2007). Additionally, miR-31 is the only member of a
broadly conserved miRNA “seed family” that is present in vertebrates and Drosophila (i.e., miR-
31 is the only known miRNA possessing a particular eight nucleotide motif that acts as the major
determinant of miRNA targeting specificity) (Grimson et al., 2007).
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Of interest, in Chapter Two, I demonstrated that miR-31 is endowed with the ability to
concomitantly inhibit several distinct steps of the invasion-metastasis cascade. More specifically,
miR-31 impedes local invasion, one or more early post-intravasation events (intraluminal
viability, extravasation, and/or initial survival in the lung parenchyma), and metastatic
colonization. Remaining unresolved by these analyses, however, is a detailed understanding of
the particular early post-intravasation event(s) affected by the biological actions of miR-31.
Accordingly, one potential future direction for this work involves dissecting this observed effect
in greater detail. Experimentally, this could be accomplished by intravenously injecting
fluorescently labeled tumor cells into mice, waiting for a relatively short period of time (between
one and three days), intravenously injecting the mice with rhodamine-conjugated lectin to stain
the pulmonary vasculature, and then assessing whether the labeled tumor cells were still located
intraluminally or had instead extravasated into the lung parenchyma (Gupta et al., 2007).
At the time of this study, only a limited number of miRNAs with pro- (miR-10b, -21, and
-373/520c) or anti-metastatic (miR-34b/c, -126, -148a, -206, and -335) functions had been
identified (Ma et al., 2007; Huang et al., 2008; Tavazoie et al., 2008; Asangani et al., 2008; Zhu
et al., 2008; Lujambio et al., 2008). However, the contributions of miR-10b, miR-21, and miR-
373/520c specifically to metastasis-promotion are not easily discerned due to their mitogenic
and/or anti-apoptotic roles (Voorhoeve et al., 2006; Ma et al., 2007; Si et al., 2007). Similarly,
the anti-metastatic miRNAs miR-34b/c, miR-126, and miR-148a impair primary tumor growth
(Lujambio et al., 2008; Tavazoie et al., 2008), while miR-206 and miR-335 inhibit proliferation
or promote apoptosis (Sathyan et al., 2007; Kondo et al., 2008), again obscuring their precise
roles in metastasis. In contrast, miR-31 obstructs metastasis without exerting confounding
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influences on primary tumor development. As such, mir-31 might aptly be categorized as a
“metastasis suppressor gene” (Steeg, 2003).
Previous studies described effects of specific miRNAs only on an early stage of the
invasion-metastasis cascade – local invasion. In contrast, the work described in Chapter Two
demonstrated that miRNAs can also influence subsequent steps of metastasis and that an
individual miRNA can intervene at multiple distinct stages of the invasion-metastasis cascade.
Notably, miR-31 suppresses metastatic colonization – the final and rate-limiting step of
metastasis (Fidler, 2003; Gupta and Massagué, 2006). Because clinical observations link
colonization efficiency with ultimate disease outcome in human carcinoma patients (Fidler,
2003; Gupta and Massagué, 2006), miR-31’s ability to impede metastatic colonization may be
quite significant.
Of additional interest, in Chapter Two, I found that loss of miR-31 activity enhances
invasiveness, motility, and anoikis resistance in primary normal human mammary epithelial
cells. Hence, inactivation of miR-31 in a normal epithelial cell may facilitate its dissemination
even prior to its transformation to a fully neoplastic state. This suggests one possible mechanism
by which the invasion-metastasis cascade could be initiated very early during the course of
primary tumor progression, a phenomenon that has recently been observed in clinical breast
tumors (Hüsemann et al., 2008).
All of my studies were conducted using breast cancer cells. Therefore, the functional
ramifications of miR-31 expression for metastatic progression in carcinoma cells originating
from other tissue types remain unclear. This represents an important question to investigate
moving forward, as these analyses will reveal whether miR-31 downregulation is a common
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event that causatively drives metastatic progression across a variety of carcinoma types or,
alternatively, if the anti-metastatic roles of miR-31 are more tissue-specific.
My analyses relied on established human cell lines and xenograft studies, approaches that
cannot fully simulate clinical carcinomas. For example, cell lines accumulate genetic changes in
culture, while xenografts fail to recapitulate species-specific interactions between tumor cells and
their stroma. However, the consistency of my results upon use of multiple independent cell lines
(including a single-cell-derived population), the convergence of my gain- and loss-of-function
findings, and my correlative studies in human breast cancer patients and murine mammary tumor
cell lines argue against major confounding influences stemming from my experimental models.
Collectively, the findings of the studies presented in Chapter Two carry significant
implications regarding our understanding of the pathogenesis of high-grade malignancies. My
data suggest that the loss of a single gene product can facilitate the completion of multiple
distinct steps of the invasion-metastasis cascade; this pleiotropic action may help to explain how
tumor cells can accumulate enough genetic and epigenetic aberrations over the course of a
human lifespan to overcome the numerous barriers that normally operate to prevent metastasis.
Moreover, because distant metastases are responsible for patient mortality in the vast majority of
human carcinomas, miR-31’s ability to impede metastasis may prove to be clinically useful in
the development of diagnostic, prognostic, and/or therapeutic reagents.
Correlations Between miR-31 Levels and Disease Progression in Human Tumors
In Chapter Two, I documented an inverse association between miR-31 levels in primary
human breast tumors and the propensity for these patients to suffer from metastatic relapse. Of
note, in contrast to existing clinically utilized biomarkers for breast cancer (Desmedt et al.,
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2008), the inverse correlation between miR-31 levels and the tendency for disease relapse
operated independently of both the grade and molecular subtype of the primary tumor. In this
respect, miR-31 may stand apart from the great majority of biomarkers that are currently utilized
prognostically for this disease. Additionally, my prior investigations in Chapter Two concerning
miR-31 expression in patient-matched primary tumors and distant metastases revealed that
selective pressures may operate that act to diminish the prevalence of miR-31-expressing cells
during the course of metastatic progression.
Concordant with my own observations was a recent report indicating that reduced miR-
31 expression is a hallmark of the acquisition of an invasive phenotype in clinical bladder
cancers (Wszolek et al., 2009). Similarly, microarray expression profiling of clinical breast
tumors revealed reduced miR-31 in luminal B (relative to luminal A), basal-like, and HER2+
tumors (Mattie et al., 2006; Blenkiron et al., 2007) – patterns of reduction that correlate with
aggressive disease (Sørlie et al., 2001).
miR-31 expression has also been found to be attenuated in human carcinomas of the
breast (Calin et al., 2004; Zhang et al., 2006; Yan et al., 2008), prostate (Schaefer et al., 2010),
ovary (Creighton et al., 2010), and stomach (Guo et al., 2009; Zhang et al., 2009). Indeed,
homozygous loss of the miR-31-encoding genomic locus has been described in human urothelial
carcinomas (Veerla et al., 2009) and acute lymphoblastic leukemias (Usvasalo et al., 2010).
Paradoxically, upregulation of miR-31 in human colorectal (Bandrés et al., 2006; Motoyama et
al., 2009), liver (Wong QW et al., 2008), and head-and-neck tumors (Liu et al., 2009; Liu et al.,
2010), as well as squamous cell carcinomas of the tongue (Wong TS et al., 2008), has also been
observed. Importantly, none of these studies stratified their patient cohorts based on metastasis
status.
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In light of these diverse clinical findings, it is plausible that downregulation of miR-31 is
associated with malignant progression in a variety of types of human neoplasias; however, at
present, I cannot exclude a more tissue-specific anti-malignant role for this miRNA, potentially
arising due to restricted expression patterns of certain functionally relevant downstream effectors
of miR-31 in carcinoma cells originating from different tissues. One important subject for future
investigation will involve deciphering whether miR-31 expression levels in primary tumors are
associated with the propensity for metastasis formation in carcinomas arising in epithelial tissues
other than the breast. In these studies, it will be critical to carefully case-control patient cohorts
with respect to potentially confounding variables that are known to correlate with metastatic
propensity, including lymph node status and tumor grade (Desmedt et al., 2008).
Ectopic miR-31 Expression Enhances Primary Mammary Tumor Growth
An unexpected finding from my analyses presented in Chapter Two stems from the
observation that – despite miR-31’s metastasis-suppressing roles – ectopic expression of this
miRNA enhanced primary mammary tumor growth in orthotopic implantation xenograft assays.
One possible interpretation of this result would be that the high levels of ectopic expression
achieved with my viral delivery system are not physiologically relevant and that this phenotype
may represent an artifact of high-level overexpression. However, data presented in Chapter Two
indicated that the retrovirus-mediated ectopic expression of miR-31 in aggressive human breast
cancer cells achieved a level of mature miR-31 that was quite comparable to the endogenous
levels of this miRNA expressed by primary normal human mammary epithelial cells.
It is therefore plausible that miR-31’s capacity to promote primary mammary tumor
growth does not represent an overexpression artifact. Consequently, an oncogenic role for this
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metastasis-suppressing miRNA cannot be formally excluded. Such duality of action is not
unprecedented (Massagué, 2008) and is consistent with notions that metastasis- and
tumorigenesis-enabling attributes can be biologically distinct and acquired via independent
selective pressures during distinct stages of malignant progression. Mechanistically, findings
detailed in Chapter Three indicated that the capacity of miR-31 to enhance primary tumor growth
operates independently of the protein machinery deployed by miR-31 to mediate its anti-
metastatic activities.
The recent work of others may provide insight regarding miR-31’s capacity to promote
primary tumor growth. It was reported that miR-31 increased the oncogenic potential of head-
and-neck squamous cell carcinoma cell lines in vitro and also slightly augmented their ability to
form primary tumors in vivo (Liu et al., 2010). The authors also discovered that miR-31 directly
targeted FIH, a negative modulator of hypoxia-inducible factor (HIF) signaling under normoxic
conditions (Liu et al., 2010). Thus, miR-31 fostered ectopic HIF-mediated signaling even under
conditions devoid of oxygen deprivation. Given the well-described roles of HIF in pro-survival
and hyper-proliferative signaling (Semenza, 2003), it is possible that miR-31-evoked stimulation
of primary tumor growth in vivo may one day be traced to the ability of this miRNA to activate
HIF-dependent tumor-promoting signaling circuitry.
In contrast, an independent global miRNA expression profiling study discovered that
miR-31 was the most strongly downregulated miRNA in serous ovarian tumors (Creighton et al.,
2010). Functional analyses subsequently demonstrated that miR-31 expression inhibited
proliferation and promoted apoptosis in ovarian tumor cells; interestingly, these tumor-
suppressing effects were observable only in cell lines with a dysfunctional p53 signaling
pathway (Creighton et al., 2010). This relationship between miR-31-dependent cell cycle arrest
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or apoptosis and defective p53-mediated signaling also applied to osteosarcoma and pancreatic
carcinoma cell lines (Creighton et al., 2010). At a mechanistic level, the authors attributed these
anti-tumorigenic functions to miR-31’s capacity to directly target the E2F2 cell cycle regulator
(Creighton et al., 2010). This supposition was consistent with the p53 status-dependence of these
responses, as high-level E2F2 activity typically leads to p14ARF-evoked upregulation of p53-
mediated apoptosis in cells possessing an intact p53 pathway; in contrast, E2F2 readily promotes
cell cycle progression in a p53-deficient cellular context (Sherr and McCormick, 2002).
Although not investigated in this report, it will be important for future work to determine
whether miR-31 impacts the in vivo behavior of ovarian carcinoma cell lines grown as tumor
xenografts, as well as the p53 status-dependence of these putative effects.
When taken together, these studies indicate that miR-31 may exert multiple cancer-
relevant functions in different tissue types and genetic contexts. This initially perplexing
observation has also been documented for a number of other miRNAs that critically regulate
tumor biology, including the let-7 (Brueckner et al., 2007; Kumar et al., 2008) and miR-200
(Dykxhoorn et al., 2009; Wellner et al., 2009) seed families. I speculate that many of these
differences arise as a consequence of differential expression patterns of the repertoire of miR-31
target genes in distinct tissue types, although direct validation of this model awaits future studies.
Concomitant Suppression of Integrin _5, Radixin, and RhoA Can Explain the Impact of
miR-31 on Breast Cancer Metastasis
Work presented in Chapters Two, Three, and Four investigated the molecular
mechanisms underlying miR-31-imposed metastasis suppression. In Chapter Two, I identified
frizzled3 (Fzd3), integrin _5 (ITGA5), matrix metallopeptidase 16 (MMP16), myosin
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phosphatase-Rho interacting protein (M-RIP), radixin (RDX), and RhoA as direct downstream
effectors of miR-31 and discovered that modulation of the levels of ITGA5, RDX, and RhoA
(but not Frzd3, MMP16, or M-RIP) affected miR-31-evoked inhibition of a variety of in vitro
surrogate markers of metastatic capacity. In Chapter Three, I found that the concurrent re-
expression of ITGA5, RDX, and RhoA was sufficient to override the full spectrum of miR-31’s
described influences on metastasis in vivo. Finally, in Chapter Four, I extended these prior
observations by determining that the simultaneous short hairpin RNA (shRNA)-mediated
suppression of ITGA5, RDX, and RhoA sufficed to closely phenocopy the pleiotropic actions of
miR-31 on in vivo metastasis. Assessed collectively, these studies revealed that miR-31’s ability
to antagonize metastasis is likely to be intimately associated with the capacity of this miRNA to
concomitantly downregulate the expression levels of ITGA5, RDX, and RhoA. Perhaps
surprisingly, my data further indicated that even a relatively modest change in the levels of
ITGA5, RDX, and RhoA can profoundly impact the metastatic potential of human mammary
carcinoma cells in vivo.
In consonance with these findings, others have previously described positive associations
between elevated levels of ITGA5, members of the RDX family, or RhoA in carcinoma cells and
disease progression in human tumors (Sahai and Marshall, 2002; McClatchey, 2003; Sanchez-
Carbayo et al., 2006). One question that remains unanswered concerns whether the elevated
levels of ITGA5, RDX, and RhoA encountered in patient tumor specimens arise as a direct
consequence of decreased miR-31 function or, alternatively, through unrelated regulatory
mechanisms. In the future, it would be worthwhile to address this issue by simultaneously
analyzing the expression levels of miR-31, ITGA5, RDX, and RhoA in the same human tumors.
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Notably, the concomitant suppression of ITGA5, RDX, and RhoA impedes not only the
initial escape of neoplastic cells from a primary tumor, but also the ability of already-
disseminated cancer cells to thrive at distant organ sites. In light of the fact that significant
numbers of disseminated tumor cells are frequently already present in the systemic circulation,
bone marrow, and/or distant organs of human carcinoma patients even at early stages of disease
progression (Nagrath et al., 2007; Hüsemann et al., 2008), ITGA5, RDX, and RhoA may
represent attractive therapeutic targets owing to their actions in metastasis-promotion at
secondary organ sites. In particular, the capabilities of these proteins to alter metastatic
colonization efficiency may be quite significant, as completion of this rate-limiting step of the
invasion-metastasis cascade is believed to dictate disease outcome in many human cancers
(Fidler, 2003; Gupta and Massagué, 2006).
Collectively, the findings of Chapters Three and Four suggested that a miRNA’s effects
on a given phenotype can be explained by its ability to suppress a relatively modest number of
downstream targets. In the present case, the relevant effectors comprise only a small percentage
of the total roster of mRNAs targeted by the miRNA under investigation. My observations are
confined to a single miRNA and a single biological endpoint; accordingly, the extent to which
this phenomenon is generalizable awaits future investigation. Nevertheless, several recent studies
describe strong, but partial, effects on miRNA-mediated phenotypes by modulating individual
target genes of miRNAs of interest (Xiao et al., 2007; Ma et al., 2007; Yu et al., 2007; Kumar et
al. 2008). Such reports suggest the existence of other similarly organized miRNA response
networks, in which a miRNA’s impact on a biological process can be attributed to its ability to
inhibit only a small sub-fraction of its mRNA targets.
277
miR-31 is predicted to regulate >200 mRNAs (Krek et al., 2005; Grimson et al., 2007).
The findings of Chapters Three and Four, which indicated that miR-31’s anti-metastatic effects
can derive largely – if not entirely – from the ability of this miRNA to suppress a cohort of only
three downstream target genes, are therefore quite surprising. Nonetheless, my data do not
preclude the existence of still-uncharacterized miR-31 target genes that impinge upon the
metastatic process in a manner that is functionally masked by the consequences of altering
ITGA5, RDX, or RhoA levels. Also, it is possible that one or more bona fide targets of miR-31
that have relevance to the process of metastasis fail to be significantly downregulated by this
miRNA in my breast cancer cell lines. Finally, my observation that the simultaneous suppression
of ITGA5, RDX, and RhoA fails to recapitulate miR-31’s ability to enhance primary mammary
tumor growth suggests that additional miR-31 downstream effectors can mediate miR-31-
dependent influences on the in vivo behavior of carcinoma cells that are mechanistically
unrelated to metastasis.
One area that remains largely unexplored concerns the elucidation of additional
functionally relevant direct downstream effectors of miR-31-imposed metastasis suppression.
The work of others has implicated E2F2 and FIH as miR-31 target genes of putative relevance to
neoplastic progression in ovarian carcinoma and head-and-neck squamous cell carcinoma,
respectively (Creighton et al., 2010; Liu et al., 2010); however, the contributions of miR-31-
mediated suppression of these two mRNAs to breast cancer progression remain unresolved.
Moreover, while my in vitro analyses and in vivo findings upon intravenous injection suggested
that miR-31-evoked modulation of Fzd3, MMP16, and M-RIP levels did not alter malignant
behaviors, my preliminary data suggest that restored expression of Fzd3 or MMP16 may
partially reverse miR-31-imposed metastasis suppression upon orthotopic implantation (data not
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shown). Similarly, my preliminary data reveal that shRNA-mediated suppression of Fzd3 or
MMP16 appears to impair the metastatic potential of orthotopically implanted otherwise-
aggressive human breast cancer cells (data not shown). These preliminary observations merit
future attention, as will deciphering the extent to which the metastasis-relevant functions of Fzd3
and MMP16 overlap with those of ITGA5, RDX, and RhoA.
Finally, in order to identify novel downstream effectors of miR-31 in an unbiased
manner, I have performed microarray gene expression profiling on metastatic human breast
cancer cells transduced with either a miR-31 expression vector or a control vector; these analyses
revealed changes in the levels of a large number of mRNAs (data not shown). In the future, it
will be essential to validate these microarray data by RT-PCR, as well as determine whether
verified mRNA level changes reflect direct targeting of the transcript by miR-31 or instead an
indirect effect of ectopic miR-31 expression. To this end, computational approaches and reporter
gene assays utilizing mutagenized 3’ untranslated region (UTR)-driven luciferase constructs will
prove invaluable.
Whereas the individual re-expression of ITGA5, RDX, or RhoA largely reversed certain
miR-31-imposed metastasis-relevant defects in vitro, individual restoration of ITGA5, RDX, or
RhoA levels only partially rescued miR-31’s effects on metastasis in vivo. This underscores the
fact that available in vitro assays inadequately model the fully complexity of in vivo metastasis;
caution must therefore be exercised when deploying these techniques, particularly in the absence
of parallel in vivo analyses.
In summary, the data presented in Chapters Two, Three, and Four indicated that miR-31
sits atop ITGA5-, RDX-, and RhoA-containing regulatory pathways that affect multiple steps of
the metastatic process, altering both the capacity of cancer cells to exit from a primary tumor and
279
the ability of already-disseminated neoplastic cells to survive and thrive in the foreign
microenvironment afforded by the site of metastasis. As such, miR-31’s pleiotropic anti-
metastatic capabilities appear to position this miRNA as a critical safeguard against the
acquisition of metastatic competence.
Therapeutic Potential of miR-31 Mimetics for the Remediation of Metastatic Disease
The data delineated in Chapter Five demonstrated that the temporally controlled re-
activation of miR-31 in already-established metastases leads to marked regression of those
malignant lesions; in contrast, acute re-expression of miR-31 in primary mammary tumors does
not elicit cytostatic or cytotoxic responses. Recently, several laboratories have described
effective methodologies for the in vivo delivery of either direct miRNA mimetics or miRNA-
encoding genetic elements in murine model systems (Kota et al., 2009; Takeshita et al., 2010;
Trang et al., 2010). These technological advances, when coupled with the findings presented in
Chapter Five, provide a strong impetus for further evaluation of the safety and efficacy of miR-
31-based therapeutic agents.
The majority of anti-cancer drugs in pre-clinical or clinical testing are designed to reduce
primary tumor burden; moreover, most therapeutics intended for the remediation of metastatic
disease block the initial dissemination of tumor cells but fail to affect the proliferation and
survival of already-established metastases (Coussens et al., 2002; Steeg, 2006; Smith and
Theodorescu, 2009; Ma et al., 2010). Because carcinoma patients frequently already harbor
numerous disseminated tumor cells at the time of initial diagnosis and greater than 90% of
human cancer mortality is attributable to distant metastases (Fidler, 2003; Gupta and Massagué,
2006; Nagrath et al., 2007; Hüsemann et al., 2008; Pantel et al., 2008), existing therapeutic
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strategies are unlikely to satisfactorily address the principal cause of cancer-associated deaths.
However, my observations in Chapter Five raise the possibility that intervention approaches
centered upon restoring miR-31 functional activity may prove useful for combating metastatic
disease in certain human carcinomas.
At present, I am undertaking several lines of investigation to address the major
unresolved questions stemming from the data presented in Chapter Five. First, although acute
miR-31 re-activation was found to trigger metastasis-specific cell cycle arrest and apoptosis, the
downstream effector(s) of miR-31 responsible for mediating these phenotypic outcomes
remained unexplored. In an endeavor to implicate specific miR-31 target genes as the key
effectors of miR-31-evoked metastatic regression, I have created the 16 potential combinations
of MDA-MB-231 metastatic human breast cancer cells (“231 cells”) expressing either
doxycycline (dox)-inducible miR-31 or control vector, plus constitutive ITGA5, RDX, and/or
RhoA (data not shown). These cells have now been implanted into mice either orthotopically or
intravenously in metastasis intervention assays similar to those outlined in Chapter Five. Given
the vital roles of ITGA5, RDX, and RhoA downstream of miR-31 during breast cancer
metastasis demonstrated in Chapters Three and Four – including the effects of ITGA5, RDX, and
RhoA on the post-intravasation proliferation and survival of disseminated tumor cells – it is
reasonable to hypothesize that one or more of these effector molecules will prove to be a critical
target for the metastatic regression elicited by acute re-introduction of miR-31. However, it is
also plausible that miR-31’s capacity to elicit anti-metastatic therapeutic responses when re-
activated in already-established metastases is mechanistically independent from its ability to
control the expression levels of ITGA5, RDX, and/or RhoA. Should this prove to be the case,
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additional miR-31 target genes must be assayed in the future for their respective abilities to
reverse miR-31-dependent metastatic regression.
To further extend the work described in Chapter Five, I have also forged a collaboration
with Thomas Andl of Vanderbilt University. A dox-inducible miR-31 transgenic mouse has been
created (data not shown). In the future, it will be possible to cross this dox-inducible miR-31
mouse with established transgenic mammary carcinoma models – such as Mouse Mammary
Tumor Virus (MMTV)-Neu and Polyoma Middle T (PyMT) mice (Muller et al., 1988; Maglione
et al., 2001) – in order to perform metastasis intervention experiments analogous to those
detailed in Chapter Five, but now in well-defined genetic models of breast cancer progression.
As will be described in greater detail below, I am also in the process of generating Cre-loxP
conditional miR-31-deficient mice that might similarly prove useful for dissecting the
consequences of acutely perturbing miR-31 function in already-established metastases generated
by genetic mouse models of breast cancer.
Together, these ongoing studies are anticipated to provide a more detailed understanding
regarding the therapeutic potential for miR-31 mimetics in preventing and reversing metastatic
progression. If the more sophisticated model systems described in the preceding paragraphs
confirm the efficacy of miR-31 re-introduction as a form of anti-metastatic intervention, it is
possible that future work will need to address the anti-metastatic activities of miR-31-based
therapeutic agents in more rigorously structured pre-clinical and clinical trials.
What are the Upstream Signaling Events that Control miR-31 Expression Levels?
This thesis has focused largely on defining the biological consequences of altered miR-31
functional activity, as well as the efferent downstream mechanisms by which miR-31 elicits
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these phenotypic responses. In contrast, Chapters Two, Three, Four, and Five provide little
insight regarding the afferent upstream stimuli that serve to control miR-31 expression levels. In
fact, I have previously attempted to implicate a number of candidate signaling pathways in the
regulation of endogenous miR-31 expression levels in both metastatic human breast cancer cells
and primary normal human mammary epithelial cells. My results, however, indicate that
exogenously supplied bone morphogenetic protein-2 (BMP-2), epidermal growth factor (EGF),
fibroblast growth factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor
(IGF), keratinocyte growth factor (KGF), platelet-derived growth factor (PDGF), transforming
growth factor _ (TGF_), or tumor necrosis factor (TNF) failed to affect miR-31 expression levels
in both of these cell types (data not shown). Similarly, pharmacological and genetic inhibition of
these pathways did not affect miR-31 expression in metastatic human breast cancer cells or
primary normal human mammary epithelial cells (data not shown). It has previously been
reported that endogenous miR-31 expression levels can be enhanced by TNF or BMP-2
treatment of endothelial cells and mesenchymal stem cells, respectively (Suárez et al., 2010; Sun
et al., 2009); however, my data suggest that these regulatory circuits do not operate in breast
epithelial cells. Instead, it appears plausible that miR-31 expression is regulated in an intricate
lineage- and cell type-dependent manner.
Given the important role of the epithelial-mesenchymal transition (EMT) in regulating
metastatic progression (Thiery, 2002; Polyak and Weinberg, 2009), I hypothesized that miR-31
levels might be controlled by the actions of one or more transcription factors known to induce an
EMT; however, I found that endogenous miR-31 expression in untransformed human mammary
epithelial cells was unaltered by ectopic expression of the EMT-inducing transcription factors
Snail, Twist, and Zeb1, as well as the EMT-inducing shRNA-conferred suppression of E-
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cadherin (data not shown). Hence, the introduction of various EMT-provoking genetic alterations
does not seem to elicit changes in endogenous miR-31 expression levels.
I have also examined the possibility that miR-31 might be epigenetically silenced in
metastatic human breast cancer cells. While miR-31 expression remained unchanged upon
treatment with a DNA methyltransferase inhibitor, endogenous miR-31 levels were dramatically
increased when metastatic 231 cells were cultured in the presence of a histone deacetylase
(HDAC) inhibitor (data not shown). In contrast, miR-31 expression in SUM-159 cells – another
line of aggressive human breast cancer cells – was unaffected by treatment with this same
HDAC inhibitor (data not shown). Taken together, these findings indicate that although miR-31
is epigenetically silenced in certain metastatic human breast cancer cell lines, the expression of
this miRNA is downregulated by alternative mechanisms in other aggressive human breast
cancer cell lines.
Because of the very limited success of the above-mentioned candidate-based approaches
designed to uncover miR-31-regulating signals, I am also currently attempting to identify
upstream transcriptional modulators of miR-31 expression in both metastatic human breast
carcinoma cells and primary normal human mammary epithelial cells in an unbiased manner.
One approach that I am deploying to achieve this goal involves deriving cell lines in which a
luciferase reporter gene has been knocked in to the endogenous miR-31 locus (data not shown).
These cells will then be used for high-throughput screening to uncover both shRNA hairpins and
small molecules that impact reporter gene activity driven by the endogenous miR-31 promoter. It
is anticipated that these analyses will yield insight regarding upstream stimuli – both genetic and
epigenetic in nature – that act to dictate miR-31 expression levels. In light of the findings
presented in Chapters Two, Three, Four, and Five, some of these miR-31-controlling proteins
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and small molecules may merit further investigation concerning their potential prognostic and/or
therapeutic utility in the diagnosis and/or remediation of metastatic disease.
Relevant to this proposed high-throughput reporter-based screening strategy is the recent
demonstration that reduced mature miR-31 levels in certain cancer cell lines may arise due to the
defective post-transcriptional processing of the miR-31 RNA precursor rather than
transcriptional repression of the miR-31 gene itself (Lee et al., 2008). More specifically, while
miR-31 precursor RNA was detected in a variety of tumor cell lines, levels of the fully processed
mature miR-31 were almost entirely absent in some of the lines (Lee et al., 2008). In a portion of
these cases, the defect in miR-31 processing may have derived from retention of the miR-31
precursor RNA in the nucleus (Lee et al., 2008), thereby precluding its endonucleolytic cleavage
by the cytoplasmically confined Dicer endonuclease. These findings are particularly noteworthy,
as this mode of regulation was observed for only a very small minority of individual miRNAs
within a given cell type; in contrast, many other miRNAs in the same cell type were not
regulated by this post-transcriptional mechanism (Lee et al., 2008). It will be of critical
importance to discern whether post-transcriptional regulation of miR-31 is a peculiarity of
certain genetically abnormal tumor cell lines or, alternatively, if this mode of control is an
important determinant of the levels of functionally active miR-31 in a variety of normal and
malignant cells. If post-transcriptional regulation of miR-31 processing is indeed a widespread
means of titrating the functional levels of this miRNA, then the report-based screening approach
described above is likely to fail to detect certain biologically important regulators of mature miR-
31 levels. Moreover, a further topic for future work would involve deciphering the relevance of
post-transcriptional control of mature miR-31 levels in primary tissue specimens derived directly
from human cancer patients.
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Another mechanism by which miR-31 expression might be downregulated in breast
carcinomas is physical deletion of the miR-31-encoding genomic locus. Indeed, deletion of the
mir-31 locus has been observed in a variety of types of human carcinomas (Beroukhim et al.,
2010). This observation is of particular interest in light of the fact that 9p21.3 – the chromosomal
region within which the miR-31 gene resides – harbors the genomic loci encoding several bona
fide tumor suppressor genes (p16, p14ARF, and p15) (Sherr and McCormick, 2002), in addition to
the metastasis suppressor miR-31. In fact, mir-31 is located less than 450 kb from these
neighboring tumor suppressor-encoding loci (Beroukhim et al., 2010). Consequently, even small
deletions in the 9p21.3 region are likely to simultaneously abrogate the function of multiple gene
products relevant to carcinoma pathogenesis. It is therefore striking that 9p21.3 is the single most
frequently deleted chromosomal region across a wide variety of human cancers originating from
a diverse array of tissue types (Weir et al., 2007; Beroukhim et al., 2010). Moreover, it is
interesting that p16 – the best-studied of the three validated 9p21.3 tumor suppressors – is known
to be inactivated predominantly by “regional mechanisms” (e.g., deletion or DNA methylation)
rather than “local mechanisms” (e.g., point mutation) in human tumor specimens (Boström et al.,
2001). I hypothesize that 9p21.3 deletions are so frequent because they represent an efficient
means by which incipient tumor cells can concomitantly abolish the functions of multiple gene
products that would otherwise act to oppose malignant progression.
In response to these findings, I am currently working with Andrea Richardson and
Zhigang Wang – both faculty at Brigham and Women’s Hospital – to further investigate the
clinical relevance of 9p21.3 deletions for metastatic progression in human breast tumors. More
specifically, we are characterizing the frequency of 9p21.3 deletions in a case-controlled cohort
of human breast cancer patients of known metastasis outcome, determining which cancer-
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relevant locus or loci (miR-31, p16, p14ARF, and/or p15) is disrupted by each 9p21.3 deletion,
and then deciphering the association between deletion of the various potential combinations of
these genes and the propensity for metastatic relapse (data not shown). I speculate that these
studies may unearth information of potential utility to the diagnosis of human carcinomas of the
breast, and may also provide further mechanistic insights regarding the startlingly high
prevalence of 9p21.3 deletions in clinically arising tumors.
I believe that future work will reveal a variety of cellular mechanisms by which mature
miR-31 expression levels are controlled. Current evidence suggests that these mechanisms of
modulation will include traditional transcriptional regulation, epigenetic control, physical
deletion of the genomic locus encoding this miRNA, and post-transcriptional strategies that alter
the efficiency of processing of the miR-31 precursor RNA to its mature form.
What are the Roles of miR-31 in Normal Organismal Development and Physiology?
The work reported herein has focused almost exclusively on the consequences of altered
miR-31 functional activity in carcinoma cells. Hence, the studies reported in Chapters Two,
Three, Four, and Five largely fail to illuminate the likely roles of miR-31 in normal cellular and
organismal biology. Comprehending the contributions of miR-31 to normal development and
physiology therefore represents a topic of great interest for future studies.
Work emanating from several other laboratories has begun to investigate the functions of
miR-31 in normal physiology. For example, miR-31 has been found to be under-expressed in T
regulatory (Treg) cells, as compared to the levels of this miRNA in other T cell populations
(Rouas et al., 2009). Of interest, miR-31 was found to be capable of directly targeting the mRNA
encoding the forkhead box P3 (FOXP3) transcription factor, a master regulator of Treg cell
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differentiation and functional activity (Rouas et al., 2009). Thus, it is plausible that miR-31
antagonizes a Treg phenotype by suppressing the expression levels of this important transcription
factor.
A role for miR-31 during inflammatory responses has been suggested based on the
observation that the cytokine TNF was capable of enhancing miR-31 expression in endothelial
cells, resulting in suppression of the endothelial adhesion molecule E-selectin (Suárez et al.,
2010). This downregulation of E-selectin led, in turn, to reduced physical interactions between
endothelial cells and neutrophils in vitro, ultimately triggering negative feedback control of
inflammatory signaling (Suárez et al., 2010). These findings therefore raise the possibility that
miR-31 levels are dynamically regulated in response to acute stressors in order to mount an
appropriate inflammatory response.
Yet other investigators have evaluated changes in miR-31 expression patterns in
multipotent progenitor cells and stem cells upon induced differentiation. For example, miR-31
was one of three miRNAs whose expression levels decreased in human unrestricted somatic stem
cells upon osteogenic differentiation (Schaap-Oziemlak et al., 2009). Another group observed
reduced miR-31 expression in rat adipose-derived stem cells that had been triggered to undergo
adipogenic differentiation; in this study, several known adipogenic differentiation genes were
identified among the computationally predicted downstream targets of miR-31, although no
attempt was made to experimentally validate these computational predictions (Tang et al., 2009).
Others found that the addition of exogenous BMP-2 stimulated miR-31 expression levels in
mesenchymal stem cells (Sun et al., 2009). These authors also reported that ectopic expression of
miR-31 prevented the differentiation of mesenchymal stem cells into adipocytes, a phenotype
likely mediated – at least in part – by the capacity of miR-31 to directly target the gene encoding
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CCAT/enhancer-binding protein-alpha (CEBPA), an established promoter of the adipocytic
differentiation program (Sun et al., 2009).
Taken together, these studies begin to provide evidence that miR-31-mediated signaling
events are of fundamental importance in a diverse array of normal cell types. However, these
prior studies provide only rudimentary insight regarding the full spectrum of likely roles for
miR-31 in normal development and physiology. Definitive resolution of the normal cellular and
organismic functions of miR-31 therefore necessitates the creation of more sophisticated genetic
models of altered miR-31 function.
For these reasons, I am currently in the process of generating miR-31-deficient murine
genetic model systems. More specifically, I have already derived a traditional knockout vector
targeting the miR-31-encoding genomic locus and I am also now in the process of creating a Cre-
loxP conditional knockout vector against mir-31 (data not shown). Working with the MIT Koch
Institute ES Cell and Transgenics Core Facility, the traditional knockout vector has been
electroporated into murine embryonic stem cells and I am now identifying successfully targeted
clones suitable for blastocyst injections (data not shown).
I speculate that the miR-31-deficient mice that will ultimately be generated from this
work will represent an important tool for dissecting the contributions of miR-31 function to both
embryonic development and the homeostatic maintenance of various adult tissues. Moreover,
these miR-31-knockout mice may prove useful for further refining our understanding of the roles
of miR-31 in disease pathogenesis. For example, the miR-31-deficient animals could be crossed
with well-characterized mammary carcinoma transgenic murine models (e.g., MMTV-Neu mice
or PyMT mice) in order to obtain stringent genetic evidence concerning the contributions of
miR-31 activity to both primary tumor development and subsequent metastatic progression. In
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this respect, the miR-31 conditional knockout mice will be of particular value, as they will allow
me to conduct metastasis intervention studies analogous to those described in Chapter Five – but
now using a genetic miR-31-deficient experimental system.
Similarly, the dox-inducible miR-31 transgenic mice that were created in collaboration
with Thomas Andl of Vanderbilt University and described above may also prove useful for
dissecting the roles of miR-31 in normal development and physiology. Very preliminary initial
characterization of these mice reveals a variety of apparent abnormalities in multiple tissue types
in the wake of long-term dox-dependent induction of miR-31 (data not shown). In the future, it
will be critical to cross the inducible miR-31 transgenic mice to animals carrying various tissue-
specific reverse tetracycline-controlled transactivator (rtTA) or tetracycline-controlled
transactivator (tTA) elements and then activate miR-31 expression in a spatially defined manner
at various specific timepoints during development, as well as in adult mice. For example, if the
dox-inducible miR-31 transgenic mice were bred to animals bearing a mammary-specific dox-
responsive element, I could discern the effects of miR-31 on normal mammary gland
development or, alternatively, the effects of modulating miR-31 expression during important
physiological processes such as pregnancy.
To complement insights that might be obtained from the miR-31 knockout mice and the
dox-inducible miR-31 transgenic mice, I have also initiated in vitro studies to investigate the
roles of miR-31 in normal human mammary epithelial cells. For example, I found that MCF10A
cells contain relatively high levels of endogenous miR-31 (data not shown), and I have now
generated MCF10A cells that stably express either constitutive or dox-inducible miR-31 sponge
constructs (data not shown). MCF10A cells are an established line of spontaneously
immortalized, untransformed human mammary epithelial cells; importantly, when cultured under
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appropriate conditions, MCF10A cells form three-dimensional structures that closely recapitulate
the glandular architecture of normal breast epithelial tissue (Debnath and Brugge, 2005). Brugge
and colleagues have previously demonstrated that this system is a powerful and tractable tool for
ascribing the functional impact of genetic factors of interest on numerous aspects of epithelial
cell biology (Debnath and Brugge, 2005). Future work will therefore assess the effects of
perturbing miR-31 functional activity in MCF10A three-dimensional culture models.
The Contributions of miR-31 to Other Pathological Conditions
The research outlined in this thesis has focused on the role of miR-31 in one specific
pathological condition: cancer. However, the work of others has implicated aberrant miR-31
activity in the pathogenesis of several other disease states. For example, miR-31 expression was
found to be diminished during the course of ischemia-induced retinal neo-vascularization (She et
al., 2008). Mechanistically, the authors proposed that miR-31 might elicit these angiogenesis-
related phenotypes via its capacity to downregulate the expression levels of PDGFb and HIF1_ –
two known neo-vascularization-promoting factors. Additionally, the authors reported that
injection of miR-31 RNA precursor mimetics significantly decreased the extent of ischemia-
induced retinal neo-vascularization and choroidal neo-vascularization in vivo in mice (She et al.,
2008). Together, these observations suggest that miR-31 functions as a negative regulator of
nutrient deprivation-induced neo-vascularization.
Another report, which employed a transgenic rat model, has indicated that miR-31 is
downregulated upon the onset of polycystic kidney disease (Pandey et al., 2008). This study also
suggested that computationally predicted miR-31 target genes involved in the processes of
calcium signaling and cell cycle regulation exhibited changes in their mRNA levels that
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coincided with downregulation of miR-31 during the course of polycystic kidney disease
pathogenesis (Pandey et al., 2008). Thus, miR-31 may affect the progression of polycystic
kidney disease by targeting effector molecules involved in core signaling pathways associated
with this malady.
Other groups have reported that miR-31 expression is diminished in granulocytes from
patients afflicted with primary myelofibrosis, relative to the levels of miR-31 present in
granulocytes from unaffected individuals (Guglielmelli et al., 2007). Consequently, certain
aspects of hematopoietic homeostatic maintenance may be modulated by the actions of miR-31.
Finally, miR-31 was upregulated by more than 70-fold in a mouse model of muscular
dystrophy, as compared to the levels of this miRNA in wild type littermates (Greco et al., 2009).
The authors of this study proposed that miR-31 may promote skeletal muscle regeneration upon
tissue insult; however, experimental validation of this mechanistic model was not provided
(Greco et al., 2009). Hence, hyper-activation of miR-31 – and not just the reduced expression of
this miRNA – can contribute to the progression of human diseases.
Assessed collectively, the above-described studies reveal that aberrant miR-31 signaling
occurs in a variety of pathological conditions and may play a functional role in mediating these
disease phenotypes. Future studies will be necessary to explore the contributions of miR-31 to
the etiologies of these diseases in greater detail, as well as to define additional roles for this
miRNA in the onset and maintenance of various other pathologies. Notably, the miR-31-
deficient murine genetic systems that I am endeavoring to generate – as described above – may
prove useful for elucidating miR-31’s functional contributions to these various disease states.
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An Experimental System for the Unbiased Discovery of Genes Relevant for Breast Cancer
Metastasis
While miR-31 appears to represent a key regulator of metastatic progression in breast
carcinomas, a number of additional genetic factors are also certain to play critical roles in
controlling aspects of the invasion-metastasis cascade during breast cancer pathogenesis.
Therefore, in Chapter Six, I undertook to determine the identity of additional genes whose
encoded products function in the acquisition of metastatic competence. In order to do so, I
established an experimental system that allowed me to preserve and assay the functionally
critical, intrinsic intercellular diversity that pre-exists within tumor cell populations. More
specifically, I derived a relatively large number of single-cell clones (SCCs) from a
heterogeneous bulk population of metastatic human breast cancer cells. I then characterized their
phenotypic diversity with regard to several metastasis-relevant parameters of interest (including
in vitro cell motility and in vivo metastasis formation) and performed gene expression profiling
on those SCCs that displayed noteworthy phenotypic differences. Together, these analyses have
elucidated a number of candidate regulators of the processes of interest.
One assumption that the successful utilization of this SCC-based screening system is
predicated upon is that the various SCCs are relatively stable at a genomic level. Importantly, the
SCCs appear to be stable even after extended in vitro culture, as the phenotypic behaviors of the
SCCs in the described in vitro and in vivo assays have proven robust even after long intervening
intervals of in vitro passage (data not shown). However, in the future, it will be important to
directly demonstrate that this functional robustness is accompanied by relative genomic stability;
to do so, I will compare the global gene expression profiles of early-passage and late-passage
samples drawn from the same SCC. Similarly, one might wish to derive a relatively large
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number of individual clones from a single SCC and subsequently assess the extent of genetic
diversity and functional heterogeneity that exists amongst these various “clones of a clone” in
order to address this point further.
With regard to the proof-of-concept screen conducted in Chapter Six to identify putative
regulators of in vitro cell motility, several lines of experimentation are still ongoing. First,
additional phenotypic characterization of the biological consequences of perturbing RhoJ
expression is currently underway. More specifically, both gain-of-function and loss-of-function
approaches are being taken to investigate the effects of altering RhoJ levels on in vitro invasion,
in vitro proliferative kinetics, in vivo primary tumor formation, and in vivo metastatic capacity
(data not shown). Together, these experiments are anticipated to provide further resolution
concerning the spectrum of RhoJ’s impacts on malignancy-associated attributes. Additionally,
more refined mechanistic studies regarding the particular biochemical activities of RhoJ that
underlie its impact on in vitro cell motility, as well as the identity of important downstream
effectors of RhoJ-evoked suppression of cell migration, will soon be undertaken.
Second, additional candidate genes identified by the in vitro motility screen will be
assayed in greater detail in future work. To this end, shRNA vectors targeting a number of these
mRNAs of interest have been created and transduced into appropriate target cells (data not
shown). Analogous to the experiments conducted involving RhoJ, both gain-of-function and
loss-of-function approaches will be performed to determine whether the activity of each of these
factors is either necessary or sufficient to impact in vitro cell motility. In certain cases, the results
obtained from these assays may prompt me to conduct more detailed follow-up experiments. For
example, several of the genes implicated in my initial screen encode transcription factors of
unknown function. An important topic for future studies would therefore involve enumerating
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the rosters of downstream effectors of these transcription factors whose deregulation is likely to
account for the observed phenotypic impacts of perturbation of the transcription factors
themselves. This might be accomplished, for example, by combining data obtained from
microarray-based gene expression profiling upon overexpression or shRNA-mediated
suppression of the transcription factor of interest with independently conducted genome-wide
chromatin immunoprecipitation analyses of the promoter sequences occupied by the transcription
factors under investigation.
Similarly, the functional consequences of altering the expression levels of many of the
candidate genes identified in the screen for novel regulators of in vivo metastasis outlined in
Chapter Six remain unexplored. At present, shRNA hairpins targeting many of the genes of
interest have been cloned and then introduced into appropriate target cells (data not shown). In
the future, a number of experiments – including in vivo spontaneous metastasis assays – will be
conducted using these genetically modified cells. Based on the outcome of these studies, more
detailed investigation of the particular step(s) of the invasion-metastasis cascade impacted by a
subset of these genes may prove fruitful. Moreover, the mechanistic bases responsible for any
observed phenotypes will need to be dissected in detail.
Concerning the more general utility of the SCC system, in the future, it will be possible to
expand upon my previous analyses by assaying additional phenotypes of interest, such as
sensitivity to chemotherapeutic agents, enrichment for tumor-initiating cells (TICs), regulation of
the EMT, in vivo tumor neo-angiogenesis, in vivo cell proliferation, and resistance to various
forms of stress-induced apoptosis. Moreover, miRNA expression profiling could be performed to
complement the previously conducted mRNA microarrays in an endeavor to implicate novel
miRNAs whose functions are relevant for the processes of interest. Taken together, the data
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currently amassed suggest that this SCC-based screening platform may represent a valuable tool
for the identification of novel genes that contribute to malignancy-associated attributes;
therefore, future utilization of this experimental system appears to be warranted.
Final Perspective
Collectively, the research described in this thesis has endeavored to (1) elucidate novel
genes that regulate breast cancer metastasis, (2) determine the cell-biologic consequences
conferred by the altered expression of these molecules, and (3) uncover the mechanistic
underpinnings for these genetically dictated phenotypic changes. The insights attained from these
studies have implications for our understanding of metastatic progression and provide evidence
that may aid in our comprehension of the cellular origin and subsequent genetic evolution of
incipient metastatic carcinoma cells. Moreover, this work identifies previously unappreciated
genetic factors that may one day serve as clinically useful prognostic biomarkers for aggressive
malignancy and/or potential therapeutic targets for the remediation of metastatic carcinomas.
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